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Abstract 
Introduction: Chronic Fatigue Syndrome (CFS) is a varied and complex disorder with a common set 
of core symptoms and a large array of secondary symptoms. After more than four decades of 
research, no causative factor has been identified and more recently scientific opinion has shifted 
towards recognising the presence of immune disruption within this disorder. Underlying chronic 
infection has been advocated as a contributing factor to CFS, yet its role and the extent of its impact 
are unconfirmed. This study compares evidence of infections of two groups of CFS patients, those 
with co-diagnoses of infections transmissible through tick bite (CFT subgroup), and those without 
(CFX subgroup) compared to a healthy control group. Method: Blood samples were obtained from 
eighty-eight CFS patients and twenty nine age and sex matched controls. Forty-seven of the eighty-
eight CFS patients did not have tick transmissible co-diagnoses, the CFX subgroup and forty one did, 
the CFT subgroup. Evidence of infection by Borrelia afzelii, Borrelia burgdorferi, Borrelia garinii, 
Chlamydophila pneumoniae, Mycoplasma pneumoniae and Rickettsia spp. was tested for through 
the use of PCR, nested PCR, western blot, ELISA and IFA. Results: 82% of CFS participants had 
evidence of exposure to at least one of the pathogens investigated which was not significantly 
different to the control group (72%).  19% of CFS participants had evidence of exposure to 3 out of 4 
pathogen species compared to 3% of controls (p = 0.04).  There was a high level of exposure to 
Chlamydophila pneumoniae in both CFS (49%) and control groups (31%) and similarly for 
Mycoplasma pneumoniae (46% of CFS and 62% of controls) and was not significantly different 
between groups. The high prevalence of positive serology for the respiratory pathogens observed in 
this study is consistent with other research. When comparison was made on tick-borne (TB) 
pathogens, 56% of CFS participants had exposure to at least one, compared to 14% of controls (p < 
0.001). Six percent of CFS participants had exposure to both Borrelia species and Rickettsia species 
compared to 0% controls. Exposure to at least one TB and one respiratory pathogen was significantly 
different between CFS participants (40%) and controls (3%) (p > 0.001) . There was no identified 
2 
 
significant difference between the two CFS groups. Discussion:  The high prevalence of exposure to 
multiple pathogens within the test group suggests some level of relationship between CFS and 
infective agents. Each of the analysed bacterial pathogens has been shown to be capable of 
developing chronic infections within hosts. As hypothesised in previous studies, the results of this 
study could contribute towards the argument that chronic infections, as a result of contributing to 
immune dysregulation over extended periods of time, may lead to fatiguing symptoms. The 
conclusions that can be derived from serological results are limited as they are a measure of immune 
response rather than clear isolation of bacteria, and more specific forms of investigation using 
methods that directly measure pathogen levels should be undertaken. No difference was found 
between CFX and CFT subgroups, indicating that levels of exposure to infection are similar 
throughout the CFS cohort.  
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Introduction 
Chronic Fatigue Syndrome (CFS) is a complex disorder that presents with a broad symptomology. It is 
primarily characterised by a chronic or recurrent debilitating fatigue (Holmes et al. 1988) that has 
lasted for six months or longer and is of unknown origin, but can be accompanied by various 
combinations of other non-specific symptoms.  CFS is thought to have a worldwide prevalence of 
0.006-3% of the population, with an Australian prevalence thought to be between 0.2-0.7% of the 
population (RACP, 2002). However, the criteria used to define CFS can vary greatly across the world, 
affecting the ability to reliably collect prevalence data. CFS presents with a higher incidence in 
women than men (Reid et al. 2000), and is less common in childhood or adolescence (Fernández et 
al., 2009) but due to its different manifestations and representations it is hard to gain accurate 
numbers due to variations in diagnoses. Currently there are various criteria used for diagnosis of 
CFS, the most common being those put forward by Fukuda et al. in 1994 and the Canadian 
guidelines for Medical practitioners in 2003. The main difference between the two being their 
approach to the psychiatric aspects of CFS; the Canadian guidelines have been found to select fewer 
patients with psychiatric co-morbidity and more patients with physical functional impairments, 
neuropsychiatric illnesses, fatigue/weakness and neurological symptoms than the outlines prepared 
by Fukuda et al. (Jason et al., 2004). 
 
1.1 Clinical History of Chronic Fatigue Syndrome 
CFS was first recognised in 1988 as a diagnostic entity by the Centre for Disease Control (CDC). Up 
until this point it had received varying nomenclature, the most common being Myalgic 
Encephalomyelitis (ME), yet it was also known as: neuromyasthenia, post-viral fatigue syndrome, 
chronic Epstein-Barr virus/mononucleosis syndrome, Icelandic disease, Akureyri disease, royal free 
disease, chronic brucellosis and fibromyalgia syndrome (Swenson, 2000). 
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 It has been suggested that CFS has originated from the disease neurasthenia which was commonly 
diagnosed in the late 19th Century. Neurasthenia had a very similar symptomology to modern day 
CFS, with bed-rest the common treatment course (Friedberg & Jason, 1998).  During the 20th Century 
there were various outbreaks of unexplained fatiguing illnesses, the two most prominent being in 
1934 at the Los Angeles County Hospital and in 1955 at the Royal Free Hospital in Great Britain. 
Although most of the patients in these cases recovered within a few months of onset, some 
remained chronically ill (Briggs & Levine, 1994). During the 1960’s and 70’s, a greater proportion of 
patients were diagnosed with chronic brucellosis as the cause for their excessive fatigue, however 
this was commonly viewed with mainly having psychiatric roots, including depression (Friedberg & 
Jason, 1998).  Several studies during the 1980’s linked chronic fatigue to infectious acute 
mononucleosis, and chronic Eppstein-Barr virus infection became an extensive diagnosis for those 
suffering long-term fatigue symptoms (Straus, 1991).  
 
 Since the CDC released its definition for CFS, it has been updated and altered to now include 
patients with psychiatric problems that it originally discounted. The prevalence of anxiety and 
depression in patients who typified CFS was too high to ignore. The current school of thought is that 
the psychiatric problems represent affective consequences of a constitutional disturbance that can 
also impose a failure to recover normally from infectious and other physical insults (Straus, 1991).  In 
2003 a new set of guidelines were released; the Canadian Guidelines for Medical Practitioners,  
which had its major criteria based around post-exertional malaise and fatigue, sleep dysfunction, 
pain, neurocognitive and neuroimmunoendocrine symptoms (Carruthers et al. 2003). There is no set 
laboratory test for CFS. This is currently being investigated, through looking for protein biomarkers 
and if discovered, will revolutionise the clinical approach to CFS (Devanur and Kerr, 2006).  
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1.2 Symptomology of Chronic Fatigue 
The most common symptom-based diagnostic criteria used for CFS is the Centre for Disease Control 
(CDC) guidelines (Fernández et al., 2009). These guidelines, developed primarily to standardise 
patient groups for research (Goshorn, 1998), state that “a CFS diagnosis requires three criteria: 
1. The individual has had severe chronic fatigue for 6 or more consecutive months that is not 
due to ongoing exertion or other medical conditions associated with fatigue (these other 
conditions need to be ruled out by a doctor after diagnostic tests have been conducted) 
2. The fatigue significantly interferes with daily activities and work 
3. The individual concurrently has 4 or more of the following 8 symptoms:  
o post-exertion malaise lasting more than 24 hours 
o unrefreshing sleep 
o significant impairment of short-term memory or concentration 
o muscle pain 
o pain in the joints without swelling or redness 
o headaches of a new type, pattern, or severity  
o tender lymph nodes in the neck or armpit 
o a sore throat that is frequent or recurring”. 
Of these symptoms, the post-exertion malaise (PEM), which is most commonly a feeling of 
discomfort or unease after any amount of exercise, is the most common. PEM is considered to be a 
symptom which is wholly unique to CFS (Davenport et al., 2011).  The CDC guidelines continue by 
adding a list of other ‘secondary’ symptoms which “are not part of the CFS case definition and do not 
contribute to the diagnosis of CFS” but are often present as additional symptoms in some patients. 
These symptoms include: abdominal pain, alcohol intolerance, bloating, chest pain, chronic cough, 
diarrhea, dry eyes or mouth, earaches, irregular heartbeat, jaw pain, morning stiffness, nausea, night 
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sweats, psychological problems (depression, irritability, anxiety, panic attacks), shortness of breath, 
skin sensations and weight loss.   The broad and variable nature of many of these non-specific 
symptoms makes CFS diagnoses difficult and often inconsistent. Similar to CFS is Fibromyalgia 
Syndrome (FMS) which is also characterised by an inconsistent symptomology so close to that of CFS 
that it has been shown that 70% of patients with FMS have coexisting CFS diagnoses, and conversely 
35-70% of patients with CFS diagnoses have a coexisting FMS diagnosis (Endresen, 2003).  
 
1.3 Aetiology of Chronic Fatigue Syndrome 
After more than 30 years of research, there is no consensus as to the etiological basis for CFS, yet 
there is an agreement that is it most likely to be multifactorial (Lorusso et al. 2009).  Early proposed 
theories of aetiology include: primary muscle disorder, chronic immune dysfunction, neuroendocrine 
disorder, primary sleep disorder and neuropsychiatric disorders (Farrar et al. 1995). Yet more recent 
research has indicated chronic infection may be a predisposing factor. Bacterial infections such as Q-
fever (Hickie et al., 2003), Rickettsia spp. (Unsworth et al., 2008), Chlamydophila pneumoniae 
(Nicolson et al., 2003), Mycoplasma spp. (Nijs, et al., 2002), Borrelia spp. (Treib et al., 2000; Gaudino 
et al., 1997) have all been indicated. Similarly viral infections such as, Epstein Barr (White et al. 
1998), HHV-6 Human Herpes virus – 6 (Buchwald et al. 1992) and Ross River Virus (Hickie et al., 
2006) have likewise been implicated as potential root causes of chronic fatigue.  There have also 
been genomic implications of Chronic Fatigue with five genes (APP, CREBBP, GNAS, PDCD2 and 
PDCD6) being found to have some involvement in the aetiology of the illness (Zhang et al. 2009). The 
disease mechanisms are complex, (White, 2004) but there are indications that infections and 
irregular immunological function contribute to, and maintain symptomology, and this may be 
influenced by interactions with genetic and psychosocial factors (Brurberg et al., 2014). The wide-
spread nature of the various factors that have been studied and found to have some effect in CFS 
adds further weight to the idea that there is no singular cause of CFS, and that there are many, non-
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exclusive factors that can give a patient a level of pre-disposition to CFS. It has previously been 
reported that 72% of sufferers report an infectious illness closely related with the onset of their CFS 
(Salit, 1997), However there is also research suggesting that the aetiopathogenisis may be attributed 
to negative and/or stressful life events and other non-infectious factors in the three – 12 months 
preceding CFS onset (Theorell et al., 1999).  International opinion appears to be growing towards 
differentiating CFS into clinically relevant sub-categories that could represent various disease states 
(Nijs et al., 2002). It is thought that one or more of these subgroups may include patients with 
chronic systemic infections that could potentially cause their illness, be a co-factor for the illness or 
cause an opportunistic infection that exacerbates the illness (Nijs et al., 2002). The importance of 
infection is an idea that is echoed by Englebienne and Meirleir, who note De Becker et al, 2002. 
when concluding that as causative agents; the hypothesis of immune dysregulation after a (viral) 
infection or persistent stealth infections remains eligible and that the simultaneous occurrence of 
infectious and non-infectious factors, seem to be important onset-associated events in CFS 
(Englebienne and Meirleir, 2002).  
 
1.4 CFS and Infection 
Research conducted in the previous two decades has noticed an association of CFS with chronic 
infections.  Research conducted has higher levels of apoptotic neutrophils in CFS patients, as well as 
decreased levels of viable neutrophils and increased annexin V binding than healthy participants. 
Increased neutrophil apoptosis is often a result of fighting pathogenic contagions and is a hallmark 
of systemic infection (Kennedy et al., 2003). These results give strength to the argument that CFS 
patients have underlying immune abnormalities. Similarly lower numbers of repressor T cell 
populations and increased CD8 activation markers (such as CD-38 and HLA-DR) have been noted in 
CFS patients compared to healthy controls, indicating immune disorders that have resulted from 
infectious agents (Landay et al., 1991). There is a large amount of cross over in the signs and 
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symptoms of CFS and those of chronic infections, especially some vector-borne diseases which have 
been linked with CFS such as Borreliosis and Rickettsiosis and Q-fever.  Bacterial infections such as 
Borrelia spp., Rickettsia spp. and Chlamydophila spp. can become intracellular and hence, develop 
protection from immune response in intracellular niches. Individual bacteria have developed 
immunoevasive techniques aiding them in establishing infections. Rickettsia species can escape 
destruction via phagocytosis through the secretion of lysins, which lyse the vacuolar membrane 
responsible for ingestion of intracellular organisms (Sansonetti, 2004). Similarly Mycoplasma and 
Chlamydophila are also obligate intracellular bacterial infections and have been detected in CFS 
patients (Chia & Chia, 1999; Nasralla et al., 2000; Nicolson et al., 2003).  Intracellular Chlamydophila 
infections can inhibit key host responses such as Bax, Bak and caspase-3 integration as well as 
blocking mitochondrial cytochrome C release (Fan et al., 1998). Chlamydophila have also been 
shown to possess a type III secretion system that can modulate its intracellular environment and 
potentially apoptosis (Finlay & McFadden, 2006). Through the establishment of chronic infection, 
intracellular pathogens have been shown to contribute to CNS inflammation (Contini et al., 2010) 
which has been linked “relatively specifically” to fatigue (Bower et al., 2011).  
 
1.5 Chronic Fatigue Syndrome and Lyme Borreliosis.  
Lyme Borreliosis (LB) is a vector-borne bacterial infection, the major vector being ticks (Bacon et al., 
2008).  LB is a multi-system infection with broad, non-specific clinical manifestations involving 
dermatological, neurological, musculoskeletal and cognitive components, which increases the 
likelihood of an initial misdiagnosis (Bhate & Schwartz, 2011).  LB is widely acknowledged in the 
Northern Hemisphere as a severe and debilitating infection and is treated with urgency as a result 
(Bacon et al., 2008). There were 194,400 cases of LB reported to the centre for disease control (CDC) 
in the United States between 2002 – 2009 (CDC, 2012). Current statistics estimate there may be as 
many as 300,000 people diagnosed with LB each year in the USA (CDC, 2013). The causative 
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organisms of LB is Borrelia burgdorferi sensu lato (bbsl), a group of spirochete bacteria, consisting of 
at least 23 genospecies, 18 of which have been well documented (Rudenko et al., 2011).  
Bbsl has advanced immuno-evasive techniques, where it can exist in three forms within the body; 
spirochete, dormant cystic form, or L- form (cell wall deficient). By alternating its state within the 
body, it can avoid detection from the host for long periods of time (Miklossy et al., 2008). This 
contributes to infections of Borrelia being hard to diagnose, as onset of symptoms can occur at a 
much later time than the original infection. Furthermore Bbsl has the ability to modify its outer 
surface proteins A-F (Osp A-F) to aid in the evasion of circulating immune cells. Osp A can interact 
with toll-like receptor 2 (TLR-2) and increase regulation of suppressors of cytokine signalling (SOCS) 
(Dennis et al., 2006). Osp C aids binding to host plasminogens, allowing Bbsl dissemination from the 
high-surveillance area of circulation into the tissues and low immuno-surveillance areas like the CNS 
and within the synovium (Sigal, 1997). Osp E aids in complement down-regulation through its 
binding to ‘factor H’ resulting in protection from complement pathways (Alitalo et al., 2001). Bbsl 
can also produce polysaccharide based adherent biofilms which further facilitate chronic infection 
(Stricker & Johnson, 2011).  
The geographical distribution of the known species of Borrelia demonstrates an adaptive ability. 
Only three species (Bbss, B.bissettii and B.carolinensis) are known to be common to Europe, America 
and Asia. There are four further species thought to be endemic to North America (B. americana, B. 
lonestarii, B.kurtenbachii and B. andersonii), and 11 species endemic to Eurasia including B. garinii, 
B. afzelii, B. bavariensis and B. japonica (Rudenko et al., 2011). In the last decade studies in Mexico 
(Gordillo-Perez et al., 2003) Northern Africa (Bouattour et al., 2004) and Cuba (Rodriguez et al., 
2012) have all confirmed the presence of Bbsl in areas previously thought to not contain LB, 
supporting that the notion of a novel Australian strain of Bbsl may be entirely possible. Furthermore, 
contra to the understanding that LB does not exist south of the equator (Franke et al., 2013), Bbsl 
infections have been reported in Brazil (Yoshinari et al., 2003) and Chile (Neira et al., 1996), and Bbsl 
10 
 
species in Ixodes pararicinus ticks in Uruguay  (Barbieri et al., 2013) and in Ixodes stilesi ticks in Chile 
(Ivanova et al., 2014).  
The potential for LB in Australia has been studied since the first reported case of a Lyme like illness in 
1982 (Stewart et al. 1982). While no novel strain has been identified, and the inability to infect 
Australian ticks with the American strain of B. burgdorferi (Piesman & Stone, 1991), ‘Borrelia-like 
spirochetes’ with antigens that were shared with Borrelia burgdorferi were isolated from the gut of 
two Australian ticks (Wills & Barry, 1991). Similarly there have been serological tests confirming the 
presence of 28 cases of LB thought to be acquired in Australia (Mayne, 2011). 
The NSW Department of Health denies the existence of locally acquired LB in Australia due to a lack 
of decisive evidence (NSW Government, 2012).  This is a contentious health debate in Australia, and 
recently the Australian government has established a clinical advisory committee that is currently 
advising clinicians to be open to the possibility of LB. However due to the multiple overlapping signs 
and symptoms, the majority of which are highly non-specific, CFS can be the diagnosis. In a pilot 
study held at the University of Sydney looking for locally acquired Lyme in 2012/13, 20% of patients 
diagnosed with Lyme disease also had CFS diagnoses from local physicians. The co-diagnoses are not 
limited to Australia, in a study conducted in the USA of patients referred to a LB clinic, 20% of 
patients tested serologically positive for underlying previous Lyme disease infection and had a 
different current illness, most commonly CFS. To further demonstrate the difficulty of diagnosing LB 
through symptomology alone, in the same trial 57% of patents did not have evidence of any LB 
infection; the majority of these were also found to have CFS (Steere et al., 1993).  It has even been 
suggested that the incidence of LB within the population could be ten times higher than the 
reported level due to underreporting of cases and common misdiagnosis (Young, 1998). This idea is 
supported by the 2013 CDC estimates mentioned earlier.  
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1.6 Chronic Fatigue and Chlamydophila pneumoniae (Chlamydia pneumoniae). 
Chlamydophila pneumoniae is an obligate intracellular parasite from the genus Chlamydophila. It 
was previously known as Chlamydia pneumoniae, and the names are often used interchangeably 
(Blasi et al., 2009). C. pneumoniae is a gram negative bacterium that is between 0.2-1µm. It has a 
unique biphasic life cycle split between being an infectious yet metabolically inactive elementary 
body (EB) when it is between hosts, and becomes a reticulate body (RB) after host lysosome 
phagocytosis, where it is non-infectious but metabolically active, often until the death of the host 
cell, where it will resume being an EB (Hammerschlag. 2000; Contini et al. 2010).  Transmission 
methods are still uncertain, but it is thought to occur via infected respiratory secretions as C. 
pneumoniae can survive within aerosol droplets (Theunissen et al., 1993). Recently, there have been 
large advances in undertstanding C. pneumoniae’s ability to cause chronic infections due to 
improvements in sensitivity and specificity of molecular analysis techniques and an expanding 
knowledge base. It has been seen that C. pneumoniae is able to create an intracellular niche for itself 
within a non-lysosomal vacuole where it is separated from cell cytoplasm and can regulate host cell 
signalling pathways, bypass host cell defence mechanisms and promote host cell survival or death, 
thus often rendering the host incapable of completely eliminating the pathogen (Yucesan & Siriam, 
2001; Stratton & Siriam, 2003; Stratton & Mitchell, 1997). By remaining within the host, C. 
pneumonaie is able to establish a state of chronic infection through which it colonises mononuclear 
cells, and commences a cyclical existence of inactivity with intermittent bursts of replication and 
antigenic variation (Contini et al., 2010). It is thought that C. pneumonaie may have developed an 
ability to cross into the CNS, as it can promote the migration of monocytes through human brain 
endothelial cells. The presence of the organism within the CNS may result in chronic injury 
(MacIntyre et al., 2003), or CFS inflammation (Contini et al., 2010), leading to the up regulation of 
inflammatory cytokines, which have been suggested to have an important role in CFS (Pall, 2000; 
Chao et al., 1992; Sheng et al., 1996). 
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C. pneumoniae antibodies in serological samples demonstrate an increasing level of exposure with 
age.  30-40% of the population contain antibodies by adolescence, and often over 80% of the elderly 
population also are serologically positive (Hammerschlag, 2000).  
 The research linking C. pneumoniae with Chronic Fatigue Syndrome is limited, yet fatigue is a 
common symptom of those who have evidence of persistent C. pneumoniae infections (Chia and 
Chia, 1999). C. pneumoniae upon development of chronic infection can up regulate heat shock 
proteins (HsP60) which may lead to the development of autoimmunity to Human HsP60, and 
consequentially to the development of some chronic diseases (Contini et al., 2010). It has previously 
been found that CFS patients who had titre levels that were elevated to anti-bodies for C. 
pneumoniae had improvements in serological and clinical symptoms when treated with one-to-two 
month courses of antibiotics (Chia and Chia, 1999). Similarly, it has been noted that C. pneumoniae 
has been found, more commonly as a co-infection with Mycoplasma spp. or Human Herpes Virus-6 
(HHV-6), in 7.5% of CFS patients (Nicolson et al., 2003). Some research conducted looking to link C. 
pneumoniae with CFS has previously established a link between the conditions, yet other studies 
have ruled out a connection (Komaroff et al., 2002).  
 
1.7 Chronic Fatigue and Mycoplasma pneumoniae. 
Mycoplasma pneumoniae is a minute bacterium from the class Mollicutes. They are a parasitic 
species that normally reside in epithelial linings (Dallo & Baseman, 2000). Mycoplasma’s miniature 
size and simple structure mean that they are the smallest self-replicating organisms but they are also 
the smallest in ultrastructure (Razin, 1999). M. pneumoniae has an elongated shape between 1-2µm 
long and less than 0.2µm in width (Waits and Talkington, 2004) and it is a parasite in the human 
respiratory tract.  Mycoplasmas lack a cell wall which may enable direct interaction with the 
cytoplasm of the parasite with that of its host. M. pneumoniae has several surface proteins that can 
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act as exposed adhesins (including P1 and P30) and others which can preserve distribution and 
nature of adhesins in the Mycoplasma membrane (Razin et al., 1998).  
 Mycoplasmas cause chronic, but normally mild infections that rarely kill their host (Razin, 1999). A 
M. pneumoniae infection usually manifests with sore throat, fever, cough, headache, chills, myalgia 
and general malaise (Waits and Talkington, 2004) and are similar to many of the symptoms of CFS.   
M. pneumoniae infections are often similar in symptomology to other atypical infections such as C. 
pneumoniae, and there is emerging evidence in both human and animal models that M. pneumoniae 
infection may precede and somehow intensify subsequent infections (Waits and Talkington, 2004).  
 In studies conducted on CFS and fibromyalgia syndrome (FMS) patients, using polymerase chain 
reaction (PCR) methods, Mycoplasma spp. blood infections can be detected in about 50% of patients 
with a CFS and/or FMS diagnosis, (Endresen, 2003). This is a large increase in the infection rate on 
healthy individuals, which is around 10% (Ryan et al., 2004). Similar results were found when 
Mycoplasma species were tested for in European CFS patients. Analysis of rates of infection in a 
group of 261 CFS sufferers found 68.6% to have some form of Mycoplasma spp. infection (the most 
prevalent being M. pneumoniae), as opposed to 5.5% of healthy controls tested (Nijs et al., 2002). 
These results are in accordance with earlier findings (Nasralla et al., 2000). 
 
The argument can be made that it is not clear whether the Mycoplasma spp. act as causal agents, 
cofactors or opportunistic infections in connection with the CFS/FMS. However it was found that 
most patients with CFS/FMS with mycoplasma infections were able to recover to their pre-illness 
health with long-term doxycycline antibiotic therapy (Endresen, 2003). It is argued that due to the 
similarities in symptomology between CFS/FMS and mycoplasma infection, as well as the fact that 
the infections and syndromes may be overcome through long-term antibiotic therapy that 
mycoplasma infection may open the door for a further sub-classification of CFS/FMS. This may help 
with the difficulties of classification and treatment of CFS (Endresen, 2003). Furthermore, 
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Mycoplasma spp. have been shown to have the ability to enter host cells through fusion, and exist as 
an intracellular pathogen (Rottem, 2002). Intracellular existence could facilitate the instigation of 
chronic or latent states of infection (Waits & Talkington, 2004). While the exact pathogenic factors 
M. pneumoniae uses to establish itself within host cells are unclear, it is shown to be able to survive 
and replicate within artificial cell culture systems (Dallo & Baseman, 2000). Intracellular existence 
can result in failure of some antibiotic therapies, explaining difficulties experienced in eradicating M. 
pnuemoniae in previous experimental work. Other Mycoplasma species have been shown to fuse 
with host cells that are not normally phagocytotic (Rottem, 2002). M. pneumoniae cell membrane 
and host cell wall fusion may result in the release of various hydrolytic enzymes, resulting in the 
insertion of mycoplasmal cell membrane components into the host cell membrane. This in turn, may 
effect cytokine expression and production and alter cell recognition sites (Rottem, 2002). The extent 
to which M. pneumoniae establishes chronic infection, and the subsequent effects are still being 
investigated, and the clinical significance is yet to be proven (Waits & Talkington, 2004), however the 
fatiguing effects of chronic infection have been well documented (Contini et al., 2010) 
 
1.8 Chronic Fatigue and Rickettsia spp. 
Rickettsia is a gram negative highly pleomorphic bacteria, that can present as rods, cocci or be 
‘thread-like’. It is an obligate intracellular parasite, with its survival depending on colonisation of 
host cytoplasm (Walker, 1996). Rickettsia is vector borne, harbouring in ticks, lice, fleas and mites 
(Azad and Beard, 1998). Rickettsia genus is split into two defined groups antigenically, spotted fever 
group (SFG) and typhus group (TG). Formerly there was a third group; scrub typhus group (STG), 
which differed physically through its lack of lipopolysaccharide and peptidoglycan layers, which has 
been reclassified into the related Orientia genus (Walker, 1996). SFG group contains nine different 
species of Rickettsia which are usually restricted to certain parts of the world, including R. rickettsia 
(Northern hemisphere) which can cause Rocky Mountain spotted fever, R. australis (Australia) which 
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can cause Australian tick typhus, R. felis (North and South America, Australia and Southern Europe) 
which can cause flea-borne spotted fever and R. japonica (Japan) which can cause Oriental spotted 
fever. TG group contains two groups, both of which are globally spread; R. prowazekii which can 
cause epidemic typhus and R. typhi which can cause Murine Typhus (endemic typhus) (Winkler, 
1990). The STG group consists of the species formally known as R. tsutsugamushi which is the 
causative agent of scrub typhus (Tamura et al., 1995). 
There are some consistent factors in the symptomology of the various conditions that Rickettsia 
species can cause; fever, headaches, rash, joint swelling and muscle pain are constant across the 
major conditions (Parola et al., 2005). All of these, except rash are notable symptoms of CFS via the 
CDC guidelines (Goshorn, 1998).  In an Australian study of patients with chronic illness including 
fatigue in 2007, rickettsial DNA was positive in real-time PCR testing in 3% of 526 participants as 
opposed to 0% of the 400 tested control participants (Unsworth et al., 2007) as well as positive 
serology titres of ≥ 1:256 were seen in 39% of patients in Melbourne and in 41% of patients in 
Adelaide. Only 15% of the control participants produced positive serological titres. Unsworth et al. 
concluded that rickettsial DNA or seropositivity could indicate underlying rickettsial diseases in 
patients with chronic illnesses including fatigue. The authors did acknowledge that the relationship 
between rickettsiae and the chronic illnesses of unknown origin may be causal, or be indicative of 
reactivation of latent rickettsial infection.  A similar relationship was noted in a 33-year old man in 
Sydney who experienced fatigue, fevers, joint pain, stiff joints and rashes. The man serologically 
tested positive to SFG and TG in tests conducted at periods up to two years following the initial day 
of presentation, although rickettsial PCR testing was negative.  The man was treated with 
Doxycycline, and the majority of symptoms resolved, the fatigue and other chronic symptoms lasted 
for two years however. The lack of response to repeated anti-microbial treatments allowed the 
authors to postulate the symptoms being indicative of some kind of post-infectious phenomenon as 
opposed to a chronic infection (Watts et al., 2008). There is, however the possibility that the 
rickketsial strain had developed resistance to doxycycline, as has been demonstrated before (Kim et 
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al., 2007). The positive serological tests, yet negative PCR test could be indicative of the Rickettsia 
having developed a chronic infection, having disseminated out of the blood stream. A chronic 
infection could explain the inability of the antibiotic therapy to completely rid the patient of the 
infection, as the doses may have been inadequate to penetrate the tissues where the bacteri was 
established. There is evidence of some forms of Rickettsia being able to develop chronic infections 
(Dobler et al., 2009).  
 
1.9 Aims of the Project. 
Current research reflects the lack of knowledge and understanding surrounding CFS. This project 
aims to investigate one theory of aetiology; that CFS may be due to a chronic bacterial infection.  
Using a case-controlled group of patients diagnosed with CFS, investigations will be conducted to 
detect four pathogens in peripheral blood that have been implicated in CFS; two tick-borne 
pathogens Borrelia spp. and Rickettsia spp. and two respiratory borne pathogens Chlamydophila 
pneumoniae and Mycoplasma pneumonia, using tests that include immunofluorescence assay (IFA), 
western blot, enzyme linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). It is 
hoped that any evidence of a relationship between underlying infections and CFS will be established, 
or at least indicate the necessity of further investigation.   
Through the use of detailed questionnaires, it is also hoped that further understanding of the 
symptomology and possible environmental risk factors for those who suffer from CFS can be gained. 
Furthermore, the CFS group will be divided into two subgroups; those with a previous diagnosis of 
an infection of a tick borne disease (CFT) and those without a previous diagnosis of an infection of a 
tick borne disease (CFX), to establish if there are any differences between the groups in relation to 
symptomology and pathogens detected. 
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Finally, by testing for certain organisms through more than one technique, it is hoped to establish 
which techniques are the most appropriate for testing for evidence of infection in an Australian 
setting and in particular for a Borrelia species which has not yet been identified in Australia.  
An important outcome of this study, and consequently any further research that is conducted in this 
field would be hopefully reducing the level of unnecessary morbidity in those with treatable 
infections as physicians may run serologic tests to assist with a differential diagnosis .  
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Materials and methods 
 
2.1 Study Outline and Human Ethics approval.  
A case-controlled pilot study that investigated the presence of tick-borne pathogens in participants 
with Chronic Fatigue Syndrome diagnoses was conducted between April 2013 and March 2014.  The 
study tested for evidence of exposure to Borellia spp., Mycoplasma pneumoniae, Rickettsia spp., and 
Chlamydophila pneumoniae.  The study was conducted at the Tick-Borne Diseases Unit (TBDU), 
School of Medical Sciences, The University of Sydney.  Human ethics approval was granted by the 
Human Research Ethics Committee (HREC), The University of Sydney (project number 2013/644 and 
2012/217). 
 
2.2 Recruitment of Participants. 
A cohort of 88 participants was recruited to take part in the study. This included 23 participants from 
a database of 133 participants enrolled in current studies being conducted by the TBDU investigating 
the role of tick-borne diseases in Australia. These participants were selected as they fit the criterion 
established for this study (see below). The remaining 65 participants were recruited through 
advertising – the majority through the Karl McManus Foundation and CFS/ME Australia and its state-
level subsidiaries. Furthermore some participants were recruited into the study via General 
Practitioners who were aware of the study and informed their patients. An information sheet 
regarding the study was sent to all potential participants who expressed interest in the study 
(appendix 1). 
The cohort was selected on the basis of all paperwork and blood samples being submitted by the 
10th of January 2014.  All participants had a diagnosis of Chronic Fatigue Syndrome from a licensed 
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medical practitioner; in some cases participants also had a previous diagnosis of a tick-borne 
disease. The participants were placed into groups accordingly. 
A total of 29 age and sex matched controls were selected from the TBDU’s database of existing 
controls or were recruited during the study.  
Upon the completion of the appropriate signed consent form (appendix 2) being returned, each 
participant was enrolled in the study. The consent form for participants recruited from a previous 
study is shown in appendix 3. Participants were given individual participant codes, and asked to 
complete and return a reference questionnaire (Appendix 4) and a symptomology questionnaire 
(Appendix 5) The participants were also given a pathology request from for a commercial pathology 
centre that was close to their location, and asked to have  blood samples taken.  
 
2.3 Assessing Participants.  
The reference questionnaire allowed researchers to develop an understanding of the demographical 
variation of the participants. Information obtained included; age, sex and residence as well as travel 
history, details of tick exposure risks including pet ownership and outdoor activity, past history of 
tick bites and tick-borne illnesses and current forms of treatment, both anti-microbial and non-anti-
microbial.   
The symptomology questionnaire was based on Burrascano’s (2008) Lyme disease questionnaire. It 
covered a variety of signs and symptoms that are evident in a multitude of tick-borne diseases.  The 
signs and symptoms were classed in various categories including; musculoskeletal, neurological, 
systemic, cognitive and behavioural, cardiovascular, sensory, respiratory, gastrointestinal and 
genitourinary. The participants were asked to score on a scale of 0-3 the severity of each symptom, 
with the scores reflecting none (0), mild (1), moderate (2) or severe (3). Similarly, the participants 
were asked to score on a scale of 0-3 the frequency of each symptom, with the scores reflecting: 
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never (0), occasional (1), often (2) or constant (3). To establish a comparable result for each 
symptom, the severity score was multiplied by the frequency score.  
 
2.4 Blood collection protocol.  
For the majority of participants, pathology requests were emailed to them for local commercial 
pathology centres. Most of the pathology centres used were subsidiaries of Sonic Healthcare in each 
State; i.e. Douglass Hanly Moir in NSW, Clinipath in WA. Alternatively, other pathology centres were 
used, (QML pathology – QLD, Abbott Pathology – SA, Laverty – NSW). The blood was collected by a 
trained phlebotomist at the commercial centres and couriered to the TBDU at The University of 
Sydney.  
Each participant had 9mL of blood collected – consisting of; 2 x 3 mL whole blood samples in 
anticoagulant EDTA as well as 1 x 3 mL serum separating tube (SST) sample. Plasma was obtained by 
placing one of the whole blood samples in centrifuge at 2000 g for 10 minutes at room temperature 
(RT). Serum was obtained by centrifuging the SST tube under identical conditions. 200 µL aliquots of 
serum, plasma and whole blood were labelled with the participant’s unique ID code, and stored at    
-20:C until needed.  
 
2.5 DNA analysis through Polymerase Chain Reaction (PCR).  
 Detection of pathogens through PCR is enabled through amplification of a specific isolated region 
within a gene and analysis of the sequence allows speciation of any pathogen. Nested PCR, a 
modified form of PCR, was also performed throughout this study. Nested PCR employs the use of 
consecutive rounds of reactions using two primer sets. The original primer set, known as the 
external primers, is used to amplify a large region of the gene. The product of this original reaction is 
used in the second reaction with the second set of primers, the internal primers, used to amplify a 
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more specific target region of the gene. Nested PCR has increased specificity, sensitivity and quality 
of products compared to regular PCR (Waldenström et al. 2004).  
 
2.5.1 DNA extraction from Whole Blood 
Whole blood samples were treated as per the manufacturer’s instructions on Isolate II blood DNA kit 
(Bioline) to extract total genomic DNA. Briefly outlined; 200µL of whole blood was added to 25µL of 
Proteinase K and 200µL of lysis buffer. Samples were vortexed and incubated at 70:C for 15 minutes 
to allow for cell lysis. Following incubation  100% ethanol (210µL) was added and the sample 
vortexed and transferred into an Isolate II DNA spin column and collection tube  and centrifuged for 
one minute at 11,000g. The spin column was placed in a new collection tube and 500µL of wash 
buffer 1 was added. The sample was centrifuged under the same conditions, and the spin column 
was placed into a new collection tube. Wash buffer 2 (600µL) was added and the sample centrifuged 
as previously. The collection tube was emptied and any excess liquid was extracted through further 
centrifuging.  The spin column was placed in an 1.5mL eppendorf tube and elution buffer (100µL) 
was added incubated for 1min at RT. The sample was then centrifuged once more. The spin column 
was discarded and the genomic DNA collected in the microcentrifuge tube was stored at -20:C until 
required.  
2.5.2 PCR primer design and primer selection.  
2.5.2.1 Borellia burgdorferi  
A search was undertaken for a significant genetic marker in Borrelia spp. that was well conserved 
across species. Plasmid genes that encode the surface proteins such as Osp A, Osp B and Osp C have 
been shown to be highly variable (Lin et al., 2002), and therefore were unsuitable. The genes 
encoding rRNA are well conserved in both ribosomal sub units, especially rrs encoding 16s in the 
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small ribosomal subunit (Fraenkel et al., 2002). Primers from Wodeka et al., 2010 were used as they 
were selective for rrs and had been previously used to enable comparison. 
2.5.2.2 Rickettsia spp.  
Across the traditional classification subgroups of the Rickettsial species; TG (Typhus Group - which 
contains R. typhi and R. prowazekii), SFG (spotted fever group – which contains the remainder of 
Rickettsial species) and the STG (scrub typhus group – which contains the now re-classified Orientia 
tsutsugamushi) (Tamura et al., 1995) there is genetic variation. The two groups of primers derived 
from Roux and Raoult, (2000) were chosen as they are specific for the rOmpB protein. This protein 
has an outer membrane location and would be present in members of the SFG and TG as 
demonstrated through the presence of mutually common epitopes.  The third set of rickettsial 
primers were chosen to target the rOmpA protein. The rOmpA protein is another well characterised, 
high molecular mass (135 kilo Daltons), immunodominent protein (Stenos et al., 1996).  Unlike the 
rOmpB protein, rOmpA has been shown to be absent in the TG group, and slightly more variable. 
Across the three sets of rickettsial primers used all three classification groups of Rickettsia spp.  
would be detected.  Nested primers directed against the 56kDa TSA (type-specific  antigen) gene 
were employed to detect Orientia tsutsugamushi DNA (Yang et al., 2012) 
2.5.2.3 Mycoplasma pneumoniae. 
Forward and reverse primers were selected from those used in studies by Chan et al. 2013 and 
Lucier et al., 1995.The chosen primers targeted the M. pneumoniae 23S rRNA  and were used to 
amplify the peptidyl transferase region. 23S rRNA is highly conserved in Mycoplasma spp. and 
although point mutations can occur, sometimes leading to various levels of antibiotic resistance, the 
targeted section remained a viable PCR objective.  
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2.5.2.4 Chlamydophila pneumoniae.  
Nested PCR was used to amplify the omp1 gene, a major outer surface protein on Chlamydophila 
pneumoniae. It is thought that the mRNA encoding omp1 may be in indicator for the metabolic 
and/or replicative form of C. pneumoniae (Valassina et al., 2001). The primers used were taken from 
a 2010 study by Dresses-Werringoloer et al. as they enabled the authors to reveal genetically diverse 
chlamydial populations. (Dresses-Werringoloer et al., 2010). 
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Table 2.1 PCR Primers used in this study   
Target Gene Target Primer Name Sequence (5’-3’) Reference 
Mycoplasma 
pneumoniae 
 
V domain 23S rRNA 
ext. 
 
V domain 23S rRNA 
int. 
MYCN11758F 
MYCN12684R 
 
MYCN21719F 
MYCN22154R 
GCAGTGAAGAACGAGGGG 
GTCCTCGCTTCGGTCCTCTCG 
 
TGGGGTGACACCTGCCCACT 
CCGCCCCAGTCAAACTGCCC 
Chan et al., 2013 
Chlamydophila 
pneumonia 
Omp1 CHLOMP1N1F 
CHLOMP1N1R 
 
 
CHLOMP1N2F 
CHLOMP1N2R 
AAGGCCGTTTTTCAATGATAAGAG
CTTCCT 
GTCTTGATGTGATGTGAAGTAGG 
 
TGCCTGCAGGATATCTTGTC 
TGTAGACTCTGATAACAAGGTGAG
GAG 
Dresses-
Werringoloer et 
al., 2009 
Orientia 
tsutsugamushi 
56-kDa TSA TSU34N1F-19-38 
 
TSU55N1R-1032-
1013 
 
TSU10N2F-408-428 
 
TSU11N2R895 -876 
TCAAGCTTATTGCTAGTGCAATGTC
TGC 
AGGATCCCTGCTGCTGTGCTTGCTG
CG 
 
GATCAAGCTTCCTCAGCCTACTATA
ATGCC 
CTAGGGATCCCGACAGATGCACTA
TTAGGC 
Yang et al., 2012 
Rickettsia spp. rOmpB R120-M59F 
R120-1497R 
CCGCAGGGTTGGTAACTGC 
CCTATATCGCCGGTAATT 
Roux and Raoult, 
2000 
Rickettsia spp. rOmpA R190.70F 
R190.701R 
ATGGCGAATATTTCTCCAAAA 
GTTCCGTTAATGGCAGCATCT 
Fournier et al., 
1998 
Rickettsia spp. rOmpB R120-1378F 
R120-2399R 
TAAACTTGCRGACGGTACAG 
CTTGTTTGTTTAATGTTACGGT 
Roux and Raoult, 
2000 
Borellia spp.  rrs  RRS-O19F 
RRS-593R 
RRS-38F-RLB 
RRS-1-472R-BOR 
AGAACTAACGCTGGCAGTG 
TGCATAGACTTATATATCCGCC 
CGTCTTAAGCTAGCAAGTCAACG 
CGTCATCACTTTGTCATTTCCTACA 
Wodeka et al., 
2010 
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2.5.3 PCR Conditions 
All PCR tests contained the following: 
5 µL of 10 X ThermopolTM Buffer (New England Biolabs, USA); 1 µL of 50mM MgCl2 (Bioline, 
Australia); 1 µL of 10mM dNTPs; 1 µL of the appropriate forward and reverse primers (Sigma-Aldrich, 
Australia); 1 µL Taq DNA Polymerase (New England Biolabs, USA) and 5 µL of purified genomic DNA , 
or in the case of a second round of nested PCR, 5 µL of PCR product from the first nested run. The 
samples were made up to 50 µL with molecular grade water.  
For the testing of all Rickettsial and Oriential species, control positive DNA samples were used as 
supplied by The Australian Rickettsial Research Laboratory; Orientia tsutsugamushi, Rickettsia Typhi 
and Rickettsia honei were all used. The control DNA was set up as outlined above, the only 
difference was 2 µL of DNA was used  in the positive control PCR . 
Cycling Conditions 
All PCR reactions were undertaken in a Bio-Rad T1000 thermal cycler and were optimised to run for 
the individual primers, as outlined below: 
 PCR testing for Mycoplasma pneumoniae V domain in 23rRNA 
First Round: Initial denaturation at 95:C for three minutes. 40 cycles of denaturation at 95:C for 30 
seconds, annealing at 67:C for 30 seconds and extension at 68:C for 60 seconds. Final extension step 
at 68:C for five minutes.  
Second Round: Initial denaturation at 95:C for three minutes. 45 cycles of denaturation at 95:C for 
30 seconds, annealing at 65:C for 30 seconds and extension at 68:C for 60 seconds. Final extension 
step at 68:C for five minutes. 
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Testing for Chlamydophila pneumoniae Omp1 
First Round: Initial denaturation at 95:C for three minutes. 35 cycles of denaturation at 95:C for 30 
seconds, annealing at 55:C for 30 seconds and extension at 68:C for 45 seconds. Final extension step 
at 68:C for five minutes.  
Second Round: Initial denaturation at 95:C for three minutes. 45 cycles of denaturation at 95:C for 
30 seconds, annealing at 58:C for 30 seconds and extension at 68:C for 60 seconds. Final extension 
step at 68:C for five minutes. 
 
Testing for Orientia tsutsugamushi 56-kDa TSA 
First Round: Initial denaturation at 95:C for three minutes. 37 cycles of denaturation at 95:C for 30 
seconds, annealing at 65:C for 30 seconds and extension at 68:C for 30 seconds. Final extension step 
at 68:C for five minutes.  
Second Round: Initial denaturation at 95:C for three minutes. 45 cycles of denaturation at 95:C for 
30 seconds, annealing at 65:C for 30 seconds and extension at 68:C for 45 seconds. Final extension 
step at 68:C for five minutes. 
 
Testing for Rickettsia spp. rOmpA 
 Initial denaturation at 95:C for three minutes. 45 cycles of denaturation at 95:C for 30 seconds, 
annealing at 57:C for 30 seconds and extension at 68:C for 60 seconds. Final extension step at 68:C 
for five minutes.  
 
 
27 
 
Testing for Rickettsia spp. rOmpB 
Using R120-M59F & R120-1497:  Initial denaturation at 95:C for three minutes. 45 cycles of 
denaturation at 95:C for 30 seconds, annealing at 51:C for 30 seconds and extension at 68:C for 60 
seconds. Final extension step at 68:C for five minutes. 
Using R120-1378F & R120-2399R: Initial denaturation at 95:C for three minutes. 45 cycles of 
denaturation at 95:C for 30 seconds, annealing at 52:C for 30 seconds and extension at 68:C for 60 
seconds. Final extension step at 68:C for five minutes. 
 
Testing for Borrelia spp. rrs 
First Round: Initial denaturation at 95:C for five minutes. 39 cycles of denaturation at 95:C for 30 
seconds, annealing at 50:C for 30 seconds and extension at 68:C for 60 seconds. Final extension step 
at 68:C for five minutes.  
Second Round: Initial denaturation at 95:C for three minutes. 46 cycles of denaturation at 95:C for 
30 seconds, annealing at 61:C for 30 seconds and extension at 68:C for 60 seconds. Final extension 
step at 68:C for five minutes. 
 
2.5.4 PCR Product Purification 
2.5.4.1 Direct Purification of PCR Product 
PCR products that produced a single clean band via gel electrophoresis were purified directly using the 
QIAquick® PCR Purification Kit. All centrifugation steps were performed at 17 000 x g for 1 minute at RT. Five 
volumes of Buffer PB were added to 1 volume of PCR product and vortexed. 10μL of 3 M sodium acetate 
(pH 5.0) was added to maintain optimal pH conditions. The sample was vortexed again and added to a 
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QIAquick column inside a collection tube and centrifuged. To wash, 750 μL of Buffer PE was added to the 
column and the centrifugation step repeated. Flow-through in the collection tube was discarded and the 
column was centrifuged again to remove residual wash buffer. The column was placed in a sterile 1.5 mL 
microcentrifuge tube. To elute DNA, 50 μL of elution Buffer, EB (10 mM Tris·Cl, pH 8.5) was added to the 
centre of the membrane and the column was incubated for 3 minutes at RT prior to final centrifugation. 
Purified DNA was stored at -20°C until required for sequencing.  
 
2.5.4.2  Purification of Multiple bands via Low Melting Temperature Agarose Gel 
When multiple bands were present, PCR products were purified using the ISOLATE II PCR and Gel Kit 
(Bioline, Australia). The total remaining volume of PCR product (≈40 μL) was electrophoresed through a 
1.5% UltraPure™ Low Melting Point Agarose (Invitrogen, USA) gel with 2 μL SYBR green (Invitrogen,USA) in 
TAE buffer. Bands were excised under blue light using a sterile scalpel blade. A new scalpel blade was used 
for each band to prevent cross-contamination of DNA. The excised bands were placed in individual sterile 
1.5 mL microcentrifuge tubes. 200 μL of Binding Buffer CB was added and the sample was incubated at 50°C 
for 10 minutes, with intermittent vortexing, to solubilise the gel fragment.  The sample was loaded into an 
ISOLATE II PCR and Gel Column placed inside a collection tube. The column was centrifuged for 1 minute at 
11 000 x g at RT. The flow-through was discarded. To wash, 700 μL of Wash Buffer CW was added to the 
column and centrifuged. The washing step was repeated and flow-through discarded. To dry the silica 
membrane and remove residual ethanol the column was centrifuged again. The column was placed in 1.5 
mL microcentrifuge tube. To elute DNA, 30 μL of Elution Buffer C was added directly to the membrane and 
allowed to incubate at RT for 3 minutes before a final centrifugation step. Purified DNA was stored at -20°C 
until use. 
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2.5.5 DNA Sequencing 
PCR products were sent to the Australian Genome Research Facility (AGRF) (Westmead Millennium 
Institute) for DNA sequencing.  AGRF guidelines for sample preparation were followed (www.agrf.org.au/). 
Purified DNA was quantified using the Nanodrop ND-1000 spectrophotometer and depending on the 
product size, up to 75 ng of purified DNA was added to 1 μL of forward or reverse primer and the total 
volume was brought up to 12 uL with DNase and RNase free dH2O (Invitrogen, USA). Returned sequences 
were compared to sequence data in the Genbank® database using the Basic Local Alignment Search Tool 
(BLAST®) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to identify the DNA sequence to organism species and 
gene.   
 
2.6 Western Blot to measure immune response to Borrelia (IgM and IgG) 
To investigate the presence of antibodies, both IgG and IgM, participant serum was assayed for 
presence of B.burgdoferi sensu sricto, B. garinii and B. afzelii immunoglobulins. The Euroimmun kits 
employed in this study are validated and are used in commercial diagnostic laboratories globally and 
EUROlinescan (Euroimmun, Germany) computer software was employed to analyse western blot 
strips. 
 
2.6.1 Whole Cell Antigen Western Blots: 
To ensure the investigation of potential native epitopes whole cell antigen WBs were utilised 
containing whole antigens from the bacteria as opposed to recombinant proteins. To produce the 
test strips, cultured Borellia strains were solubilised using sodium dodecyl sulphate, the proteins 
were separated according to molecular mass by gel electrophoresis and then transferred onto 
nitrocellulose. 
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 The protocol was followed as set out by manufacturer’s instructions. Briefly, 1.5mL of 1x universal 
buffer was added to each well, and a WB test strip was added. The strips were incubated at room 
temperature on a rocking shaker for 15 minutes in a process known as blocking. Universal buffer 
(1.5mL) was used to dilute participant’s serum (30µL) sample to 1:51. The serum samples were 
added to the test strips after the 15 minute blocking process had been completed and the universal 
buffer solution had been aspirated. Serum samples (1:51 dilution) were incubated on the test strips 
at room temperature on a rocking shaker for 30 minutes. Following this, the serum samples were 
aspirated from the test strips, which were then washed with universal buffer three times for five 
minutes with shaking. At the end of the third wash, the buffer solution was aspirated and 1x Enzyme 
conjugate solution (1.5mL) was added to the test trips and incubated at room temperature for 30 
minutes with rocking. Conjugate solution was aspirated and test strips were washed three times as 
before. NBT/BCIP substrate solution (1.5ml) was added to each well and the test stripes were 
incubated for 10 minutes at room temperature on a rocking shaker. Reaction was stopped by 
aspirating the substrate solution from the test strip followed by three washes (1.5mL of deionised 
water) for one minute with rocking at room temperature.  
The WB test strips each had a control band which, depending on the time each solution was left to 
react with the test strips, would darken accordingly. This helped to control for differences in the 
incubation times as the intensity of the colour on the control band was measured by the computer 
software, which standardised the results accordingly to ensure fair comparison between tests.  
The specificity and target of each test antigen for the whole cell antigen western blot test are 
outlined in the appropriate tables below: 
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Table: 2.2 Antigen composition of B. afzelii western blot strips 
Test: 
B.afzelii 
  Band Antigen  Specificity 
VlsE Variable major protein-like 
sequence, expressed 
Specific 
83 kDa Membrane - vesical protein, p 
83 
Degradation product of p 100, high specificity 
41 kDa Flagellin, p 41 Genus specific, cross reactivity to other 
spirochaetaceae and bacteria having flagella 
39 kDa Bmp A, p 39 High specificity 
31 kDa Osp A, p 31 Outer surface protein A, high specificity 
30 kDa p 30 Specific 
25 kDa Osp C, p 25 Outer surface protein C, high specificity 
21 kDa p 21 Specific 
19 kDa p 19 Specific 
17 kDa p 17 Specific 
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Table 2.3 Antigen composition of B. burgdorferi western blot strips 
 
Test: B. 
burgdorferi 
  Band Antigen  Specificity 
83 kDa Membrane - vesical protein, p 
83 
Degradation product of p 100, high specificity 
75 kDa Heat shock protein, p 75 Unspecific. 
62 kDa Heat shock protein, p 62 Unspecific. 
57/59 kDa p 57 and p 59 Unspecific. 
50 kDa p 50 Unspecific. 
47 kDa p 47 Probably genus specific. 
43 kDa p 43 Unspecific. 
41 kDa Flagellin, p 41 Genus specific, cross reactivity to other 
spirochaetaceae and bacteria having flagella 
39 kDa Bmp A, p 39 High specificity 
36 kDa p 36 Specificity unclear 
34 kDa Osp B, p 34 Outer surface protein B, High specificity 
32 kDa p 32 Unspecific. 
31 kDa Osp A, p 31 Outer surface protein A, high specificity 
29 kDa p 29 Probably specific, poorly investigated 
28 kDa p 28 Unspecific. 
25 kDa Osp C, p 25 Outer surface protein C, high specificity 
21/22 kDa p 21/22 High specificity 
18 kDa p 18 Probably specific 
17 kDa p 17 Poorly investigated 
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Table: 2.4  Antigen composition of B. garinii western blot strips 
 
Test: B. 
garinii 
  Band Antigen  Specificity 
83 kDa Membrane - vesical protein, p 
83 
Degradation product of p 100, high specificity 
75 kDa Heat shock protein, p 75 Unspecific. 
62 kDa Heat shock protein, p 62 Unspecific. 
57/59 kDa p 57 and p 59 Unspecific. 
50 kDa p 50 Unspecific. 
47 kDa p 47 Probably genus specific. 
43 kDa p 43 Unspecific. 
41 kDa Flagellin, p 41 Genus specific, cross reactivity to other 
spirochaetaceae and bacteria having flagella 
39 kDa Bmp A, p 39 High specificity 
37 kDa p 37 Specificity unclear 
31 kDa Osp A, p 31 Outer surface protein A, high specificity 
28 kDa p 28 Unspecific. 
25 kDa Osp C, p 25 Outer surface protein C, high specificity 
21/22 kDa p 21/22 High specificty 
19 kDa p 19 Specific 
 
 
2.6.2 Recombinant antigen Western blots IgG: 
Recombinant antigen Western blots were used to test and compare results from the whole cell 
antigen kits. The recombinant blots are developed from a unique mix of Borrelia specific antigens. 
The kits were supplied by EuroImmun (Germany) the blots also contained antigens for VslE for each 
strain of Borrelia tested for in the whole cell antigene testing.  The Osp C antigen used was created 
through a combination of Osp C antigens from the three Borrelia species used for the whole cell 
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antigen testing. This allows the serological hit rate to increase by 10%. The recombinant blots also 
contained antigens to lipids, which have been proven to be immunoreactive and had been extracted 
from the Borrelia membrane. The full list of antigens and specificity used in the recombinant blots is 
seen in table 2.5. 
 
Table 2.5 Antigen composition of recombinant IgG western blot strips 
Test:  Recombinant IgG 
 Band Antigen  Specificity 
VIsE-Ba Variable major protein-like sequence, expressed Specific, B. afzelii 
VIsE-Bb Variable major protein-like sequence, expressed Specific, B. burgdorferi 
VIsE-Bg Variable major protein-like sequence, expressed Specific, B. garinii 
Lba 
  LBb 
  83 kDa Membrane - vesical protein, p 83 Degradation product of p 100, high specificity 
  p 58 
 41 kDa 
 
Flagellin, p 41 
 
Genus specific, cross reactivity to other  
spirochaetaceae and bacteria having flagella 
39 kDa Bmp A, p 39 High specificity 
25 kDa Osp C, p 25 Outer surface protein C, high specificity 
21 kDa p 21 Specific 
20 kDa p20 Probably specific 
19 kDa p 19 Specific 
18 kDa p 18 Probably specific 
 
2.7 Quantifying Western Blot IgG and IgM results 
Euroimmun (Germany) computer software ‘EUROLineScan’ was used to measure the intensity of 
each band on the WB test trips. As a result of the different cultures producing a variety of test strips, 
each kit contained a positive control strip which corresponded to that specific set of WB test strips. 
To ensure reliability, the recommended scanner by Euroimmun, the Cannon LiDE 110 was used to 
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scan the positive control and test strips. Protocols were made with each participants ID code, the 
type of test and individual positive control number and each test strip. The protocol was then 
scanned into the results program and evaluated by the EUROLineScan program. The software used 
the positive control band to align the test strip so as to test the correct areas for bands indicating 
presence of antibody, as well as mediate the intensity of the bands. The software produced arbitrary 
intensity readings at each point along the test strip where a coloured band was located. 
Comparisons between tests and kits were able to be conducted as the computer software 
standardised the readings via the intensity of the control band on each test strip. All scores and 
scanned images were stored for later analysis. 
 
2.8 Rickettsial Immunofluorescence Assay (IFA) 
IFA kits were obtained from the Australian Rickettsial Reference Laboratory (Geelong, Australia). 
Each slide consisted of 30 wells containing rickettsial antigens that were acetone fixed on the slide at 
optimal working concentration. Each slide had ten wells of each; a Spotted Fever group (SFG) that 
contained antibodies to Rickettsia australis and Rickettisa honei, a Typhus group (TG) that contained 
antibodies to Rickettsia typhi and Rickettsia prowazekii, and Scrub Typhus Group (STG) that 
contained antibodies to Orientia tsutsugamushi strains Gilliam, and Sido. The slides were arranged 
as below:  
 
  
 
 
 
 
 
SFG 
TG 
STG 
Blank 
RRL 
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All test sera was diluted 1:128 in 2% casein phosphate buffered saline. A positive control serum was 
added to the first column of each well, and a negative control serum was added to last column of 
each well. The test sera was added and then incubated for 30 minutes at 37:C in a humidified 
container. The slides were then washed in a phosphate buffered saline solution (1:10 dilution) for 
five minutes and then dried. 2µL of pre-prepared anti-human (IgG+IgM+IgA) serum conjugate 
labelled with fluoroscein (1:50 dilution) was added to each well, and the slides incubated for a 
further 30 minutes at 37:C in a humidified container. The wash procedure was repeated, mounting 
fluid was added to the slides and a cover slip placed over the wells.  
Slides were examined using a 63x oil immersion objective on a Zeiss Deconvolution fluorescence 
microscope using a FITC filter. Slides were imaged using Zen software (Carl Zeiss Microscopy, 
2012).When reading the IF, the positive and negative control wells were checked first. The slides 
were discounted if all rickettsial antigens did not fluoresce in the positive wells or if there was 
specific or obvious fluorescence in the negative wells. The test wells were considered positive if they 
fluoresced in a similar way to the positive control wells and were obviously dissimilar to the negative 
control wells.  
2.9 Enzyme Linked Immunosorbent Assay (ELISA) for detection of Chlamydophila pneumoniae, 
Mycoplasma pneumoniae and Borrelia burgdorferi. 
Separate enzyme immune assays were used for qualitative determination of each; IgG and IgM class 
antibodies against Borellia burgdoferi, Mycoplasma pneumoniae and Chlamydophila pneumoniae. 
Kits were obtained from NovaTec (Germany), and are used by diagnostic laboratories globally.  
Each kit contained; a 96-well Greiner clear bottom ELIZA plate, sample diluent and conjugate and 
tetramethylbenzidine (TMB) substrate solution that had been prepared for each tests. There was 
also positive, negative and cut-off control samples and 20X washing solution.  
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Participant and control serum samples were brought to room temperature, centrifuged and then 
diluted 1:101 and vortexed. 100 µL of controls and diluted samples were dispensed into respective 
wells, leaving blank wells for reference, the wells were covered and incubated at 37:C for one hour. 
The liquid was then aspirated out of the wells and each well was washed three times with 300µL of 
diluted washing buffer. Care was taken to ensure that there was no overflow between wells and that 
the minimum soak time between each was cycle was greater than five seconds. 100µL of supplied 
conjugate was dispensed into each well, excluding blanks, the plate was covered and incubated for 
30 minutes at room temperature out of direct sunlight. The triple wash was then repeated. 100µL of 
TMB substrate solution was dispensed into all wells, and the plate was incubated for exactly 15 
minutes at room temperature in the dark. Immediately following this, 100µL of stop solution was 
added to each well.  
 
2.9.1 Measuring and analysing ELISA results 
The ELISA plates were read using Fluostar Omega microplate reader at 450nm and again at 620nm 
for reference. The absorbance data was analysed using MARS data analysis software. In order for an 
assay to be considered valid, the run had to meet the following criteria; 
Substrate blank – Absorbance value < 0.100  
Negative control – Absorbance value <0.200 and < cut-off 
Cut-off control – Absorbance value 0.150-1.30 
Positive control – Absorbance value > cut-off 
If the run did not meet the criteria it was considered invalid and was repeated.  
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2.9.2 Calculation of ELISA results 
The cut-off value was determined by the mean absorbance value of the cut-off control wells. 
Samples were considered positive if they had an absorbance value 10% above the cut-off. Samples 
were considered negative if they had an absorbance value 10% below the cut-off. All samples that 
returned absorbance values of less than 10% over or under the cut-off were deemed inconclusive 
and were repeated. If a repeated sample returned a second inconclusive absorbance value, the 
sample was deemed negative.  
 
2.10 Statistical Analysis 
Data obtained from the reference questionnaire determining differences in risk exposure was 
compared to those of the control group for reference. The data was analysed using independent 
samples t-test for continuous data and chi-squared test for nominal data. The analysis was 
undertaken between the test and control groups, and then between the subgroups and control 
group. Differences in symptomology, as detailed through the signs and symptoms questionnaire 
filled out by all participants and controls, was analysed through ANOVA to determine the level of 
significance. Observed differences between the groups and individual significance between 
subgroups was generated through the use of the Games-Howell post hoc test. This form of post-hoc 
analysis was chosen due to its ability to account for variance within the mean and cohort numbers 
‘n’ (Howell, 2002).  
Experimental results were tested against each other and in conjuncture to observe patterns.  
Positive/negative results, such as those from ELISA and IFA testing were compared to each other 
using chi-squared analysis. Scalar data such as those produced by individual antigenic responses to 
western blot tests were analysed using a combination of the Mann Whitney U test, a non-parametric 
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test of the null hypothesis, and the Vargha Delaney A test, which establishes degrees of effect 
magnitude . 
For the establishment of cut-off values within those antigens that were deemed important through 
the Mann Whitney and Vargha Delaney tests, individual antigenic receiver operating characteristic 
(ROC) curves were generated to identify a cut-off threshold to account for non-specific binding. The 
number of band intensity responses generated against each antigen above the new ‘cut-off’ value 
was established, and the summed positive values used to create a secondary ROC. The signal 
strength generated from this secondary ROC allowed calculation of combined positive response 
variations, to display positive signals for each participant, and thus the calculation of an overall 
threshold value.  
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Results 
3.1 Epidemiological Data 
A cohort of 65 participants were recruited and a further 23 were selected from 133 participants 
currently partaking in other studies being conducted by the Tick Borne Disease Unit (TBDU) at the 
University of Sydney. The cohort was selected upon the basis of having a clinical diagnosis of Chronic 
Fatigue Syndrome (CFS) and returning all blood samples, and completed questionnaires by January 
13th 2014. The participant cohort will be referred to as the ‘test group’ from hereon in. The test 
group was split into two subgroups; the CFT and CFX subgroups. ‘CFT’ subgroup consisted of those 
participants with a pre-exisiting diagnosis of CFS and of any diagnosis of previous or current 
exposure to infections known to be carried by ticks including; Borrelia spp., Bartonella, Babesia or 
Rickettsia spp . The ‘CFX’ subgroup consisted of those participants with a pre-existing diagnosis of 
CFS, but not with a diagnosis of a disease transmissible through tick bite. Together they were 
referred to as the ‘test group’. A control group of 29 age and sex-matched participants were chosen 
from those currently enrolled in studies at the TBDU.  
Completed reference questionnaires (Appendix 4) were collected for all 90 participants and 29 
controls. Australian residential states for participants and controls can be found in table 3.1.  
Epidemiological data and differences in tick-borne disease risk exposure as found through previous 
TBDU studies can be found in table 3.2. The average age for combined test group participants was 41 
± 1.5 years and for the control group it was 37 ± 3 years. The test group participant’s age range was 
from 12-73 years. The control age range was from 17-71 years. The majority of the participants in 
the test group (84.5%) and the control group (69%) were female. The ratio of female to male 
participants and controls was found to be statistically significant (p = 0.027). 
A statistically significant number of participants (94.5%) reported undertaking outdoor activities such 
as hiking or dog walking in bushland or rural areas as opposed to 76% of the control group (p = 
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0.004). Consistent with that, the test group participants reported spending a statistically significant 
number of more hours per week outdoors in rural or bushland areas. On average that was 7.8 ± 1 
hours per week compared to the 4.9 ± 1 hours spent on average by the members of the control 
cohort (p = 0.035). The most statistically significant difference noted between the test group 
participants and the control group was recollection of a tick bite in Australia. Of the test group, 44% 
had recollection of a bite which was much larger than the 3% of control participants who could 
remember a bite (p < 0.0001).  
Within the test group, the only epidemiological factor that held a significant difference between the 
CFT subgroup and CFX subgroup was that of recollection of a domestic tick bite which was 56% and 
34% respectively (p=0.038). The comparison of all epidemiological data between CFT subgroup and 
control group can be seen below in table 3.2. 
Between CFT subgroup and the control group, the percentage of those who spent time outdoors 
undertaking activities was significantly different, with 92% of CFT subgroup participants, and 75% of 
control group participants being involved in outdoor activities (p=0.048). As expected from that, the 
average number of hours spent outdoor each week was significantly different with CFT subgroup 
participants spending 7.8± 1.5 hours and control group participants spending 4.9 ± 1 hours 
(p=0.014). CFT subgroup participants also had a significantly different percentage of people who had 
undertaken jobs rurally (22%) and jobs with animal exposure (17%) compared with the control group 
which was zero for both categories (p=0.007 and p=0.019, respectively). The most statistically 
significant difference between the two groups was the recollection of a domestic tick bite with 56 % 
of CFT subgroup participants being able to recall being bitten in Australia in contrast with only 3.5% 
of control participants (p < 0.0001). The comparison of all epidemiological data between CFT 
subgroup and control group can be seen below in table 3.2. 
When comparing CFX subgroup with the control group there was a significantly higher percentage of 
females; 89% compared to 69% (p=0.011). Within the CFX subgroup, 96% of participants spend time 
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outdoors undertaking activities in bush in rural areas, this is significantly different from the 76% of 
control participants (p=0.009). Likewise, 12% of CFX subgroup participants have had jobs in rural or 
bushland areas compared with none of the control group participants (p=0.045). The CFX subgroup 
had a significantly higher percentage of participants who could recall a tick bite in Australia (34.04%) 
when compared to the control group’s 3.44% (p=0.002). The comparison of all epidemiological data 
between CFX subgroup and control group is shown in table 3.2. 
The most common state or territory for test and control group participants was New South Wales 
(26 and 25 respectively). The test group also consisted of 21 people from Western Australia, 17 from 
Victoria, 16 from Queensland, five from South Australia and one from Australian Capital Territory. 
The Control group also consisted of three people from Western Australia and one from Victoria.  
 
Table 3.1. Residence of participants by State or Territory. 
 
Test 
Group 
(n=88) 
CFX 
subgroup 
(n=47) 
CFT 
subgroup 
(n =41) 
Control 
group (n=29) 
ACT 1 1 0 - 
NSW 26 11 15 25 
QLD 16 5 11 - 
SA 5 4 1 - 
TAS 2 2 0 
 VIC 17 14 3 1 
WA 21 10 11 3 
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Table 3.2 Summary of Epidemiological data and risk exposure in participants based on information provided in reference questionnaire (appendix 4). 
 
Scalar data tested for statistical significance using independent samples t-test, nominal data using chi-squared test. Data presented as +/- SEM.  * denotes 
statistical significance at p<0.05
                                                          
1
 Referring to those bites obtained within Australia. 
Characteristic 
Test Group 
(n=88) 
Control Group 
(n=29) 
CFT subgroup 
(n=41) 
CFX subgroup 
(n=47) 
P Value (Test gp Vs 
C) 
P Value (CFT 
vs C) 
P Value (CFX 
vs C) 
P Value (CFX 
vs CFT) 
Age 40.5 ± 1.5 36.7 ± 3 40 ± 2 41 ± 2 0.23 0.37 0.239 0.764 
Sex:        Male 16% 31% 22% 10% 
0.032* 0.245 0.011* 0.148 
                Female 84% 69% 78% 89% 
Years spent in local area 11.1 ± 1 12.9 ± 3 12.7 ± 1.5 9.8 ± 1.3 0.43 0.968 0.217 0.154 
Bushland/rural activities 94% 76% 92% 95% 0.004* 0.048* 0.009* 0.536 
Bush/rural activities  (hours/wk) 7.8 ± 1 4.8 ± 1 7.8 ± 1.5 7.8 ± 1 0.035* 0.014* 0.575 0.989 
Pets 77% 61% 70% 83% 0.209 0.643 0.082 0.171 
Jobs with animal exposure 13% 0% 17% 10% 0.036* 0.019* 0.082 0.78 
Job in bush/rural area 17% 0% 22% 12% 0.017* 0.007* 0.045* 0.253 
Overseas travel 84% 93% 78% 89% 0.221 0.088 0.584 0.148 
Overseas tick bite 5% 0% 9% 2.% 0.19 0.083 0.429 0.123 
Domestic travel 94% 96% 9% 95% 0.636 0.492 0.861 0.536 
Domestic tick bite1 44% 3% 56% 34% 0.00005* <0.00005* 0.002* 0.038* 
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3.2 Symptomology Data 
Symptomology questionnaires (Appendix 5) were obtained for 86 of the 88 test group participants 
and 28 of the 29 control group members. Symptomology scores were calculated by the method 
previously outlined, the results are displayed in table 3.3.  The summed total symptom score for the 
test group participants was 225 ± 10, the CFT subgroup; 224 ± 16, and the CFX subgroup; 203 ± 13. 
The total symptom score for the control group was 12 ± 3. The most commonly reported symptoms 
were; fatigue, confusion, difficulty concentrating, difficulty absorbing new information and 
forgetfulness. The mean score of each symptom was compared between the test and control groups 
using a t-test for two samples assuming unequal variance. Every symptom except ‘unexplained milk 
production’ was found to have statistically significant variance between test and control groups (p < 
0.05) 
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Table 3.3 Symptomology scores in test and control groups. 
Characteristic 
Test Group 
(n=88) 
Control Group 
(n=29) 
P Value 
Swollen Glands 1.9 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Sore Throat 2.0 ± 0.2 0.3 ± 0.1 ≤ 0.001 
Fevers 1.4 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Hot Flushes 2.2 ± 0.2 0.2 ± 0.1 ≤ 0.001 
Cold Flushes 1.4 ± 0.2 0.2 ± 0.1 ≤ 0.001 
Sore Soles 1.8 ± 0.6 0.07 ± 0.05 ≤ 0.001 
Profuse sweating 2.0  ± 0.2  0.1  ± 0.1 ≤ 0.001 
Swollen lymph 1.7 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Rash 1.2 ± 0.4 0.2 ± 0.2 ≤ 0.001 
Unexplained weight gain 1.6 ± 0.4 0 ± 0 ≤ 0.001 
Unexplained weight loss 0.9 ± 0.2 0 ± 0 ≤ 0.001 
Unexplained hair loss 1.6 ± 0.2 0.07 ± 0.05  ≤ 0.001 
Fatigue 7.2 ± 0.2 0.6 ± 0.2 ≤ 0.001 
Heart murmur 0.4 ± 0.1 0 ± 0 ≤ 0.001 
Heart palpitations 1.9 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Chest pain 1.9 ± 0.2 0.1 ± 0.06 ≤ 0.001 
Dizziness 2.8 ± 0.2 0.1 ± 0.2 ≤ 0.001 
Dyspnoea 1.9 ± 0.2 0.07 ± 0.05 ≤ 0.001 
Chronic cough 1.0 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Back pain 3.4 ± 0.4 0.4 ± 0.1 ≤ 0.001 
Back stiffness 4.4 ± 0.3 0.5 ± 0.2 ≤ 0.001 
Muscle pain 4.5 ± 0.3 0.2 ± 0.1 ≤ 0.001 
Muscular cramps 2.2 ± 0.2 0.1 ± 0.06 ≤ 0.001 
Muscle weakness 4.2 ± 0.3 0.07 ± 0.05 ≤ 0.001 
Neck stiffness 4.6 ± 0.3 0.3 ± 0.2 ≤ 0.001 
Neck pain 3.9 ± 0.3 0.3 ± 0.2 ≤ 0.001 
Neck cracks 0.9 ± 0.3 0.3 ± 0.3 ≤ 0.001 
 Fingers/toes joint pain 2.8 ± 0.6 0.2 ± 0.1 ≤ 0.001 
Ankles/ wrists joint pain 2.5 ± 0.2 0.1 ± 0.06 ≤ 0.001 
Knees/elbows joint pain 2.4 ± 0.2 0.1 ± 0.08 ≤ 0.001 
Hips/ shoulders joint pain  2.8 ± 0.3 0.03 ± 0.04 ≤ 0.001 
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Characteristic 
Test Group 
(n=88) 
Control Group 
(n=29) 
P Value 
 Fingers/toes joint swelling 0.8 ± 0.1 0.03 ± 0.04 ≤ 0.001 
Ankles/wrists joint swelling 0.6 ± 0.1 0 ± 0 ≤ 0.001 
Knees/elbows joint swelling 0.8 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Hips/shoulders joint swelling 0.8 ± 0.2 0 ± 0 ≤ 0.001 
Twitching face 1.2 ± 0.1 0.1 ± 0.06 ≤ 0.001 
Tingling 2.2 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Numbness 2.1 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Burning 2.3 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Stabbing 1.7 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Shooting 1.5 ± 0.4 0 ± 0 ≤ 0.001 
Hypersensitive 3.8 ± 0.3 0 ± 0 ≤ 0.001 
Facial Paralysis 0.3 ± 0.1 0 ± 0 0.018 
Dental pain 1.9 ± 0.2 0 ± 0 ≤ 0.001 
Queasy stomach 2.7 ± 0.2 0 ± 0 ≤ 0.001 
Vomiting 1.2 ± 0.2 0 ± 0 ≤ 0.001 
Heartburn 1.9 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Stomach pain 2.4 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Constipation 2.6 ± 0.3 0.1 ± 0.1 ≤ 0.001 
Diarrhoea 1.8 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Abdominal pain 2.5 ± 0.2 0 ± 0 ≤ 0.001 
Abnormal hunger 1.6 ± 0.2 0.07 ± 0.05 ≤ 0.001 
Nocturia 1.7 ± 0.4 0 ± 0 ≤ 0.001 
Irritable bladder 1.1 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Irregular Menstruation 1.3 ± 0.2 0.1 ± 0.1 ≤ 0.001 
Erectile dysfunction 0.3 ± 0.1 0 ± 0 0.013 
Confusion 5.0 ± 0.2 0.1 ± 0.07 ≤ 0.001 
Concentration difficulty 5.3 ± 0.2 0.4 ± 0.1 ≤ 0.001 
Poor new information absorption 5.3 ± 0.2 0.1 ± 0.06 ≤ 0.001 
Word/ name block 4.7 ± 0.2 0.1 ± 0.07 ≤ 0.001 
Forgetfulness 4.7 ± 0.2 0.2 ± 0.1 ≤ 0.001 
Poor attention span 4.4 ± 0.2 0.5 ± 0.2 ≤ 0.001 
Disorientation 1.9 ± 0.6 0.07 ± 0.05 ≤ 0.001 
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Characteristic 
Test Group 
(n=88) 
Control Group 
(n=29) 
P Value 
Speech errors 4.3 ± 0.3 0.1 ± 0.07 ≤ 0.001 
Mood swings 2.9 ± 0.2 0.4 ± 0.1 ≤ 0.001 
Irritability 3.1 ± 0.2 0.2 ± 0.1 ≤ 0.001 
Depression 2.7 ± 0.2 0.2 ± 0.1 ≤ 0.001 
Anxiety 2.5 ± 0.7 0.2 ± 0.1 ≤ 0.001 
Psychosis 0.2 ± 0.07 0 ± 0 ≤ 0.001 
Seizures 0.3 ± 0.1 0 ± 0 ≤ 0.01 
Headache 3.7 ± 0.3 0.3 ± 0.1 ≤ 0.001 
Light Sensory 4.1± 0.3 0.03 ± 0.04 ≤ 0.001 
Sound sensory 4.3 ± 0.3 0.1 ± 0.08 ≤ 0.001 
Conjunctivitis 0.7 ± 0.1 0 ± 0 ≤ 0.001 
Double vision 0.9 ± 0.2 0 ± 0 ≤ 0.001 
Blurred vision 2.4 ±0.2 0.1 ± 0.6 ≤ 0.001 
Buzzing 1.7 ± 0.2 0.21 ± 0.15 ≤ 0.001 
Ringing 2.7 ± 0.6 0.25 ± 0.15 ≤ 0.001 
Decreased hearing 1.6 ± 0.2 0.03 ± 0.04 ≤ 0.001 
Pain in ears 0.9 ± 0.1 0.03 ± 0.04 ≤ 0.001 
Motion sickness 2.2 ± 0.6 0.07 ± 0.05 ≤ 0.001 
Vertigo 1.9 ±  0.6 0.07 ± 0.05 ≤ 0.001 
Spinning 1.6 ± 0.2 0.03 ± 0.04 ≤ 0.001 
‘Tippy’ feeling 2.6 ± 0.7 0.07 ± 0.05 ≤ 0.001 
Light headedness 3.3 ± 0.2 0.07 ± 0.05 ≤ 0.001 
Need to sit/lie 4.1 ± 0.3 0.03 ± 0.04 ≤ 0.001 
Insomnia 3.8 ± 0.8 0.2 ± 0.2 ≤ 0.001 
Frequent waking 4.4 ± 0.3 0.3 ± 0.2 ≤ 0.001 
Early wakening 2.9 ± 0.3 0.1 ± 0.1 ≤ 0.001 
Excessive sleep 2.0 ± 0.4 0.1 ± 0.1 ≤ 0.001 
Day naps 2.6 ± 0.7 0.07 ± 0.05 ≤ 0.001 
Unexplained milk production 0.1 ± 0.08 0 ± 0 0.1413 
Breast pain 0.8 ± 0.3 0 ± 0 ≤ 0.001 
    SUM 225 ± 10 12 ± 3 ≤ 0.001 
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Within the test sub-groups, between the CFT subgroup and control group, and between the CFX 
subgroup and control group, the variability of symptoms was more considerable than between the 
test and control groups. There was no difference in symptoms between the CFT subgroup and CFX 
subgroup.  Signs and symptoms which were not significantly different between the CFT subgroup 
and control group were conjunctivitis and heart murmur. Symptoms which were not significantly 
different between the CFX subgroup and the control group were psychosis and swelling in the hip or 
shoulder joint.  Symptoms with no significantly different prevalence between any individual groups 
were: erectile dysfunction, facial paralysis, unexplained milk production and seizures. All remaining 
symptoms were significant between control group and both the CFT and CFX subgroups.  
The signs and symptoms and their various significant differences between groups are shown in 
appendix 6. For clarity of presentation, Figures 3.1 – 3.8 present the symptomology variations 
between CFT subgroup, CFX subgroup and the control group for signs and symptoms grouped into 
categories below.  
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Figure 3.1 Systemic symptomology scores between test sub-groups and control group. Data 
represents mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis 
ANOVA followed by the Games-Howell post hoc test; * and # P<0.05; ** and
 ## p<0.01; *** and ### p 
< 0.001. 
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Figure 3.2 Cardiovascular and respiratory symptomology scores between test sub-groups and control 
group. Data represents mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  
Statistical analysis ANOVA followed by the Games-Howell post hoc test; * and # P<0.05; ** and
 ## 
p<0.01; *** and 
###
 p<0.001. 
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Figure 3.3  Musculoskeletal symptomology scores between test sub-groups and control group.  Data 
represents mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis 
ANOVA followed by the Games-Howell post hoc test; * and 
#
 P<0.05; ** and
 ## p<0.01; *** and ### 
p<0.001. 
 
52 
 
 
Figure 3.4 Neurological symptomology between test sub-groups and control group. Data represents 
mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis ANOVA 
followed by the Games-Howell post hoc test; * and 
#
 P<0.05; ** and
 ## p<0.01; *** and ### p<0.001. 
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Figure 3.5 Genitourinary and other symptomology between test sub-groups and control group.  Data 
represents mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis 
ANOVA followed by the Games-Howell post hoc test; * and 
#
 P<0.05; ** and
 ## p<0.01; *** and ### 
p<0.001. 
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Figure 3.6 Cognitive and behavioural symptomology between test sub-groups and control group.  
Data represents mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical 
analysis ANOVA followed by the Games-Howell post hoc test; * and 
#
 P<0.05; ** and
 ## p<0.01; *** 
and ### p<0.001. 
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Figure 3.7 Sensory symptomology between test sub-groups and control group.  Data represents 
mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis ANOVA 
followed by the Games-Howell post hoc test; * and 
#
 P<0.05; ** and
 ## p<0.01; *** and ### p<0.001. 
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Figure 3.8 Sleep/wake symptomology between test sub-groups and control group.  Data represents 
mean ± SEM CFT group n=41; CFX group n=45; control group n=28.  Statistical analysis ANOVA 
followed by the Games-Howell post hoc test; * and # P<0.05; ** and
 ## p<0.01; *** and ### p<0.001. 
 
 3.3 Testing for Borrelia spp.  
3.3.1 Nested PCR 
Nested PCR was used to target for rrs in 16S rRNA using external primers RRS-O19F and RRS-593R 
and internal primers RRS-38F-RLB and RRS-1-472R-BOR. No DNA product bands were detected from 
all samples analysed. The specificity of the primers was tested using a positive control, with the DNA 
amplicon band evident in final gel product. A photograph of the control positive band on a gel; 
shown below Figure 3.9 
 
57 
 
  
Figure 3.9 Borrelia PCR 16S rRNA gene.  Well 1-12 contain participant samples of 16S rRNA PCR 
reactions indicating no amplicons of the expected size (435bp). The negative control similarly had no 
amplicon indicating no contamination was observed. The positive control (B. burgdorferi sensu 
stricto B31 strain) yielded an amplified product of 435bp is indicated by the arrow.  Hyperladder I 
(Bioline) was used as a standard and size of DNA bands indicated to the left of image. 
 
 
3.3.2 Western Blot Testing  
Immunoglobulin (Ig) responses of participant serum were tested using commercial western blot 
(WB) kits from EuroImmun (Germany). Normalised response scores were produced and recorded 
using EuroLineScan software as outlined in methods. WB data were analysed for individual protein 
responses as well as overall positive/negative responses for each test. Examples of positive, 
equivocal and negative test strips can be seen in Appendix 8.  
 
The patient serum were serologically tested against six different whole cell antigen WB tests. There 
was no significant difference in the percentage of positive tests when the comparison is made 
individually for each test between the test and control groups, as outlined in table 3.4. 
     1    2   3    4   5     6  7  ladder 8  9 10  11 12  –ve +ve 
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When tests were grouped into immunoglobulin type analysed, the test group had more IgG positive 
responses (23.9%) compared to the control group (1.1%) (p = 0.015), table 3.5. There was no 
significant difference between CFX subgroup and CFT subgroup, but for both, the percentage of 
positive results was greater compared to the control group (p = 0.02 and p=0.008 respectively), table 
3.6 
 
Of the test group participants 56 (63.6%) returned positive results to recombinant IgG WB testing, 
which was statistically significant compared to the 10 control participants (34.5%) who also returned 
positive results (p=0.006) as outlined in table 3.4.  When individual antigenic responses were 
analysed, four antigens; p 83, p 39, Osp C and p21 all returned statistically significant (p ≤ 0.05) 
results between the test and control group. Within the test sub-groups, CFX subgroup produced a 
significantly greater response than CFT subgroup for p21, p 39 and p 83, and a significantly lower 
response for Osp C antigen. CFT subgroup’s response for Osp C was significantly greater than the 
control group’s response as outlined in table 3.7. 
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Table 3.4 Percentage of positive results for western blots for test group versus control group. 
  
Test Group 
(n=88) 
Controls 
(n=29) 
Significance 
B. Garinii IgG 10.2 3.5 0.257 
B. Garinii IgM 2.3 0 0.413 
B. Burgdorferi IgG 9.0 0 0.093 
B. Burgdorferi IgM 2.3 0 0.413 
B. Afzelii IgG 6.8 0 0.252 
B. Afzelii IgM 1.1 0 0.564 
  
    Recombinant IgG* 63.6 34.5 0.006 
 
 
Table 3.5 Percentage of positive results for immunoglobulin groups in whole cell antigen western 
blots for test group versus control group.  
  
Test Group 
(n=88) 
Controls 
(n=29) 
Significance 
 IgG* 23.9 3.5 0.015 
 IgM 5.7 0 0.19 
 
 
Table 3.6 Percentage of test sub-groups with immunoglobulin grouped response to whole cell 
antigen western blots.  
 
     
Significance 
 
  
CFT 
subgroup  
(n = 41) 
CFX  
subgroup  
(n = 47) 
Controls 
 (n = 29) 
CFT vs 
CFX 
CFT vs 
Controls 
CFX vs 
Controls 
Combined 
IgG 26.8 23.4 3.5 
0.711 0.008 0.02 
Combined 
IgM 4.9 6.4 0 0.761 0.228 0.165 
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Table 3.7   Percentage of positive results for recombinant IgG testing for test sub- groups and control 
group. 
      
Significance 
 
  
CFT 
subgroup  
(n  = 41) 
CFX subgroup  
(n = 47) 
Controls 
 (n=29) 
CFT vs 
CFX 
CFT vs 
Controls 
CFX vs 
Controls 
IgG 63.4 61.7 34.5 
 
0.869 0.017 0.021 
 
 
 
 
3.3.3 Individual Antibody Analysis. 
WB data was analysed for individual responses to antigen as well as overall positive/negative 
responses for each test.  The Tukey boxplot (Figure 3.9) shows the median value as a line with the 
upper and lower edges of the box indicating the upper quartile (Q3) and the lower quartile (Q1), i.e. 
covers 50 % of the values (interquartile range (IQR)).  The lines which extend from the boxes 
(whiskers) denote: a) upper quartile plus 1.5 times the interquartile range (Q3 + 1.5 x IQR) and; b) 
lower quartile minus 1.5 times the IQR.  The outliers are marked as either “o” called an “out”/”mild” 
value, or as a “*” to indicate a “far out”/”extreme” value. Values indicated by “*” are greater than 
1.5xIQR above the positive whisker and values indicated by “o” fall in between.  The control group is 
represented by the blue boxes and the test group is represented by the green boxes. The 
Mann-Whitney U test, a non-parametric test, was used to indicate whether the distribution of 
western blot intensity values for 80 different antigens were significantly different between the 
control and chronic fatigue patients. The Vargha Delaney A test was used to correlate the P value 
obtained with the effect magnitude of the median response spread. 
61 
 
Twenty-one antigens were removed from the original 101 antigens for the analysis, since their 
intensity values were not above zero. The boxplot shows the 14 antigens which returned P values, 
obtained from the Mann-Whitney U test, < 0.1. The degree of significance is denoted by: ### ≤ 
0.001, ## ≤ 0.01 and # ≤ 0.05. The nine antigens which returned acceptable P values from the 
recombinant IgG test were; p 18, p 21, p 58, Osp C, p 39, p 83, VlsE B. afzelii, VlsE B. burgdorferi and 
VlsE B. garinii.  One antigen was selected from the B. burgdorferi and B. garinii IgG whole cell 
antigen tests; p 83 and p 57/59 respectively. One antigen from B. afzelii, B. burgdorferi and B. garinii 
IgM tests was suitably significant; p43, Osp A and Osp C, respectively.  
Within the recombinant IgG test, the antigens were analysed depending on the percentage of 
positive responses in the test group compared to the control group. The test group was found to 
have a significantly stronger response to p 83 (p = 0.04), p 39 (p = 0.02), Osp C (p=0.001) and p 21 (p 
= 0.032). Although the VlsE responses to the various Borrelial species were not significantly different 
when compared to control group using a t-test, and weakly significant when compared individually 
to the control group using the Mann Whitney U test, when combined VlsE response from all three 
Borrelia species was analysed, the test group response had a stronger significance (0.001) as 
outlined in table 3.8. Within the test sub-groups; the CFT subgroup and CFX subgroup were found to 
have a significantly stronger response than the control group for Osp C (p = 0.002 and p = 0.007 
respectively), the CFX subgroup was also found to be significantly different from the control group 
for; p 83 (p = 0.02), p 39 (p = 0.0006) and p 21 (p = 0.024) as displayed in table 3.9.  
 
The values received by the control cohort were higher than expected relative to Borrelia serology 
studies in non-endemic population (Branda et al., 2013).  The increased percentage of positive 
controls seemed to be resulting from a few antigens and not all, namely OspC, p21, p39. In order to 
calculate a new threshold based on this; studies of healthy controls for all antigens a complicated 
series of filtering was performed using a series of receiver operating characteristic (ROC) curves. A 
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ROC was generated for each antigen (Appendix 7) to determine the western blot band intensity that 
best differentiated CFS patient responses from the controls; i.e. the intensity threshold that gave the 
maximal signal between the two groups.  Although there was a possibility that the initial procedure 
generated a percentage of false positives, it permitted conditioning of the signal so that the 
background level of control positive responses to antigens could be determined. For each antigen 
the threshold value obtained from the ROC was used to indicate whether the signal was positive. 
The number of positive signals for all 8 antigens was calculated for each patient.  The summed 
positive values for each patient were used to generate a second ROC.  From the second ROC it was 
determined that five of the eight bands generated a positive signal for 48 % of the test group 
compared with 3.4 % of the control group.  With this knowledge new threshold intensities for each 
antigen were determined from their original ROCs.  Rather than choosing the value which generated 
the greatest signal between test and control groups, the band intensity threshold level was 
determined such that the control positive percentage was below 3.5 %; this low thresholding may 
under-estimate the number of positive responses, but is consistent with the percentage of controls 
positive with the whole cell antigen tests.  With the new conditioned threshold values, the cycle was 
repeated to determine the number of antigens that generated positive signals for each patient.  The 
data was then used to generate a final ROC.  A bar figure (Figure 3.9) was created, showing the 
percent positive bands on the recombinant IgG western blot for the 8 recombinant antigens selected 
based on significance as indicated by the Mann-Whitney U test and Vargha-Delaney A-test. A similar 
figure (Figure 3.10) was created demonstrating the results for the test sub-groups, the groups were 
split into baskets for the number of positive bands above calculated threshold values returned.
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Figure 3.8. A Boxplot demonstrating the spread of response intensity of selected antigen bands within whole cell 
antigen and recombinant western blot testing. 
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Table 3.8 Percentage of positive results for recombinant IgG testing for test group and control group. Significance 
was determined using t-test (p < 0.05) 
 
    
Test 
Group 
(n=88) 
Controls 
(n=29) 
Significance 
VIsE-Ba 4.5 0 0.243 
VIsE-Bb 20.5 13.8 0.426 
VIsE-Bg 5.7 0 0.19 
VlsE 
combined 
27.3 13.8 0.001* 
Lba 0 0 n/a 
LBb 0 3.5 0.08 
p83 29.5 10.3 0.04* 
p41 100 96.5 0.08 
p39 87.5 62.1 0.002* 
OspC 98.9 79.3 0.0001* 
p58 0 0 n/a 
p21 84.1 65.5 0.032* 
p20 0 0 n/a 
p19 1.1 3.5 0.405 
p18 19.3 10.3 0.265 
   
 
65 
 
Table 3.9 Percentage of positive results for recombinant IgG testing for test group and control group. Significance 
was determined using t-test (p < 0.05) 
  
  
Significance 
  
CFT subgroup 
(n  = 41) 
CFX subgroup Controls 
(n=29)  
CFX vs C  
CFT vs 
C 
CFX vs 
CFT  (n = 47) 
VIsE-Ba 0 8.5 0 
 
0.107 n/a 0.056 
VIsE-Bb 14.6 25.5 13.8 
 
0.223 0.921 0.206 
VIsE-Bg  4.9 6.4 0 
 
0.165 0.228 0.761 
VlsE Combined 19.5 15 13.8 
 
0.076 0.532 0.187 
Lba 0 0 0 
 
n/a n/a n/a 
LBb 0 0 3.4 
 
0.2 0.231 n/a 
p83 26.8 31.9 10.3 
 
0.032* 0.089 0.602 
p41 100 100 96.5 
 
0.2 0.231 n/a 
p39 80.5 93.6 62.1 
 
0.0006* 0.088 0.063 
OspC 100 97.9 79.3 
 
0.007* 0.002* 0.348 
p58 0 0 0 
 
n/a n/a n/a 
p21 80.5 87.2 65.5 
 
0.024* 0.158 0.388 
p20 0 0 0 
 
n/a n/a n/a 
p19 0 2.1 3.4 
 
0.727 0.231 0.348 
p18 17.1 21.3 10.3 
 
0.219 0.428 0.618 
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Figure 3.9 – the percentage of positive bands on the recombinant IgG western blot to the significantly important 
antigens as calculated through ROC analysis. Thresholds were calculated using a multi-step statistical analysis using 
ROC curves to standardise intensity response levels to individual antigens. The percent of test group and control 
group who returned positive responses to these antigens (VlsE-Ba, VlsE-Bb, VlsE-Bg, p 83, p 39, Osp C, p 21, p 18) is 
shown. The VlsE responses were grouped and are shown.  
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Figure 3.10 The number of positive bands returned above calculated threshold values for the test sub groups. 
Thresholds were calculated using a multi-step statistical analysis using ROC curves to standardise intensity response 
levels to individual antigens.  The number of positive bands returned for the CFX and CFT subgroups and control 
group above the new threshold levels is shown.   
Validation of cut off criteria as calculated by ROC analysis: 
After the completed ROC analyses, 25 test group participants and 2 controls were deemed to have returned positive 
responses to two or more antigen bands on the recombinant IgG western blot. Table 3.10 shows the results for all 
forms of Borrelia tested for using ELISA and western blots during the study for those 27 participants. Sixteen of the 
test group participants (64%) showed validation of their recombinant IgG western blot result through returning a 
positive or equivocal result to some other Borrelia spp. test throughout the study. Neither of the control participants 
returned validating responses using some other Borrelia spp. test.  
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Table 3.10:  Summary of combined results using ELISA and western blots for whole cell sonicates and recombinant 
Borrelia antigens. The results for 27 participants who returned positive recombinant IgG results as determined 
through ROC analysis.  
ID Recomb 
IgG 
ELISA 
IgG 
ELISA 
IgM 
B.g  
IgG 
B.a 
 IgG 
B.b 
 IgG 
B.g 
IgM 
B.a 
IgM 
B.b 
IgM 
T103 +    +     
T024 +    +/- +    
T061 + + + +    +/-  
T055 +         
T047 + +   +/-     
T040 +  +  +/-    +/- 
T050 +    +/- +    
T091 +   +/- +     
T096 +         
X027 +         
X035 +    +/- +/-    
X036 +         
X037 +         
X038 +   +      
X039 +    +/-     
X056 +     +/-    
X059 +   +/- +     
X063 +         
X067 +         
X070 +   + +/-     
X086 +     +/-  + +/- 
X089 +   + + +    
X090 +         
X095 +    +/-    +/- 
X066 +         
C13065 +         
C13064 +         
Positive results are symbolised through ‘+’. Indeterminate results are symbolised through ‘+/-‘. Recombinant IgG 
test results are listed under the column ‘Recomb IgG’. ELISA test results for B. burgdorferi are listed under the 
columns ‘ELISA IgG’ and ‘ELISA IgM’. Western blot results for B. garinii are listed under ‘B.g IgG’ and ‘B.g IgM’. 
Western blot results for B. afzelii are listed under ‘B.a IgG’ and ‘B.a IgM’. Western blot results for B. burgdorferiI are 
listed under ‘B.b IgG’ and ‘B.b IgM’.  Participants with a ‘T’ prefix are part of the CFT subgroup, with a ‘X’ prefix are 
part of the CFX subgroup, with a ‘C’ prefix are controls.  
 
3.3.5 Enzyme Linked Immunosorbent Assay (ELISA) testing 
IgM and IgG Immunoglobulin titre against B. burgdorferi was tested using a Fluostar Omega microplate reader at 
450nm and again at 620nm for confirmation of results. Samples were classified being positive, negative or 
69 
 
indeterminate result according to the protocol supplied by the manufacturer and outlined in the methods.  Within 
the test group 9% of participants returned positive samples to the IgG ELISA, compared to 0% of the control cohort 
(p = 0.093).  The IgM ELISA returned 8% positive results in the test group, compared to 3.45% in the negative cohort 
(p = 0.404). Two participants from the test cohort returned positive results to both IgG and IgM testing, this was 
accounted for when the combined results from both tests was analysed, with the test group returning 14.8% 
positive to at least one test, and the control group producing only 3.5% (p = 0.103), as shown below in table 3.11. 
Within the test group, the CFT subgroup returned a higher percentage of positive results in the IgG (12.2%) and IgM 
(12.2%) tests than the CFX subgroup (6.38% and 4.26% respectively) as demonstrated in Figure 3.11 below. 
 
Table 3.11  Positive ELISA results as a percentage of test group compared to control group. 
  
Test Group 
(n=88) 
Controls 
(n=29) Significance 
B. Burg. IgG 9.1 0 0.093 
B. Burg. IgM 8.0 3.5 0.404 
  
   B. Burg. Combined 14.8 3.5 0.103 
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Figure 3.11 Positive ELISA results in test sub-groups and control group. The percentage of positive CFT and CFX 
subgroup and control group responses to ELISAs testing for IgG and IgM response. 
 
 
3.4 Testing for Chlamydophila spp.  
3.4.1 Nested PCR targeting Omp1 gene of Chlamydophila pneumoniae 
Nested PCR was employed to target the Omp1 protein using external primers CHLOMP1N1F and CHLOMP1N1R and 
internal primers CHLOMP1N2F and CHLOMP1N2R (Dresses-Werringoloer et al., 2009) The external primers 
CHLOMP1N1F and CHLOMP1N1R a directed to amplify a 1409 bp region of the Omp1 gene and the internal primers 
CHLOMP1N2F and CHLOMP1N2R  a 1303bp region.  None of the participant sample genomic DNA yielded any 
product using the conditions  as stated in the methods ((Dresses-Werringoloer et al., 2009)Without a positive 
Chlamydopila pneumoniae DNA control the conditions used could not be confirmed to successfully amplify the 
targeted sequence.  
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3.4.2 ELISA 
Immunoglobulin response was tested using a Fluostar Omega microplate reader at 450nm and again at 620nm for 
confirmation of results. Samples were classified as a positive, negative or indeterminate result according to the 
protocol supplied by the manufacturer and outlined in the methods.  Within the test group 46.60% of participants 
returned positive samples to the IgG ELISA, compared to 31.03% of the control cohort (p = 0.142).  The IgM ELISA 
returned 4.55% positive results in the test group, compared to 0% in the negative cohort (p = 0.243). Two 
participants from the test cohort returned positive results to both IgG and IgM testing, this was accounted for when 
the combined results from both tests was analysed, with the test group returning 48.9% positive to at least one test, 
and the control group producing only 31% (p = 0.094), as shown below in table 3.12. Within the test group, the CFT 
subgroup returned a higher percentage of positive results in the IgG (51.2%) and IgM (7.3%) tests than the CFX 
subgroup (42.5% and 2.1% respectively) as demonstrated in Figure 3.12 below. 
Table 3.12 Percentage of positive ELISA results in test group and control group 
  
Test Group 
(n=88) 
Controls 
(n=29) Significance 
C. Pneumoniae IgG 46.59 31.03 0.142 
C. Pneumoniae IgM 4.55 0.00 0.243 
C. Pneumoniae 
Combined 48.86 31.03 0.094 
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Figure 3.12 Positive Elisa results in test sub-groups and control group. The percentage of positive CFT and CFX 
subgroup and control group responses to ELISAs testing for Chlamydia pneumoniae IgG and IgM response. 
 
3.5 Testing for Mycoplasma spp.  
3.5.1 Nested PCR targeting V domain of 23S rRNA gene of Mycoplasma species: 
Nested PCR was employed targeting   the V domain in the 23S rRNA using external primers MYCN11758F and 
MYCN12684R and internal primers MYCN21719F and MYCN22154R (Chan et al., 2013). External primers were 
expected to yield a product of 926bp and internal primers should yield a product of 335bp.  For the conditions used 
as described in the methods (Chan et al., 2013), no participant samples yielded bands in either round of nested PCR 
(data not shown). The sensitivity and selectivity of primers and PCR conditions could not be confirmed as a positive 
DNA control was not available.   
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3.5.2 ELISA 
Immunoglobulin response was tested using a Fluostar Omega microplate reader at 450nm and again at 620nm for 
confirmation of results. Samples were classified as a positive, negative or indeterminate result according to the 
protocol supplied by the manufacturer and outlined in the methods.  Within the test group 45.5% of participants 
returned positive samples to the IgG ELISA, compared to 62.1% of the control cohort (p = 0.121).  The IgM ELISA 
returned no positive results in the test group, and the negative cohort and as a result was removed from further 
analysis. The overall results of the ELISA are outlined in table 3.13. Within the test group, the CFT subgroup returned 
46.3% positive results in the IgG and the CFX subgroup returned 44.7% as demonstrated in Figure 3.13 below. 
 
 
Table 3.13 Positive ELISA results for test group and control group 
  
  
Test Group 
(n=88) 
Controls 
(n=29) Significance 
M. Pneumoniae IgG 45.45 62.07 0.121 
M. Pneumoniae IgM 0 0 0 
M. Pneumoniae 
Combined 45.45 62.07 0.121 
 
 
 
 
74 
 
 
 
Figure 3.13 Positive ELISA results for test sub-groups and control group. The percentage of positive CFT and CFX 
subgroup and control group responses to ELISAs testing for Mycoplasma pneumoniae IgG and IgM response. 
 
 
3.6 Testing for Rickettsia spp. and Orientia tsutsugamushi 
3.6.1 PCR 
The PCR testing for Rickettsia spp. was done with three different sets of primers as outlined in the methods section. 
3.6.1.1 Targeting the Outer Membrane proteins rOmpA and rOmp B genes in Rickettsia typhus and spotted fever 
groups: 
The OmpB gene was targeted using R120-M59F and R120-1497R primers and the expected amplicon bands 
approximately 1438bp in size. The positive control Rickettsia typhi produced a band of the expected size (Figure 
3.14). There were also smaller bands produced around 450bp in size due to non-specific amplification (Figure 3.14).  
These bands were purified and sent for sequencing, but no reliable sequencing was obtained. The other control DNA 
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Rickettsia honeii amplified a band of less intensity and Orientia tsutsugamushi did not amplify bands denoting the 
specificity of the primers targeting OmpB to typhus and spotted fever group Rickettsiae. 
  
 
 
 
Figure 3.14 Rickettsia typhus and spotted fever group PCR using R120-M59F and R120-1497R primers targeting 
OmpB gene. Wells 1-5 are OmpB PCR run with participant samples has a 450bp band that is much smaller than the 
expected OmpB band of 1438bp.  Sequencing of 450bp product failed and the source of this mis-primed product 
could not be identified.  The negative control similarly had no amplicon indicating no contamination was observed. 
The positive controls that produced the correct sized amplicon (1438bp) was Rickettsia typhi and Rickettsia honei, 
albeit at a lower concentration is indicated by arrows. Sequencing confirmed the amplicon was OmpB gene of 
Rickettsia typhi. Due to the low yield of amplicon produced by Rickettsia honei sequencing was not successful. Size 
of bands of Hyperladder I is indicated on the left. 
 
Another region of the OmpB gene was also targeted using primers R120-1378F and R120-2399R and primers were 
confirmed to amplify a 1021bp amplicon for the Rickettsia positive controls (data not shown).  All test subject DNA 
1   2    3   4 ladder  5  -ve R.h  R.t  O.ts  
1438bp 
 
10kb 
8 
6 
5 
4 
3 
2.5 
2 
1.5 
1 
0.8 
0.6 
0.4 
0.2 
450bp 
76 
 
was subjected to identical PCR conditions as outlined in methods and none of the participant genomic DNA samples 
purified from peripheral blood yielded a product (data not shown).  
Targeting rOmp A gene of Rickettsia Spotted Fever Group:  
The Omp A gene which is specific for the spotted Fever group Rickettsia was targeted using R190.70F and 
R190.701R primers (Fournier et al., 1998) were confirmed to amplify a 631bp amplicon for the Rickettsia honei 
positive control (data not shown).  All test subject DNA was subjected to identical PCR conditions as outlined in 
methods and none of the participant genomic DNA samples purified from peripheral blood yielded a product (data 
not shown).  
3.6.1.2 Nested PCR targeting 56kDa type-specific antigen (TSA) gene of Orientia Tsutsugamushi 
A 1013bp region of the 56-kDa TSA gene was targeted using external primers TSU34N1F-19-38 and TSU55N1R-1032-
1013 (Yang et al., 2012) and internal primers TSU10N2F-408-428 and TSU11N2R895 -876 to amplify an internal 
region of 487bp in size (Yang et al., 2012). External primers yielded an amplicon of 1013bp with the positive control 
DNA from Orientia tsutsugamushi and the nested internal primers yielded a product of 487bp (data not shown). All 
test subject DNA was subjected to identical PCR conditions as outlined in methods and none of the genomic DNA 
samples purified from peripheral blood yielded a product (data not shown).  
 
3.6.2 Immunofluorescence Microscopy.  
A total of 88 test participants and 29 controls were tested for evidence of exposure via antibody detection to three 
groups; STG (Scrub Typhus Group), TG (Typhus Group) and SFG (Spotted Fever Group), of rickettsial or oriential 
pathogens. Eleven of the 88 returned fluorescence indicating positive results for exposure to one of the tested 
antigens at a titre of 128:1. Samples were deemed positive depending on fluorescence as described in the methods 
section. Examples of positive control serum, positive test subject, negative control and negative participants results 
can be seen in figures 3.16-3.19. One of the 29 controls returned fluorescence indicative of previous exposure.  Six 
test group participants (6.8%) returned positive results to spotted fever group tests compared to none (0%) of the 
control group (p=0.149). Three of the test group returned positive responses (3.41%). The control group produced 
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one positive result (3.45%) to the STG test compared to two test group participants (2.27%). No single test group 
participant or control participant tested positive for exposure to more than one group of rickettsial antigen, thus 
12.5% of test group produced a positive response to some form of rickettsial antigen, compared to 3.45% of the 
control group (p = 0.163), table 3.14.  The CFT subgroup participants returned four positive responses to all 
antibodies, the CFX subgroup participants returned seven positive responses and the control group returned one, as 
indicated in Figure 3.15 below. Examples of positive and negative results obtained from IFA are shown in figure 3.16 
Table 3.14 Percent of positive IFA results for test group compared to control group. 
  
Test Group 
(n=88) 
Controls (n=29) Significance 
SFG 6.82 0.00 0.419 
TG 3.41 0.00 0.314 
STG 2.27 3.45 0.728 
  
 
  Combined 12.50 3.45 0.163 
 
 
Figure 3.15 Positive IFA results in test sub-groups and control group The percentage of positive CFT and CFX 
subgroup and control group responses to IFA for antibody response to Rickettsial groups. 
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C D 
                                  
Figure 3.16: Rickettsial IFA. A.  Positive IFA control serum  B. Positive IFA participant example C. Negative IFA control 
serum  D.   Negative IFA participant example 
 
3.7 Results Overall 
 When the results to multiple tests are considered together a relationship between the test group and multiple 
positive results emerges. 90.9% of the test group returned positive results to evidence of at least one form of 
infection this was not significant compared to the 79.3% of control group participants who returned a positive as 
well (p = 0.095). When comparison was made on tick-borne (TB) pathogens, 56% of CFS participants had exposure 
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to at least one, compared to 14% of controls (p < 0.001). Six percent of CFS participants had exposure to both 
Borrelia species and Rickettsia species compared to 0% controls. Exposure to at least one TB and one respiratory 
pathogen was significantly different between CFS participants (40%) and controls (3%) (p > 0.001) . Table 3.15 doesn 
not display the data for the  difference between the two CFS groups, this is displayed in table 3.15. 
When the test sub-groups are considered, a similar relationship is evident. Fifty-six percent of CFT and 55% of CFT 
subgroup returned positive results to one tick borne pathogen, compared to the 14% of control participants (p < 
0.001 for both). Likewise, 41% of CFT participants, and 38% of CFX participants returned positive results to at least 
one tick borne and one airborne pathogen, compared to 3% of control participants (p < 0.001 for both). The CFT 
group also reached significance over the control group when 24% of the cohort returned positive results to three 
different pathogens compared to three percent of the controls, this is outlined in table 3.16. 
 
 
 
Table 3.15 Significance between test and control groups as total percentage of positive responses to different 
pathogens are considered 
 
Number of pathogens 
Test 
Group 
(n=88) 
Controls 
(n=29) 
Significance 
0 18 28 0.277 
1 24 24 0.976 
2 39 31 0.461 
3 19 3 0.04 
1 tick borne 56 14 <0.0001 
2 tick borne 6 0 0.19 
1 respiratory 42 48 0.557 
2 respiratory 27 24 0.74 
at least 1 tick borne and 
respiratory  
40 3 0.0002 
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Table 3.16 Significance between test sub groups and control group as total precent of positive results to different 
pathogens responses are considered  
 
Number of pathogens 
CFT subgroup  
CFX 
subgroup 
Controls 
 
Significance 
(n = 41)  (n = 47) (n = 29) CFX vs C  CFT vs C 
CFX vs 
CFT 
0 22 15 28 
 
0.177 0.588 0.392 
1 22 25 24 
 
0.892 0.83 0.694 
2 32 45 31 
 
0.237 0.952 0.212 
3 24 15 3 
 
0.114 0.018 0.26 
1 tick borne 56 55 14 
 
0.0003 0.0003 0.941 
2 tick borne 2 9 0 
 
0.107 0.397 0.22 
1 respiratory 34 49 48 
 
0.955 0.235 0.161 
2 respiratory 34 21 24 
 
0.771 0.368 0.176 
at least 1 tick borne 
and respiratory  
41 38 3 
 
0.0007 0.0003 0.762 
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Discussion 
4.1 Epidemiological characteristics  
A statistically significant proportion of test participants in this study were female; 84.4%. Participants 
were not selected with any bias towards sex, and the result in this study is consistent with the 
epidemiology of CFS as reported.  Jason et al. in 1999 found 0.52% of women in a community based 
random sample had CFS, which was significantly higher than the 0.29% found in men. This is supported 
by the finding of the relative risk of fatigue in women compared to men is 1.3 (Pawlikowska et al., 
1994). The supported findings on female prevalence reduce the likelihood that the common assumption 
that higher proportions of women, in studies reporting gender differences, may be due to differences in 
illness behaviour and referral patterns has had an effect on the study (Ranjith, 2005); however it is 
possible that it may in part account for the higher proportion of female participants.  
The significantly greater hours spent outside per week by test group compared with the control group is 
indicative of environmental factors potentially playing a role in fatigue. This idea is reinforced through 
similar significant findings within test group partaking in rural or bush based activities, having a job with 
animal exposure, having a job in the bush or a rural area and having recollection of a tick bite 
domestically (Table 3.2).  The increased incidence of tick bite recollection is consistent with findings of 
those who have increased exposure to domestic animals who may serve as hosts (Hjetland et al., 2013).  
Whilst there is minimal evidence to support these factors influencing levels of fatigue at this stage, it 
seems to be an avenue warranting further research. Sadly most participants did not include in their 
response the geographical location of their bite which would’ve allowed for further analysis. 
Within the test sub-groups, the reference questionnaire only produced one significant difference; those 
with a recollection of a domestic tick bite. Understandably, the participants who were previously 
diagnosed with some form of infection that is transmissible through tick bite (CFT subgroup), had a 
significantly higher rate of recollection of a tick bite. There is a possibility of distorted recollection in 
both test group and control group however, as it has been reported that the vast majority of tick bites 
can go unnoticed by the recipient due to their small size and the painlessness of the bite (Nahimana et 
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al., 2004). Likewise, there is a possibility of ‘recall bias’ in CFT subgroup participants who may have been 
informed of their infection and possible causes including tick bite, and have since attributed their 
infection to a tick-bite (Coughlin et al., 1990).This has been shown to affect epidemiological research, 
especially in studies investigating etiological causes of conditions, whereby the affected group may 
search their memories for exposure to noted causative factors more thoroughly than the healthy 
control population (Schulz & Grimes, 2002).  
 
 
4.2 Assessment of Symptomology.  
As would be expected, the reported symptom scores calculated from severity and frequency of 
individual symptoms was significantly higher in the test group. Every sign or symptom except 
‘unexplained milk production’ was deemed to be significantly higher in the test group than the control 
group. The degree of this significance for most symptoms has led to the research team questioning the 
validity of these results. Self-reporting of signs and symptoms by participants and controls is very 
subjective, and consequentially unreliable. A large proportion of participants reported cognitive defects 
that potentially make them ineligible to adequately report their own symptoms. The stigma associated 
with CFS across many facets of the medical community has led to many sufferers feeling ostracised and 
desire for recognition may have led some of the participants to inflate the severity and or frequency of 
some of their symptoms.   Likewise the low scores returned by the control group are indicative of a level 
of nonchalance when completing the survey – 14 out of 28 control participants returned scores above 
zero to five or less signs and symptoms out of a possible 97 (5.7%) including non-specific symptoms. 
While possible that these are accurate, future studies may benefit from taking symptomology history 
personally, or distributing a signs and symptoms questionnaire to the participants treating doctor or 
having the patient complete some form of cognitive impairment testing, such as the mini mental test 
(Folstein et al., 1975), in an attempt to ensure higher reliability in reporting. 
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When the results received from the questionnaires are analysed, the high level of responses to 
cognitive and behavioural symptoms such as concentration difficulty, confusion and new information 
absorption is interesting. Of the test group participants, 100% reported some degree of cognitive 
impairment. This is substantiated by the published findings that cognitive function in CFS patients is 
impaired, even when the patient does not have any form of psychiatric disease (DeLuca et al., 1997). 
The symptoms with the highest prevalence in the test group, outside of those required for CFS diagnosis 
as outlined by the Centre for Disease Control (CDC) were; dizziness, back stiffness, confusion, poor 
attention span, speech errors, light and sound sensitivity and light headedness. Future studies may wish 
to analyse these symptoms using specialised tests, looking for causes of the prevalence of these 
symptoms either through comorbidity as a result of CFS, or concurrent disorders such as Ménière's 
disease (Lempert & Neuhauser, 2008) or autonomic abnormalities (Thijs et al., 2009). The variability of 
these symptoms across symptom groups indicates the wide-spread and multi-faceted nature of CFS.  
Within the test group, the reported symptomology was very similar, with no statistical differences 
noted between the CFX subgroup and CFT subgroup in any symptom. The symptomology score means 
between groups were analysed using ANOVA, with Games-Howell post-hoc testing performed. This 
style of statistical analysis was chosen to account for the variation of means and number of subjects ‘n’ 
between groups (Howell, 2002).  There was slight variance when the groups were compared individually 
with the control group; with neither group reaching significance for; seizures, facial paralysis/Bell’s palsy 
(Figure 3.4), erectile dysfunction and unexplained milk production (Figure 3.5). The CFT subgroup 
reaching significance for all other signs and symptoms except conjunctivitis (Figure 3.7) and heart 
murmur (Figure 3.2). The CFX subgroup having significance to all other signs and symptoms except 
psychosis (Figure 3.6) and swelling in the hip or shoulder joint (Figure 3.3).  Whilst there are small 
differences in symptomology between the groups, the similarities between the CFX and CFT subgroups 
is to be expected, as both groups of the participants had a diagnosis of CFS.  
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4.3 Borrelia spp.   
Diagnostic Criteria in Australia: 2 tier system 
In Australia  the Centre for Disease Control (CDC, USA) Borrelia serology criteria is employed , whereby 
serologic confirmation of Borrelia infection diagnosis is achieved through a two tier testing system.  
Initially ELISAs are run, and the patient requires a positive or equivocal result to qualify progressing to 
the second stage of testing; immunoblot, otherwise known as western blot (Ang et al., 2011). Research 
indicates that antigenicity varies with species, and Bbsl is highly antigenic (Dressler et al., 1994). In 
America, the five band criteria (where a patients sample has to have antibodies to at least five of ten 
identified specific antigens) was developed for surveillance purposes (Dressler et al, 1993).  In European 
diagnostic laboratories, they are finding that two antigen band responses on western blot strips are a 
more appropriate measure of infection in a European population (Goettner et al., 2005). In China one 
antigen band response is accepted as a positive (Liu et al., 2013).  Clearly the criteria for positive 
serology needs to be established in each endemic area using a healthy population to establish cut offs.  
This has not been carried out in Australia, which is presently classified as a non-endemic area.  Currently 
Australian diagnostic testing has relied on the USA criteria, as outlined above (Ang et al., 2011), 
however it may be questioned whether this is appropriate within an Australian population.  Australian 
travellers could be exposed to Asian, European or American Borrelia genospecies and as such our 
testing should be sensitive enough to detect multiple species or several separate ELISAs should be 
carried out to account for each potential species.   If an endemic Borrelia species is identified then the 
appropriate serological prevalence study would need to be conducted to allow appropriate criteria and 
cut-off values to be established. 
1st tier ELISA 
The use of ELISA to test for Borrelia has come under scrutiny in previous studies. It is currently advised 
as the first tier of a two tier testing procedure used in many places across the world (Ang et al., 2011). 
However, ELISA has been shown to result in false-positive IgM responses in up to 27.5% of patients 
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(Seriburi et al., 2012). It also leads to false negative results as demonstrated in a study where all eight 
ELISAs examined returned false negatives for samples that then tested positive to immunoblots (Ang et 
al., 2011).   In this study there was no significant difference in the percentage of people from the test 
group or the control group who produced a positive response to either IgG -9.1% of test group and 0% 
of control group Table 3.10) or IgM testing (8.0% test group and 3.5% control, Table 3.10). There was 
surprisingly one positive IgM response in the control population, which may have been a false positive 
given that ELISA testing of IgM responses can result in false positives in a quarter of tested groups (REF).  
It is possible that the positive result was caused by antigens to some other flagellated bacterium. 
Flagellin and Osp C have been shown to be two of the major antigens for IgM immune response, and 
with the highly conserved C and N-terminal regions in flagellin protein being shared with other bacteria, 
it is possible that non-specific binding took place, leading to the false positive response (Wliske et al., 
1993). Alternatively the possibility exists that the control participant may have previously been exposed 
asymptomatically to Borrelia as a result of travel to an endemic area and has since recovered.  Although 
not significant, the CFT subgroup in both cases had a higher proportion of cases than the CFX subgroup 
to both IgM and IgG tests (Figure 3.11). This is perhaps to be expected given that many of the CFT 
subgroup participants recruited for this study were from another study investigating Lyme Borreliosis in 
Australia. Numerous false positive ELISA results were reported from both the test group, with seven of 
the 12 participants who returned positive ELISA results not returning positive western blot results.  This 
may further exemplify the unreliable nature of the ELISA testing for an Australian population. It is worth 
noting that 100% of the participants with positive ELISA results who did not return positive western blot 
results, had ‘borderline’ responses, perhaps indicating non-specific binding across both tests. This may 
be due to a variant Borrelia species not specifically tested for, or some other bacteria.  
 
 
2nd Tier western blot 
Whole cell antigen western blot 
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  The number of positive responses for individual Borrelia species whole cell antigen western blots were 
not significantly different between the test group and control group. When the individual species 
western blot data were combined to compare any Borrelia species the test group returned a higher 
percentage of positive results than the control group.  The test group produced a significantly higher 
response for IgG antibodies than the control group (p=0.015), with almost a quarter of all 88 test group 
participants (23.9%) producing evidence of an IgG response to Borrelia spp infection. Only one of the 29 
control group participants (3.5%) produced a positive IgG response. When IgM response was 
considered,  5.7% of the test group returned a positive response, and none from the control group 
(Table 3.6). Interestingly, the sub-categories of the test group were almost identical in response. The 
CFT subgroup produced a slightly higher percentage response, although the results were not 
significantly different (Table 3.7).  Busson et al. (2012) highlighted the potential issues with 
manufacturers setting the rules of interpretation of blot results to sort the samples into the afore 
mentioned categories, with some manufactures having a higher cut-off between equivocal and positive 
results to minimise the number of false positive results and keep specificity high, at the expense of 
weakly positive results being categorised as borderline. The number of potential weak positive results 
that were discounted as a result of high cut-off values used by EuroLineScan is evident when you 
compare the 62.5% of test group partipants who returned equivocal results to at least one whole cell 
antigen western blot, to the 24% who returned at least one positive. While not all of these samples 
would be deemed positive, it is reasonable to assume that there would be a percent which would be 
deemed positive by a different analysis system.  
The idea that the test group as a whole produced a higher IgG response than IgM response is in 
accordance with the argument that some form of long term or chronic Borreliosis infection may have 
some level of cause or contribution to CFS rather than recently acquired Borreliosis (Trieb et al. 2000). 
However caution needs to be taken as the positive IgG serology could also indicate a previous infection 
that has been cleared.  Either culture of Borrelia or detection of Borrelia DNA would confirm a current 
infection. In their 2000 study, Trieb et al. found that in a study of healthy males for presence of Borrelia 
antibodies, chronic fatigue and malaise (one of the major secondary syndromes of CFS) were more 
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common in those with seropositive evidence of Borrelia exposure. Comparatively, IgM antibody 
response is usually indicative of an acute or recent infection, which may have a lower frequency in 
those with CFS as who are more likely to have more established, or chronic infective loads. This may 
also explain the lack of statistical significance between the test group and control group for IgM 
response.   However in the case of some pathogens a longer IgM response is observed and this is due to 
the evasive mechanisms employed by the pathogen.  For example, a prolonged IgM response has been 
observed in relapsing fever Borrelia, largely due to the pathogen changing its surface antigens during an 
infection course.  Borrelia hermsii, for example can sequentially display up to 30 different surface 
lipoproteins with each eliciting an IgM response (Stoenner et al., 1982).  Due to the low return of 
positive IgM response with whole cell antigen western blot there was no further analysis with 
recombinant IgM.   
 
The lack of significant difference between the whole cell antigen testing in producing a clear response 
to an individual Borrelial strain is not surprising in an area such as Australia that is currently reported as 
non-endemic.  Australians are avid travellers and potentially may have been exposed to a Borrelia 
species in Europe, USA, Africa or Asia. Interestingly, only 5.7% of the CFS cohort could recall a tick bite 
overseas. In contrast 44.3% of the CFS group recalled a domestic tick bite.  Since the 1980’s there have 
been reports of a Lyme-like illness (Stewart et al., 1982; McCrossin et al., 1986; Lawrence et al., 1986) 
and reports on serology suggesting a Borrelia species as causative agent (Hudson et al.,1994, 1998; 
Mayne 2011), which may suggest a unique Australian species of Borrelia. Efforts in the 1990’s to isolate 
and characterise a Borrelia species from Australian ticks produced conflicting results (Russell et al., 
1994; Wills & Barry, 1991) and as such at the time it was concluded that there was no conclusive 
evidence to support an indigenous Borrelia species in Australian ticks. A study that investigated whether 
an Australian tick, Ixodes holocyclus, more commonly referred to as the paralysis tick, could act as a 
vector for an American lab strain of Borrelia showed that although the larval tick could maintain the 
Borrelia strain, once larvae had moulted to the next life stage, the nymphal stage, there was no 
evidence of Borrelia in nymphal ticks and hence they would not be a competent vector (Piesman & 
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Stone, 1991).  The authors did state that although vector competency could not be shown for an 
American Borrelia isolate the experiments should be conducted with any Australian strains that are 
isolated. This lack of specific target pathogen species complicates serology in non-endemic areas as 
immunogenicity to certain antigens has been shown to be species specific (Schulte-Spechtel et al., 2002) 
and ideally a broad test with multiple antigens from multiple species would be used in non-endemic 
countries to provide the best chance of detecting a Borrelia species. There are genus specific antigens, 
such as flagellin, available that should theoretically bind to immunoglobulins made against any Borrelia 
species, however these antigens have also been shown to bind antibodies against other spirochetes as 
well as immunoglobulins raised against viruses (Mavin et al., 2006) and as a result, lack the specificity 
required. 
Recombinant antigen western blot 
The recombinant IgG western blot testing resulted in a significantly larger number of positive 
participants than the whole cell antigen responses. The test group returned 63.6% as positives (p = 
0.006); compared with the control group which returned 34.5% positives. This was unexpected and the 
specificity of some of the recombinant antigens were questioned due to the high response rate within 
the healthy control group. This highlighted the importance of investigating any diagnostic test within 
the healthy population it will be used so that accurate cut-off values can be obtained to ensure only 
true positives are detected.  Previous studies using the Euroline-RN-AT kits found the strips to have 76% 
positive predictive value, and a negative predictive value of 100% with an overall specificity of 95% 
(Busson et al. 2012).  However this was based on a Belgian cohort and as such would be expected to 
have high specificity for European Borrelia antigens and a good positive and negative predictive value.  
Within the limited cohort size within this study a statistical analysis was undertaken to explore whether 
it was possible to differentiate which antigens were useful in detecting a clear difference between CFS 
groups and controls and evaluating valid cut-off values to differentiate positive, indeterminate and 
negative serology.  The statistical analysis (discussed in detail below) demonstrated that within the cut-
off values as evaluated by Mann Whitney U test and Vargha Delaney A test comparisons the results of 
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the CFS test group had 27 individuals (30.7%) return a positive (CFT=9 and CFX=18) while 2 controls 
(6.9%) returned a positive which is more in line with published studies for healthy population as well as 
determined in this study for whole cell antigen western blots (3.5%). These results clearly need to be 
validated to a greater extent than was possible in this study and as described in results (Table 3.10). This 
statistical analysis was expanded to include response to whole cell antigens for both IgM and IgG classes 
as detailed below.   
In an effort to deduce and analyse response values, normalised response scores generated by the 
EuroLineScan software for each individual antigen were analysed statistically (described in section 2.10)  
It was found that the VlsE antigens, when considered as a whole, produced a highly significant 
difference in response from test group to control group (p =0.001). The VlsE is a surface protein which is 
part of the Borrelial immune-evasive strategy and can have large, highly variable surface epitopes in 
order to evade immune response (Kenedy et al., 2012; Berndston, 2013). Positive response for another 
borrelial virulence factor; Osp C was also found to be significantly higher in the test group when 
compared to the control group (p<0.0001). Osp C production has been found to be unregulated in the 
tick mid-gut during tick feeding and is used for mammalian infection (Steere et al., 2004). Borrelia 
Antigenicity: an Australian perspective 
In order to assess the most effective test antigens  in separating the test group from the control cohort, 
the individual response intensity score for each of the 101 antigens was gathered for all 117 test and 
control participants. Twenty-one antigens were excluded because they did not return a single response 
across all participants. These antigens were mostly non-specific, with the major exceptions being Osp B 
from B. burgdorferi IgM and VlsE, p 83, p 30 and p 21 from B. afzelii IgM. While the rate of detecting 
evidence of IgM responses was low throughout the whole study, there were positive results to both 
these tests. Osp B is an outer surface protein that is thought to play a strong role of the bacterial 
colonisation and survival within the arthropod vector (Kenedy et al., 2012) and would be expected to be 
detected in those with positive responses for IgM antibodies. P 83 has high specificity to the target 
bacteria, but is not one of the ten specific bands chosen by the CDC, designed for Bbss, of which five 
must be present for a positive Borreliosis diagnosis (Evans et al., 2010). P 30 and p 21 are both part of 
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the CDC array of specific antigens, however positive diagnoses can be made without either of them 
being present. These antigens also may have significance in a possible Australian strain of Borrelia and 
as for the American or European strains,  their absence may not be indicative of absence of Borrelial 
infection, but because of species variation. Of the 80 antigens that produced positive results, ten were 
found to have significant variance using the Mann Whitney U test between the test group and control 
cohort. Of these ten, eight were significantly more common in the test group than the control group, 
while the other two were significantly more common in the control group than the test group. 
Interestingly, all eight of the positively related antigens were from the recombinant IgG test (VlsE-Ba, 
VlsE-Bb, VlsE-Bg, p83, p39, OspC, p21,p18) ; with both of the significant negatively related antigens 
being extrapolated from whole cell antigen tests( p57-59 from B. garinii IgG and Osp C from B. afzelii 
IgM). Five whole cell antigen antigens were isolated as important distinguishing markers between the 
groups by the combined Mann Whitney U test and the Vargha Delaney A test analysis outlined in the 
results, they were all negatively related to the test group. No whole-cell antigen was found to be 
positively associated with the test group rather than the control group. This may be prove that 
individual whole cell antigen tests that are currently used in diagnostic laboratories in Australia for 
known USA & European Borrelial species may be lacking sensitivity and specificity. Osp A from B. garinii 
IgM test, was an antigen that was supposed to be highly specific, was the only one of the negatively 
related antigens found to be important distinguishing factors in our test. The prevalence of positive 
results for evidence of antibody towards this supposedly specific surface protein of a disease thought 
not to be endemic to Australia in a healthy control population was unexpected. There is a possibility 
that some endemic Australian micro-organism that does not exist internationally, may have a level of 
cross-reactivity for the antigen and was able to non-specifically bind to the antibodies, alternatively 
there is a possibility of an Australian Borrelia or Borrelial-like species binding to the designed sites. The 
ambiguity around this is something that merits further investigation.   
The overall results generated from the EuroLineScan program, especially in the case of the recombinant 
IgG testing, were unreliable. It is unknown as to whether there was a technical problem when 
preforming the tests, however upon repeat analysis of the samples, reliability was not ensured. The 
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‘positive’ result levels produced by the control cohort were higher than could be reasonably expected. It 
is possible that a ‘background noise’ level was being produced by something almost universally 
prevalent in the Australian population tested that is not present in European populations, and 
consequentially does not cause the same ‘background noise’. Through individual antigen analysis and 
the use of statistical modelling through ROC graphs it was possible to adjust the cut-off points in antigen 
intensity as described above. 
 Very late in the study, when investigating potential causes of error, it was learnt that for Euroimmun 
kits testing trays  reuse was not recommended, however when this was tested, it was not found to be a 
significant cause of variation in the results. In contrast other diagnostic kits do recommend re-use of 
incubation trays.  Relationships and trends were able to be extrapolated from the individual antigenic 
responses, which were potentially more reliable than the overall result produced by the software.  
Within the tests themselves, the potential for cross-reactivity has been identified by previous studies, 
with the non-specific antigens more commonly the problem, especially flagellin p 41 and the heat shock 
proteins; p 57, p 60 and p 62 (Busson et al., 2012).  This was particularly evident for flagellin p41, in our 
test group and control cohort there was a high prevalence of a strong antigenic IgG response in both 
recombinant blots and whole cell antigen western blots.  Other studies have found that this can be due 
to other spirochetes as well as other micro-organisms (Busson et al., 2012).  Due to this cross-reactivity 
flagellin is usually not included as part of the analysis in diagnostic assays.  
Detection of Borrelia DNA: 
There are many difficulties associated with the use of PCR to detect Borrelia in patients. Borrelia, 
especially in chronic infection exists in very low levels in the blood, as it can disseminate quickly into 
tissue after infection (Dykhuizen et al., 2006). For this reason the sensitivity of PCR drops with more 
advanced manifestations (German Borreliosis guidelines, 2010).  Similarly the outer surface proteins 
(OSPs) of Borrelia are highly variable, there are significant genetic differences between European and 
American strains (Schmidt, 1997), and it serves as logical that a strain of Borrelia if present in Australia 
would once again display variation that does not lend itself to the primers selected for the known 
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American or European strains. Although a conserved gene, 16S rRNA, was targeted in this study, no 
Borrelia DNA was amplified from any test participant or control. The absence of a positive finding was 
not because of technical issue because conditions and primers selected were proven to work, as 
demonstrated through the successful amplicon formation through the use of a positive control; DNA B. 
burgdorferi B31. False negative results from PCR analysis are relatively common when testing for B. 
burgdorferi as a result of several immune evasive techniques, a product of this being negative PCR 
results do not rule out the possibility of infection (Mayne, 2011).  Possible improvements to the 
sensitivity of PCR to detect Borrelial DNA could be made through; culturing samples prior to PCR which 
has been shown to improve sensitivity of the test (Schwartz et al., 1993), taking skin (if erythema 
migrans present) or tissue biopsy samples as opposed to blood samples to maximise possibility of 
obtaining positive cultures. Similarly, primers could be selected to target other forms of Borrelia such as 
relapsing fever Borrelia. Other options would include the use of an isothermal amplification (IA) assay as 
used by Eschoo et al. which was developed to amplify seven Borrelial target regions in whole blood 
samples, thus ensuring the amplification of the low levels of Borrelial DNA found in blood (Eschoo et al., 
2012). PCR is a useful diagnostic when one can sequence an amplified gene target confirming a current 
infection.  Unfortunately a negative PCR cannot rule out the presence of an infection. 
Borrelia and immune evasion 
Borrelia has a multitude of immune evasive mechanisms which allow it the ability to establish itself as a 
chronic infection within host cells and resist antibiotic challenge. It has been shown to be able to use 
Osp C to commandeer Salp 15 salivary protein from the tick vector upon transmission from tick, to new 
host.  Salp 15 can inhibit host immune responses including; CD 4+ T cell response through blocking 
receptor binding as well as inhibiting macrophages, dendritic cells and natural killer cells. This level of 
immediate host immune manipulation, albeit short lived, allows Borrelia to establish its other virulence 
factors before the host can mount a defence (Ramamoorthi et al., 2005; Berndston, 2013). Borrelia Osp 
C is also able to create a plasminogen receptor on the surface of the bacteria. This allows the pathogen 
to use host plasmin to work its way out of the high traffic areas of immunosurveillance and into the 
extracellular matrix (ECM) (Önder et al., 2012; Berndston, 2013). By removing itself into the ECM, 
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Borrelia is able to establish infection without constant attack from host immune response, as well as 
becoming more difficult to target with administered antibiotics.  
Borrelia’s ability to bind to a plasminogen receptor is being investigated as a possible mechanism 
whereby it might transverse the blood-brain barrier and enter the CNS (Grab et al., 2005). Borrelia is 
also able to use the highly variable major protein like sequence, which expresses on the surface as VlsE, 
to elude immune detection through the use of the continual shuffling of genetic information and 
adaptable surface epitopes (Zhang et al., 2012; Kawabata et al.,1998). Both Osp C and VlsE were found 
to bind produce responses in IgG testing at significantly different levels in the test group and control 
group in this study.   
The role of biofilms in bacterial persistence is increasingly considered and Borrelia has been shown to 
be able to create biofilms, “complex polymicrobial communities embedded within an exopolymeric gel” 
(Berndston, 2013). Biofilms have been noted as a common form of persistent infection (Costerton et al., 
1999) Where a structured bacterial population can embed itself within a matrix composed of 
extracellular DNA, polysaccharides and proteins (Olivares et al, 2013). The effectiveness of antibiotic 
treatments has been shown to be greatly reduced against cells growing within biofilms comparatively to 
those not (Mah & O’Toole, 2001). This may be due to several causes including variant structure of the 
ECM and the alternate physiological and metabolic states of the biofilm growing bacteria (Olivares et 
al., 2013).  The ability to create and survive within biofilms further exemplifies the immune-evasive 
abilities of Borrelia. 
  Australian Borrelia diagnostic tests : potential short fall of ELISA 
It is not known whether Bbsl species are present within Australian vectors which makes it difficult to 
predict which diagnostic test will be most sensitive and specific for detecting a Borrelia infection within 
the Australian population. The current Centre for Disease Control (CDC) guidelines of using a two-tiered 
testing is utilised in Australia.  ELISA is the first tier and if positive or equivocal then the patient serum 
sample proceeds to second tier western blot where a minimum of five out of ten specific antigens are 
required to be labelled as a positive. Based on the limited results of this study, it would seem this 
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system may not be appropriate for Australian use unless all samples tested in this study were not the 
result of previous or chronic exposure to Borrelia. Sixteen out of 21 (76.2%) of the test group 
participants who returned a positive whole cell antigen western blot and 27 (30.7%)of the test group 
participants who returned a positive recombinant WB IgG result did not return a positive or equivocal 
ELISA. Under the current Australian guidelines, none of those participants who returned a 2-band 
positive whole cell western blot result, but a negative ELISA, would have progressed to the western blot 
testing level upon returning negative ELISA results. This area of the study would definitely highlight the 
necessity of further research on the reliability of ELISA results.   
There was no significant difference in any test for Borrelia between the CFT subgroup and CFX subgroup 
indicating that although one group was comprised entirely of participants with previous exposure to 
known tick borne pathogen infections combined with their CFS diagnosis, the group with no knowledge 
of concurrent or previous infection appeared to have a similar level of response to Borrelial antigens. 
Further investigation is required to determine sensitivity and specificity of antigens to be used in both 
ELISA and western blot diagnostics in an Australian population.  The data from this limited study would 
suggest the following candidate antigens for further development, VlsE, OspC, p83, p39, p21, p18.  
 
4.4 Chlamydophila pneumoniae.  
Infection with C. pneumoniae occurs commonly worldwide; in Australia a 40% prevalence of serum 
antibodies in a Western Australian population at ≥ 1:32 has been reported (Black et al., 1994). Although 
this is not indicative of current infection rates as serological positives can be reported by antibodies to 
previous infection being detectable in serum (Verkooyen et al., 1998). The high percentage of mild or 
asymptomatic infections caused by C. pneumoniae can cause many cases to go untreated. It was initially 
suggested that C. pneumoniae was an uncommon but treatable cause of CFS (Chia & Chia, 1999). This 
theory has been updated to encompass the notion that CFS can have an infectious nature that could 
either be causative, a co-factor or an opportunistic infection, a percentage of these infections could be 
to C. pneumoniae (Nicolson et al., 2003).  
95 
 
The difference in percentage of positive ELISA response between the test group and the control group 
was not significant (p = 0.09). Further study with an increased sample size is warranted.  The presence 
of one infection may predispose patients to other infections (Nicolson et al., 2003) and it is possible that 
a chlamydophilial infection may be part of the potential causative, co-factor or opportunistic infection 
load mentioned earlier.  The 46.6% prevalence of IgG response in our test group is only slightly higher 
than the 40% reported in the literature as community prevalence, and although over 15% higher than 
the level found in the current control cohort, it does not constitute a significant difference and cannot 
be used to signify any real difference as in serological studies there is no way to tell when the 
participant was originally exposed. The high percentage in the control group could potentially be 
accounted for through previous infection since which, the participant has returned to full health, or 
previous asymptomatic infection, which can occur in approximately 4% of the population (Miyashita et 
al., 2001), of which the participant was unaware.  
Detection of Chlamydophila pneumoniae DNA 
No CFS participant returned a positive PCR which may indicate no C. pneumoniae DNA present in the 
blood stream or it may indicate a failure in the PCR conditions.  Unfortunately due to the lack of positive 
control DNA it was not possible to confirm the primers and conditions worked correctly. However, the 
conditions were very similar to those used by Dresses-Werringoloer et al., 2008 when they used the 
same primers, except for a change in annealing temperature. The low number of participants with 
positive IgM ELISA responses indicates that there were few participants with a current or recent 
infection therefor the participant would have certainly had levels in blood that could be detectable 
through PCR analysis.  
 
Chlamydophila pneumoniae and immune evasion 
The immune evasive abilities of the C. pneumoniae bacteria allow it to establish an intracellular niche 
within its Chlamydial inclusion (non-lysosomal vacuole), where it maintains the ability to affect cell 
signalling pathways, bypass host cell immune response mechanisms and stimulate survival or death of 
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the host cell (Yucesan & Siriam, 2001; Stratton & Siriam, 2003; Stratton & Mitchell, 1997).  By existing 
within these inclusions, C. pneumoniae is able to develop a chronic infection due to the inability of the 
host to eradicate it. C. pneumoniae can exist in this state for decades where, upon entry into 
mononuclear cells, it can adapt into a state of quiescence which is spasmodically broken with bursts of 
replication where pro-inflammatory cytokines, antigenic variation and heat shock protein production 
are up regulated. The results of these periods of activity lead to host tissue damage (Stratton & 
Mitchell, 1997). Chronic Chlamydial infection is characterised through the persistence of clinical 
symptoms, potentially similar to those experienced by our CFS test group. The variance of 
symptomology within those affected could be produced by a combination of personal host factors, 
including genetic variability and individual traditional risk factors (Contini et al, 2009). A contributing 
factor to this may be the expression of the 60kDa heat shock proteins (HsP60), which are produced with 
increased expression in chronic Chlamydial infections, and constant host defence against Chlamydial 
HsP60s may lead to autoimmunity to host HsP60s. This autoimmune function has been shown to 
contribute to the development of some chronic diseases e.g. asthma (Hahn and Peeling, 2008) and 
coronary heart disease (Ciervo et al, 2002) and therefor may contribute to levels of fatigue as well. 
Further Chlamydial immune-evasive techniques have been discovered, but not completely understood. 
It has been shown that C. pneumoniae has the ability to dictate apoptotic cell signalling pathways, yet it 
is still unclear as to why it induces apoptosis or necrosis at different times, although it is thought to be 
associated with the replication cycle of the pathogen (Byrne, 2003).  
The noted ability of C. pneumonaie to infect a broad spectrum of human cells including; macrophages, 
monocytes, lymphocytes and epithelial, endothelial and smooth muscle cells, combined with the 
knowledge that C. pneumonaie can infect a broad range of tissues (as indicated by the presence of 
chlamydial DNA in peripheral blood cells) is indicative of systemic colonisation following respiratory 
infection (Boman et al., 1998). Additionally, a potential pathway for C. pneumoniae to cross the blood-
brain barrier into the CNS has been postulated, as the ability of C. pneumonaie to promote the 
transmigration of monocytes through human endothelial cells can be demonstrated (MacIntyre et al., 
2003). These additional factors contribute possible corridors by which C. pneumoniae can contribute to 
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fatigue, with total systemic infection being linked to fatigue (Nicolson et al., 1998; Nijs et al., 2002), and 
CNS inflammation post infection being similarly linked to CFS via the increased production of numerous 
inflammatory cytokines including; TNF-α, IL-6, IL-8, MCP-1 and MIP-1α (Pall, 2000; Chao et al., 1992; 
Sheng et al., 1996; Netea et al., 2000). 
4.5 Mycoplasma pneumoniae. 
The community prevalence of M. pneumoniae is hard to analyse due to endemic infection tending to 
work on a 4-7 year spike (Hammerschlag, 2001). At baseline rates, the community prevalence is around 
10% (Ryan et al., 2004), but can be as high as 40-50% during adulthood (Tuuminen et al., 2000). The 
results gained from the Mycoplasma ELISA were surprising, with 62% of the control being positive. This 
is higher percentage prevalence than previously reported in an asymptomatic control cohort 
(Hammerschlag, 2001). This high prevalence can possibly be explained through familial transmission; in 
a study of 36 families with at least one case of atypical pneumonia caused by M. pneumoniae, it was 
found that in 64 % of the families there was at least one other family member infected. Within those 
families it was found that 84 % of children and 41 % of the adults were infected (Foy, 1966). In the 
present study 93% of the control participants came from a previous tick-borne diseases study.  Fourteen 
percent of the controls were therefore from families where a family member was diagnosed with a tick-
borne illness.  While the rate of M. pneumoniae is not known in those diagnosed with the tick-borne 
illness, it is possible that at least a percentage of the control group could have contracted M. 
pneumoniae from an ill family member, potentially explaining the surprisingly high positive result from 
the ELISA test.  The test group’s result of 45.5% positive is also high, but it is consistent with the upper 
end of the reported prevalence levels. While this higher level of infection is interesting, it is not 
significantly different from that obtained by the control group.  
Detection of Mycoplasma pneumoniae DNA 
Similar to the PCR testing for Chlamydophila pneumoniae, no CFS participants returned a positive PCR 
and once again the lack of positive control DNA meant that the specificity and reliability of the primers 
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and cycle conditions could not be tested. The primers used and cycling conditions were similar to those 
used by Chan et al. (2013) except for a decrease in annealing temperature from 72:C to 68:C. 
Mycoplasma pneumoniae and immune evasion 
Like, C. pneumonaie and Borrelia spp. previously discussed, Mycoplasma spp. have recently been shown 
to have the ability to enter host cells through fusion, and exist as an intracellular pathogen (Rottem, 
2002). It was hypothesised that if Mycoplasma spp could exist intracellularly it could allow for the 
development of a chronic infection (Waits & Talkington, 2004). While the way in which Mycoplasma 
pnuemonaie establishes itself within host cells is not yet clear, the clinical relevance of this hypothesis 
was strengthened by the finding that M. pneumoniae can survive and replicate within cell cultures 
(Dallo and Baseman, 2000).  This would indicate that M. pneumoniae, once established within a host, is 
able to remove itself from high traffic immuno-surveillance channels, allowing the colonisation of cells 
with less immune regulation. Futhermore, intracellular existence can reduce the effectiveness of some 
antibiotic therapies, explaining difficulties experiences eradicating M. pnuemoniae in previous 
experimental work. Other Mycoplasma species have been shown to fuse with host cells that are not 
normally phagocytotic (Rottem, 2002). M. pneumoniae cell membrane and host cell wall fusion may 
result in the release of various hydrolytic enzymes, resulting in the insertion of mycoplasmal cell 
membrane components into the host cell membrane. This in turn, may effect cytokine expression and 
production and alter cell recognition sites (Rottem, 2002). The extent to which M. pneumoniae 
establishes chronic infection and the subsequent effects, are still being investigated, and the clinical 
significance is yet to be proven (Waits & Talkington, 2004). However the fatiguing effects of chronic 
infection have been well documented (Contini et al., 2010) and it is possible that Mycoplasma 
pneumoniae if chronically embedded, would at least have an additive effect on fatiguing symptoms, 
even if they originated from another source. The high level of exposure found in the control group and 
test groups may be indicative of an endemic M. pneumoniae strain within Australian populations which 
is effective at resisting the host immune response.  
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4.6 Rickettsia spp. 
 
Evidence of Rickettsia exposure as determined by IFA was observed in 12.5% of test group participants 
compared with 3.45% of controls. Other studies that also used IFA for evidence of rickettsial infection in 
humans have found positive serologic samples in approximately 5% of humans in endemic areas (Horta 
et al., 2004). The study was conducted in Brazil, which makes a comparison with Australian results 
difficult. In an Australian study using IFA conducted across three metropolitan centres serological 
prevalence rates of 31%, 41% and 15% were found in Melbourne, Adelaide and Newcastle, respectively 
(Unsworth et al., 2007). The study size was on a much larger scale, with 526, 581 and 400 participants 
from their respective areas. The slightly higher sero-prevalence rate found in Unworth et al.’s study in 
Melbourne and Adelaide is not surprising considering the participants were selected from medical 
centres specialising in chronic illnesses and thus did not represent a controlled patient cohort. The 
results from Newcastle with a sero-prevelence of around 15% were recruited randomly from a medical 
centre as a ‘control’ population, indicating that they too may not have been completely healthy.  The 
12.5% positive test participants in the present study is similar to the 15% for the Newcastle cohort.  
Although the Newcastle cohort was not made up specifically with CF sufferers, the similar percentages 
may be reflective of similar geographic location with similar species/strains of Rickettsia being tested.  
Further testing within the rickettsial groups used in this study is required to establish, which strain the 
participant’s antibodies are targeting. Testing is required within those positive for the spotted fever 
group, namely Rickettsia australis and Rickettisa honei, the typhus group, namely Rickettsia typhi and 
Rickettsia prowazekii, and those positive for the scrub typhus group, namely Orientia tsutsugamushi 
strains Gilliam and Sido. There was around a 50% correlation between the strains of Rickettisa that 
Unsworth et al assessed, i.e. R. akari, R. australis, R. conorii, R. honei, R. rickettsii and R. sibirica.   IFA is 
currently the principal diagnostic tool of rickettsial infection in humans and animals (Bakken et al., 
2006).  The relatively equal spread of positive results across the three groups of rickettsia tested for in 
the present study is not surprising as the strains chosen were selected for the likelihood of their 
presence in Australia.  Interestingly, no single participant or control tested positive to more than one 
group of rickettsia, potentially indicating the lack of co-infection of more than one group of Rickettisa 
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spp and confirming the specificity of the species used for IFA. However, when the individual strains 
within the test group are identified, a clearer understanding regarding the specificity of the test species 
used and possible co-infections would be developed.  
There were difficulties encountered when using the microscope which may have led to a small level of 
experimental error. The fluorescence within the test wells on the slide was found to bleach very quickly 
when exposed to the light. There is a possibility that exposed wells lost their fluorescence before being 
viewed properly under the light, but this is unlikely. To counter this, a random collection of 
approximately 20% of the slides were run in duplicate, no discrepancies were found for these samples 
between runs.  The IFA would be improved greatly by substituting the fluorescein tag with FITC which 
does not bleach as readily as fluorescein, allowing more time to image the slides. 
Detection of Rickettsial DNA 
The use of three separate PCR tests was designed to increase the stringency of the testing procedure. 
The use of multiple positive controls was to help identify species should amplicons develop post the 
procedure. The positive controls, Rickettisa honei, Orientia tsutsugamushi and Rickettsia typhi all 
produced amplicons confirming the conditions and primers used. No amplicons of the correct size were 
produced from any participant in the present study.  There was some mispriming occurring with 
amplicons of smaller size than was expected.  Attempts to sequence the amplicons did not yield 
sufficient sequence to identify which organism or gene was being amplified.  Unsworth et al (2007) 
found that 3% of participants were positive for rickettsial DNA, therefor considering the high sero-
prevalence within their study it is not surprising that we did not find any participant with rickettsial 
DNAn in the present study.  Unsworth et al (2007) also states that the number of Rickettsia-positive 
participants was very low, and was only detectable with the use of a highly specific and sensitive real 
time- PCR assay. Furthermore, Unsworth and co-workers (2007) could not be certain as to the presence 
of current or recent infection with those participants who did return a positive PCR, as it was impossible 
to rule out reactivation of a latent rickettsial infection.  As noted when discussing PCR as a diagnostic 
procedure throughout this study, CFS has been reported to have connections with chronic infection, 
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and certain Rickettsia species have been shown to disseminate out of the bloodstream into endothelial 
cells and smooth muscle cells (where they multiply) upon infection, thus PCR of DNA extracted from 
whole blood may not have been the most appropriate measure when looking for evidence of long-term 
infection. Furthermore it has previously been found that rickettsaemia is seasonal, with winter months 
bringing higher levels of infection (Unsworth et al., 2007), all the laboratory testing for this study was 
done between October and February, the peak of summer. This may have also contributed to the lack 
of results found.   
It’s possible that IFA is a more sensitive form of testing for rickettsial exposure but a comparison 
between the two studies is difficult, as testing for antibodies in IFA can produce evidence of long-term 
previous exposure, where PCR results are more indicative of a current or recent infection.   
 
 
4.7 Case studies.  
4.7.1 Participant T61 
Participant T61 is a 27 year old female from Western Australia. She has never travelled overseas and 
only domestically in WA. Due to the extent of her fatigue, she no longer spends any time outdoors or in 
the bush. Previously she spent many hours rurally in Western Australia, working on a pig farm for over 
three years, coming into contact with all forms of farmyard and common rural animals as well as 
owning many domestic pets. She has been bitten by ticks in WA, the most recently recalled bite was in 
late 2007. In 2009 she was diagnosed with CFS. In 2013 she was diagnosed with Lyme Borreliosis. She 
has previously tested positive to Mycoplasma pneumoniae in 2013 as well as Epstein-Barr virus in 2007 
and 2010 and Varicella- Zoster virus in 2012. She has also tested IgG positive to cytomegalovirus, but 
was unaware of an onset date.  In this study she tested positive to M. pneumoniae IgG, C. pneumonaie 
IgG and IgM, B. burgdorferi IgG and IgM through ELISA, she also tested positive to B. garinii IgG and 
equivocal to B. azfelii IgG via whole cell antigen western blot, and positive to IgG recombinant western 
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blot. At the time blood samples were taken T61 was not taking any medication for her conditions, but 
has since started. She returned a symptomology score of 323, 144% of the average score, but only 61% 
of the maximum symptom score reported. It is possible that her CFS diagnosis in 2009 was contributed 
to or caused by infections she sustained as a result of the tick bite in 2007 or any previously. Her further 
bacterial infections may have preceded or followed her diagnosis, but treatment will hopefully reveal 
the extent they have contributed to her symptomology. It is entirely possible that her viral infections 
have contributed to her fatigue, as there is much literature supporting a relationship between viral 
infection and fatigue (Bansal et al., 2012).  
4.7.2 Participants X100 and X101 
Participant X100 is a 20 year old male and participant X101 is his sister, a 19 year old female. They are 
both from Sydney, NSW and have both lived there their whole lives. They have both travelled 
extensively domestically. Internationally, X100 has travelled to the west coast of the USA and X101 has 
travelled to Vanuatu. They have one cat and one dog. X101 has recollection of a tick bite in Northern 
Sydney, X100 has no recollection of a tick bite. Both participants have been diagnosed with CFS, X101 in 
2003, X100 at an unspecified date. Preceding this study, neither participant had diagnoses for any viral 
or bacterial infection. X100 has been diagnosed with fibromyalgia, an underactive thyroid, asthma and 
coeliac disease. In this study, X101 tested positive to B. burgdorferi IgM, M. pneumoniae IgG and C. 
pneumoniae IgG by ELISA, positive to B. garinii IgM and equivocal to B. burgdorferi IgM and B. afzelii IgG 
by whole cell antigen western blot, and equivocal to recombinant IgG western blot. X100 tested positive 
to C. pneumoniae IgG and IgM and M. pneumoniae IgG by ELISA, equivocal to B. afzelii IgG, B. 
burgdorferi IgG and B. garinii IgG by whole cell antigen western blot and positive to recombinant IgG 
western blot. This high exposure to multiple pathogens in both participants may have had a level of 
effect on their morbidity and fatigue levels. X101 reported a total symptom score of 68, only 30% of the 
average symptom score. X100 reported a symptom score of 219, 97% of the average score.  X100 is 
currently taking hormone replacements and pain killers for his other ailments. Neither participant is 
taking any form of antibiotic treatment. It is possible that X100’s fatigue may be contributed to as a 
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result of his hormonal imbalance from hypothyroidism (Louwerens et al., 2012), but the hormone 
replacement therapy should counteract any effect this has.  
4.7.3 Participant T15 
Participant T15 is a 50 year old female from Mid North Coast of NSW. She lives surrounded by the bush, 
and preceding her fatigue levels, worked for ten years as a bush regenerator. She has not had a pet in 
the last ten years, and does not come into contact with animals often. The only international travel she 
has undertaken is to New Zealand, and has many recollections of tick bites during her time in bush 
regeneration. She was diagnosed with Lyme Borreliosis in 2011, and also has diagnoses of Babesia, 
Bartonella and Coxiella. In this study she tested positive to B. burdorferi IgM and IgG, M. pneumoniae 
IgG and C. pneumoniae IgG by ELISA, equivocal to B. burgdorferi IgG by whole cell antigen western blot 
and equivocal to recombinant IgG. She is currently taking Doxycycline and azithromycin which may 
explain the lack of PCR result. Her overall symptom score was 219, 97% of the average symptom score.  
4.8 Future directions 
Chronic infection levels 
Confirming the presence of chronic infections within CFS participants is key to understanding the 
potential impacts they may have on the symptomology of the condition. More advanced levels of 
testing are required to accurately determine the presence of these infections. Serological responses as 
produced in this study can be indicative of these infections but not confirmatory. The use of tissue 
biopsy instead of blood sample could be useful for confirming presence of these infections that may 
have become intracellular. Culture from tissue biopsies may be worth undertaking to assist in isolation 
and molecular characterisation. Likewise the use of specifically targeted immunothermal amplification 
(IA) (Echoo et al., 2012) may enable detection of low concentration levels of bacteraemia.  
The TBDU has recently received biosafety approval to commence a collaborative project with Dr Stuart 
Fraser of the Department of Physiology, USYD. This collaboration will involve testing using an 
established flow cytometry method (Sanchez-Perez et al., 2013) to enable direct detection of 
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intracellular organisms in clinical samples.  Although taxonomic identification of intracellular organisms 
will not be available through this method, it will be able to produce evidence of intracellular infection.  
This technique may enable a potential avenue for correlation of CFS participants and evidence of 
intracellular infection, as is common in established chronic infections. Further, once samples are 
identified to contain an intracellular infection molecular methods can be used to characterise the micro-
organism. 
Borrelia investigation 
The presence of numerous Borrelial antigenic responses was higher than that expected in a population 
without an endemic species. This may be partly due to this study employing the European western blot 
criteria of 2 specific antigen bands as determined by the EuroImmun software rather than the CDC 
criteria as is currently employed in Australian diagnostic laboratories.  We thought it was appropriate to 
use the European criteria to increase sensitivity in detecting a possible exposure to a Borrelia species, 
whether it be European, Asian or American (Dressler et al 1994, Branda et al., 2013, Goettner et al., 
2005, Liu et at 2013).  The level of IgG response to various whole cell antigens from several Borrelia 
species as well as the recombinant antigens was surprising yet inconclusive. It was interesting that the 
following antigens seemed to be the best in discerning the CFS group from the control group VlsE, OspC, 
p83, p39, p21, p18 and would be worthwhile investigating in a larger cohort of Australians that may 
have Borreliosis as well as a healthy control population to address issues of specificity and sensitivity. In 
recent publications the suggestion has been made to move away from a 2 tier ELISA/Western blot 
diagnostic algorithm and to move to a 2 tier ELISA system with the 2nd tier being an ELISA based on the 
C6 invariable region of the VlsE protein which has been shown to be highly specific (Branda et al., 2011).  
Results from this study would suggest that VlsE or the C6 polypeptide may prove useful in Australian 
diagnostic tests.  The specificity of C6/VlsE would need to be determined in individual endemic areas 
and areas such as Australia where endemicity for a Borrelia species is still being investigated. 
The high prevalence of tick bite recollection within the chronic fatigue population examined in this 
study, may suggest a relationship and would require further investigation. 
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Future research should focus on isolating a Borrelia species to identify with certainty any specific strains 
within Australian populations. In addition isolation and characterisation of a Borrelia species in an 
Australian arthropod vector would need to be conducted.  The case study of participant T61 who 
produced positive responses to antigens for numerous Borrelial species without ever having left 
Australia and would be an ideal candidate  to investigate further with culture and molecular techniques 
to assist in isolating a Borrelia species if T61 has a current infection with a Borrelia species.  
Furthermore, the current CDC criteria used in Australia has been shown to be less sensitive for 
detection of the European species in American travellers infected in Europe, a certain percentage not 
returning a positive with American diagnostic kits/criteria (Branda et al., 2013) this would suggest the 
CDC criteria may not be appropriate in the Australian situation and particularly in establishing 
prevalence of positive Borrelia serology within Australian populations. Upon determination of strains of 
Borrelia present in Australia, a full review regarding the specificity and effectiveness of the CDC 
guidelines for use in detection of infections caused by those strains can be performed.  The 
development of appropriate sensitive and specific serology diagnostics for any endemic Borrelia species 
would then assist in determining prevalence.  
 
 
4.9 Conclusions 
Between the test and the control groups, there were significant differences in epidemiological data 
compiled for sex and for outdoor related activities and exposure to tick bite. Likewise there was a 
significant difference in mean symptom score returned for 92/93 symptoms assessed. This significant 
difference between the epidemiology and symptomology data of the two groups would indicate a large 
difference between the CFS and contol groups which was expected for symptomology score and it is 
interesting that differences in outdoor related activities and tick bite were significantly different..  
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The lack of data obtained from PCR testing across the entire study would seem to indicate the level of 
current or recent infection across the spread of those being tested was low. However, this needs to be 
considered in the context of limitations of PCR detection of micro-organisms in blood, as well as 
previously outlined; each of the bacteria tested for is capable of producing a chronic infection and may 
exist in immune protected niches and would only be expected to be in low levels in peripheral blood. 
Low levels of bacteria in blood may not be detected in a DNA extraction of a 200ul blood sample and 
further the PCR methods employed would not have been sensitive enough to pick up very low copy 
numbers of DNA    
IgG Western blots were the only diagnostic test to provide a significant difference between CFS group 
and control.  Whole cell antigen Borrelia western blot (combined for B. burgdorferi sensu stricto, B. 
garinii and B. afzelii) returned 23.9% positive (European 2 band criteria) in CFS group compared to 3.5% 
in controls (p=0.015).  Similarly with the recombinant IgG western blot with cut-offs calculated on the 
control population 30.7% of CFS returned a positive (European 2 band criteria) and 6.9% controls (p = 
0.01)  A comparison of the results of all testing procedures, indicates there is a distinct correlation 
between the test group returning positive results compared to controls. Although many of the 
individual tests may not have produced significant differences between test group and control group by 
themselves, when looked at as a ‘testing battery’ a more obvious relationship appears, although 
consistency between the Borrelia ELISA and the different WB test warrants further investigation. When 
the groups are analysed with ‘more than one positive result’ considered, a significant difference 
develops. This difference may be indicative of the body’s immune system being compromised from 
dealing with multiple co-infections (Balmer & Tanner, 2011).  During this study, 17.5% of the test group 
returned positive results to four or more tests, compared to 0% of the control group. Similarly, 37.5% of 
the test group returned positives to at least three tests, compared to 17.2% of the control group. The 
notion that underlying chronic infection(s) contribute to CFS is hard to state clearly, but the evidence 
seems to be indicative of this. Interestingly, of the 15 test group participants who returned positive 
results to at least four tests, six of them returned symptom scores over 270, markedly higher than the 
test group mean, 225. Given the unreliable nature of self-reported symptoms, a cluster of high 
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symptom scores within those returning the highest levels of exposure to pathogens, even though not 
statistically significant, further emphasises a possible relationship between CFS and bacterial pathogens.   
Through the use of ROC curve analysis, the recombinant Borrelia IgG western blot showed an 
approximately 20% split between those in the test group classified as  positive and those in the control 
group. On the basis of CFS being a multifaceted and multifactorial illness, with increasing likelihood 
multiple causative effects, the fraction of the test group with positive responses to bacterial infections 
was, in all probability going to be a small percentage. Likewise degree of ‘effect’ the chronic infections 
had on the CFS was always going to be difficult to measure.  Further testing is warranted in many 
aspects of this study, in particular the significant difference between CFS group and control group that 
have at least 3 pathogens (p< 0.05) or exposure to one tick borne pathogen and one respiratory 
pathogen (p<0.01) in the overall results appears to be indicative of exposure to multiple infections, 
which through a multitude of previously described ways can evade immunogenic responses, and cause 
long term effects.  Nicolson et al. found non-clustered multiple infections in CFS patients, indicating not 
a specific group of infectious organisms causing fatiguing symptoms, but more the presence of multiple 
non-specific co-infections that may cause fatigue (Nicolson et al., 2003) and this study corroborates 
those findings. 
Between the test subgroups, in order to gain an understanding as to the extent known infections 
contribute to CFS, comparative analyses were conducted. However, there was no significant difference 
between the CFX and CFT cohort for any individual serological test and there was no evidence of DNA  
of the four pathogens in either cohort or controls., . Furthermore, no difference was found when 
symptom loads were analysed between the two groups, and the only significant difference found in 
reference data was the recollection of a domestic tick bite. The lack of distinguishable characteristics 
between the CFX and CFT group and similar exposure levels to the four pathogens investigated 
regardless of how they were recruited to the study may indicate that the levels of prevalence found in 
this study may be indicative of the wider CFS population.  Larger studies on a global level would need to 
be carried out to confirm whether this would hold true and whether differences between CFS and 
controls could be detected for the pathogens which did not return significance in this small study. 
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This study highlights that bacterial infections such as those investigated should be investigated as part 
of a differential diagnosis in CFS as well as other bacterial and viral micro-organisms.  As diagnostic PCR 
methodology becomes more sensitive and able to detect low level or latent infections it will be able to 
assist clinicians in the diagnosis of such infections which presently can only be inferred as a previous 
exposure by serology or suggest recent exposure if IgM seroconversion to IgG can be demonstrated. 
Further research into possible aetiological and contributing factors will assist in decreasing the 
morbidity of CFS.  
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Appendix 1: Participant information sheet. 
 
 
 
Tick-borne Diseases Unit 
Discipline of Pharmacology 
School of Medical Sciences 
Faculty of Medicine 
  
 ABN 15 211 513 464 
 
  Researcher: Thomas Kelly 
 Chief Investigator: Dr Ann Mitrovic 
 Supervisor: Dr Brent McParland 
Room 238 
Blackburn Building D06 
The University of Sydney  
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9351 6735 
Facsimile:  +61 2 9351 3868 
Email: tkel2180@uni.sydney.edu.au 
Web: http://www.sydney.edu.au/ 
 
 
Chronic Fatigue Syndrome: is there a link with tick-borne infections? 
 
PARTICIPANT INFORMATION STATEMENT 
 
(1) What is the study about? 
 
You are invited to participate in a study of Chronic Fatigue Syndrome investigating 
the presence and possible role of the following bacteria; species of Borrelia; 
Bartonella; Ehrlichia, Anaplasma, Rickettsia, Chlamydophylla, Mycoplasma and 
species of the piroplasm Babesia.  We will investigate blood samples from 
participants diagnosed with Chronic Fatigue Syndrome for evidence of each of the 
above listed species employing methods that detect DNA of the micro-organisms 
and also serology which will detect an immune response that is, detection of 
antibodies against each micro-organism.   
 
(2) Who is carrying out the study? 
 
The study is being conducted by researchers Dr Ann Mitrovic, Dr Brent McParland, 
Dr Mualla McManus, Ms Ann Cincotta and research student Mr Thomas Kelly and 
will form the basis for the degree of Master of Philosophy (Medicine) at The 
University of Sydney under the supervision of Dr Brent McParland, Senior Lecturer 
and Dr Ann Mitrovic. 
 
(3) What does the study involve? 
 
- Participants will receive a questionnaire via email/post 
- The questionnaire will ask participants to detail their experience with Chronic 
Fatigue Syndrome, including questions regarding: 
o Date of diagnosis 
o Clinical symptoms 
o Current/previous medications 
o Tick bite history 
- Blood collection will then be organised at a location convenient to participants 
through Douglass Hanly Moir pathology clinics. 
- Participants will be asked to complete a symptoms questionnaire on the day of 
blood collection as well as a fatigue questionnaire. 
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- If a participant is found to have evidence of exposure to any of the above listed 
micro-organisms a report will be sent to the nominated doctor for a follow up 
appointment to be arranged to discuss possible treatment options. 
- If a participant is started on treatment and has consented to further blood 
collections and symptom questionnaires then blood collection and 
questionnaires will be organised at 12 and 24 weeks to monitor evidence of 
pathogens as well as any change to health outcomes with progress of 
treatment.  Participants who do not require treatment will also be invited to 
submit blood samples and questionnaires at 12 weeks and 24 weeks to allow 
for a comparison between treatment and non-treatment CFS participant groups. 
 
- As is possible with any blood collection, the procedure may cause the 
participant some psychological distress. Swelling and/or bruising may occur 
around the site of blood collection on the arm. The procedure will be carried out 
by people who are appropriately trained to deal with both issues should they 
arise. 
 
(4) How much time will the study take? 
 
Researchers will endeavour to make the study as convenient as possible for 
participants. The questionnaires will take approximately half an hour but participants 
are able to complete the survey over a time course that suits them. Blood collection 
will be organised for a time that suits participants and will take approximately 15 
minutes, three blood samples will be needed in total.  Participants will be required to 
spend approximately 1.5 hours on the questionnaire and 45mins on blood collection 
over the 6 month time period. 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to 
consent and - if you do consent - you can withdraw at any time without affecting 
your relationship with The University of Sydney. 
 
Being in this study is completely voluntary and you are not under any obligation to 
consent to complete the questionnaires.  You can withdraw from this study at any 
time. If you have already completed one or more questionnaires, those responses 
can also be withdrawn from the study if that is your preference. 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the 
researchers will have access to information on participants.  You can nominate your 
doctor to receive a report of your results. 
 
A report of the study may be submitted for publication, but individual participants will 
not be identifiable in such a report. 
 
(7) Will the study benefit me? 
 
We cannot and do not guarantee or promise that you will receive any benefits from 
the study. 
 
(8) Can I tell other people about the study? 
   
  Participants are welcome to discuss the study with others. 
 
(9) What if I require further information about the study or my involvement in it? 
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When you have read this information, Tom Kelly is available to discuss it with 
you further and answer any questions you may have.  If you would like to know 
more at any stage, please feel free to contact Tom Kelly, via email 
tkel2180@uni.sydney.edu.au or  
via phone on +61 2 9351 6735. 
 
(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can 
contact The Manager, Human Ethics Administration, University of Sydney on +61 2 
8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
 
This information sheet is for you to keep
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Tick-borne Diseases Unit 
Discipline of Pharmacology 
School of Medical Sciences 
Faculty of Medicine 
  
ABN 15 211 513 464 
  
 
 
    
Researcher: Thomas Kelly 
 Chief Investigator: Dr Ann Mitrovic 
 Supervisor: Dr Brent McParland 
Room 238 
Blackburn Building D06 
The University of Sydney  
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9351 6735 
Facsimile:  +61 2 9351 3868 
Email: 
tkel2180@uni.sydney.edu.au 
Web: http://www.sydney.edu.au/ 
 
 
PARTICIPANT CONSENT FORM 
 
 
I, ...........................................................................................[PRINT NAME], give consent to my participation in the 
research project 
 
TITLE: Chronic Fatigue Syndrome: is there a link with tick-borne infections? 
Human Research Ethics Committee approval number XXXXX 
 
In giving my consent I acknowledge that: 
 
1. The procedures required for the project and the time involved have been explained to me, including any 
inconvenience, risk, discomfort or side effect, and their implications and any questions I have about the 
project have been answered to my satisfaction. 
 
 
2. I have read the Participant Information Statement and have been given the opportunity to discuss the 
information and my involvement in the project with the researcher/s. 
 
 
3. I understand that being in this study is completely voluntary – I am not under any obligation to consent. 
 
 
4. I understand that my involvement is strictly confidential. I understand that any research data gathered from 
the results of the study may be published however no information about me will be used in any way that is 
identifiable. 
 
 
5. I understand that I can withdraw from the study at any time, without affecting my relationship with the 
researcher(s) or the University of Sydney now or in the future. 
 
6. I understand that I can stop the questionnaire at any time if I do not wish to continue and the information 
provided will not be included in the study. 
  
 
  
 
 
7. I consent to:  
 
 Periodic Blood Collection YES  NO  
 Periodic Questionnaires  YES  NO  
 Receiving Feedback YES  NO  
 
If you answered YES to the “Receiving Feedback” question, please provide your details i.e. mailing 
address, email address. Feedback will be a 1 page summary of results from the overall study. 
 
Feedback Option 
 
Address:  _______________________________________________________ 
 
_______________________________________________________ 
 
Email: _______________________________________________________ 
 
 
8. Consenting to this study requires multiple blood samples and questionnaires.  The researchers will need to 
contact you to organise postage/email of questionnaires and appointments for blood collection.  Please 
provide your contact details: 
 
Name:                          
  
Address:                .     
 
Email:         
 
Phone:        
 
 
 
9. I would like results of blood tests sent to my doctor*: 
 
YES    NO    
 
 Doctor’s Contact Details: 
 
Name:                          
  
Address of Practice:       
 
Email:         
 
Phone:        
* Please note participants results can only be sent to nominated doctor and not  to participants directly. A copy of 
results can be obtained by participants from their doctor. 
 
 
 
  
 
 
 ................................... ................................................... 
Signature  
 
 
 
 .................................. .................................................... 
Please PRINT name 
 
 
.................................................................................. 
Date
  
 Appendix 3: Participant consent form 2 
 
 
Tick Borne Disease Laboratory 
Discipline of Pharmacology 
School of Medical Sciences 
Faculty of Medicine 
  
  ABN 15 211 513 464 
 
 
  Chief Investigator: Dr Ann Mitrovic 
Room 297 
Blackburn Building D06 
The University of Sydney  
NSW 2006 AUSTRALIA 
Telephone:   +61 2 9351 3217 
Facsimile:    +61 2 9351 3868 
Email: ann.mitrovic@sydney.edu.au 
Web:   http://www.sydney.edu.au/ 
 
 
PARTICIPANT CONSENT FORM 
 
 
I, ...........................................................................................[PRINT NAME], give consent to my participation 
in the research project 
 
TITLE: Tick-borne Disease in Australia: An Investigation of Causal Pathogens and Effect of 
Treatments on Symptomology and Pathogen Load 
Human Research Ethics Committee approval number 15366 
 
In giving my consent I acknowledge that: 
 
10. The procedures required for the project and the time involved have been explained to me, including 
any inconvenience, risk, discomfort or side effect, and their implications and any questions I have 
about the project have been answered to my satisfaction. 
 
 
11. I have read the Participant Information Statement and have been given the opportunity to discuss 
the information and my involvement in the project with the researcher/s. 
 
 
12. I understand that being in this study is completely voluntary – I am not under any obligation to 
consent. 
 
 
13. I understand that my involvement is strictly confidential. I understand that any research data 
gathered from the results of the study may be published however no information about me will be 
used in any way that is identifiable. 
 
 
14. I understand that I can withdraw from the study at any time, without affecting my relationship with the 
researcher(s) or the University of Sydney now or in the future. 
 
15. I understand that I can stop the questionnaire at any time if I do not wish to continue and the 
information provided will not be included in the study. 
 
  
 
 
16. I consent to:  
  
 
 Periodic Blood Collection  YES  NO  
 Periodic Questionnaires   YES  NO  
 Receiving Feedback  YES  NO  
 Blood Collection by finger stick YES  NO  
 
If you answered YES to the “Receiving Feedback” question, please provide your details i.e. 
mailing address, email address. 
 
Feedback Option 
 
Address:  _______________________________________________________ 
 
_______________________________________________________ 
 
Email: _______________________________________________________ 
 
 
17. Consenting to this study requires multiple blood samples and questionnaires.  The researchers will 
need to contact you to organise postage/email of questionnaires and appointments for blood 
collection.  Please provide your contact details: 
 
Name:                          
  
Address:                .     
 
Email:         
 
Phone:        
 
 
 
18. I would like results of blood tests sent to my doctor: 
 
YES    NO    
 
 Doctor’s Contact Details: 
 
Name:                          
  
Address of Practice:       
 
Email:         
 
Phone:        
 
 
 
 
 
 ............................. ................................................... 
Signature  
 
 
 
  
 ............................ .................................................... 
Please PRINT name 
 
 
.................................................................................. 
Date 
  
Appendix 4: Participant reference questionnaire 
CFS & tick-borne diseases study: Reference Questionnaire 
Registration 
What is the date you’re completing this survey? (dd/mm/yy) 
    
What is your age? (years) 
    
What is your gender? (M/F) 
   
In which suburb & state is your home address? 
      
How many years have you lived in this suburb/area for? 
           
In which other suburbs/states have you lived in the last 15 years? (Please list all) 
             
Exposure Risks 
Researchers hope to gain a picture of any risk factors that are present which may have increased your 
chance of a tick bite. 
Have you ever been involved in bush walking? If so, how often would you participate in this activity? This 
activity may include walking any pets through bush areas or camping. 
  
             
             
How many hours per week do you think you may spend in your garden or outside areas immediate to your 
home? 
             
             
Please list any pets (mammals) you currently have or have had in the past 10 years. 
             
             
Have you had a job that has required you to spend time in the bush in the past 10 years?     If so, please 
give details. 
             
Have you had a job that has required frequent contact with animals in the past 10 years? 
             
Travel History 
Tick-borne illnesses including Lyme disease and babesiosis are endemic in some parts of the world. 
Researchers would like to know of your travel history to identify any travels that could have increased your 
exposure to these diseases. 
Have you travelled overseas? (Y/N) 
   
  
Have you, on any overseas trips, spent time in rural or bushland areas? If so, please name the country, 
area and date. 
              
             
Can you recall a tick bite whilst travelling overseas? If so, please state the country and area. Please also 
describe where, on your body, you were bitten. 
             
             
Please list any domestic travels in the last 10 years, in which you have stayed in bushland or coastal areas. 
Please also include the year of each relevant trip. 
             
             
Can you recall a tick bite whilst travelling within Australia? If so, please state the area in which this 
occurred. Please also describe where, on your body, you were bitten. 
             
             
 
Past Diagnosis of Illness 
In order to find correlations between various pathogens and illnesses, researchers need some information 
regarding your past diagnosis/diagnoses. 
  
Have you been diagnosed with Chronic Fatigue Syndrome? (Y/N) 
____________ 
In which year were you diagnosed? 
___________________ 
Have you been diagnosed with any other Illness?  Please list illness and the year of diagnosis. 
Illness Year of Diagnosis 
  
  
  
  
  
  
  
  
 
Please list any infections (Y/N) you have been diagnosed with and the year you were diagnosed.  Please 
add any infections not listed. 
Infection Y/N Year of Diagnosis 
Epstein Barr Virus (EBV) –Glandular Fever 
(Infectious mononucleosis) 
  
HHV-6 Human Herpes Virus-6   
Ross River Virus   
  
Varicella Zoster  Virus- Chicken Pox/ 
Shingles 
  
Mycoplasma infection   
Chlamydia infection   
   
   
   
   
   
   
   
   
   
 
Have you been diagnosed with any of the listed tick-borne illness and in which year were you diagnosed? 
Please add any tick-borne infections not listed which you have been diagnosed. 
Tick Borne Illness Y/N Year of Diagnosis 
Lyme Borreliosis   
Babesia infection   
Bartonella infection (Cat scratch disease)   
Ehrlichia infection   
Anaplasma infection   
Coxiella burnetii (Q fever)   
Francisella tularensis infection   
Rickettsia infection    
  
(Scrub typhus, Tick typhus, Flinders Island Spotted Fever) 
   
   
   
   
 
Please include any other information regarding the diagnosis of your disease eg which test confirmed 
diagnosis if known. 
             
             
             
             
‘Bullseye’ Rash 
Many Lyme disease patients experience a ‘bullseye’ rash, clinically termed ‘erythema migrans’. 
Researchers would like to know some details regarding the appearance of this rash if you experienced it. 
Did you experience this ‘bullseye’ rash? If so, how long was there between the tick bite and the 
appearance of the rash? 
             
How long did the rash originally last for? 
             
 
  
At which site on your body did the rash occur? Was this the same site as the tick bite? 
             
If the rash was measured by yourself or a doctor, please state the size of the rash (from outer edge to 
outer edge). 
             
Please describe the rash. This description may include its colour, if it was itchy, if it was painful, burning or 
anything you can remember about your original bullseye rash. 
             
             
             
             
Do you experience recurring bullseye rashes? 
             
 
Did/do you have any other rashes that are not bulls-eye like? Please describe the appearance of the rash. 
             
             
             
             
  
Treatment 
In this last section, researchers would like to know details of the treatments you are currently using. Many 
patients will also be utilising melatonin and various naturopathic remedies, researchers are also interested 
in these treatments.   
Researchers are also interested in antibiotics and antimicrobial treatments being taken.  A ‘herxheimer’ 
reaction is a severe fever occasionally experienced by Lyme Borreliosis patients in response to effective 
antibacterial treatments. Researchers would like to know all details of your treatments, including any 
‘herxheimer’ reactions. 
Below is an explanation of each term: 
Antibiotic/antimicrobial: this is the drug prescribed by your doctor, for example it might be doxycycline, 
amoxicillin, ceftriaxone or tinidazole. Using the generic name or the name on the packet are both 
acceptable. 
Dosage: this is the amount that you are prescribed to take in ‘mg’ or ‘g’. Please also include how often you 
take this. For example, your dosage might be ‘2 x 500mg tablets 3 times daily’. This can be found on the 
prescribed drug packet. If you are unaware of the dose, please contact your doctor for details. 
Route of administration: this refers to the way the drug is administered to you and may involve oral 
(tablet form), intramuscular injections or intravenous injections. 
Duration of treatment: this refers to how long you have been using this particular treatment for. 
Please list details of each treatment below: 
1. Drug or naturopathic remedy:        
 
Dosage:         ______ 
  
 
Route of Admin:        ______ 
 
Duration of Treatment:        ______ 
 
2. Drug or naturopathic remedy:        
 
Dosage:         ______ 
 
Route of Admin:        ______ 
 
Duration of Treatment:          
 
3. Drug or naturopathic remedy:        
 
Dosage:           
 
Route of Admin:          
 
Duration of Treatment:          
 
4. Drug or naturopathic remedy:        
 
Dosage:           
 
  
Route of Admin:          
 
Duration of Treatment:          
 
5. Drug or naturopathic remedy:        
 
Dosage:           
 
Route of Admin:          
 
Duration of Treatment:        _____ 
 
6. Drug or naturopathic remedy:        
 
Dosage:           
 
Route of Admin:          
 
Duration of Treatment:          
 
7. Drug or naturopathic remedy:        
 
Dosage:           
 
Route of Admin:          
  
 
Duration of Treatment:          
 
8. Drug or naturopathic remedy:        
 
Dosage:           
 
Route of Admin:          
 
Duration of Treatment:          
 
Below, please list any other treatments you have used: 
             
             
             
             
             
             
 
Below, please list any other methods you have used e.g. exercise programs, meditation, relaxation 
classes, dietary supplements etc: 
             
  
             
             
             
             
             
             
             
             
             
             
If there is any other information regarding your illness that you think may be useful for researchers 
please include it below (add extra pages if required). 
              
              
              
              
              
              
              
  
              
              
              
              
              
              
              
              
              
              
              
 
Thank you very much for your time in completing this questionnaire, if you have any questions regarding 
this questionnaire or the study in general, please do not hesitate to contact Tom Kelly on +61 2 9351 6735 
or email : tkel2180@uni.sydney.edu.au 
 
  
  
Appendix 5: Symptomology questionnaire 
Date Completed:  
For each of the following symptoms, please place a ‘1’ in the boxes which best represent the current severity of the symptom, 
and how often you currently experience that symptom. For example, if you frequently suffer from swollen glands, but they are 
uncomfortable rather than painful, you might tick "mild" for the severity and "constant" for the frequency. 
 Current Severity Current Frequency 
 
N
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SYSTEMIC SYMPTOMS         
Swollen glands         
Sore throat         
Mouth Ulcers         
Cold Sores         
Fevers         
Hot flushes         
Cold flushes         
Cold sensitive         
Heat sensitive         
Night sweats         
Difficulty swallowing         
Sore soles, esp. in the morning         
Profuse sweating         
Hot/cold flushes         
Swollen/enlarged lymph nodes         
Rash         
Skin lumps         
Skin lesions         
Skin bruising         
Unexplained weight gain         
Unexplained weight loss         
Unexplained hair loss         
FATIGUE         
Fatigue, tired, poor stamina at rest         
Post exertional fatigue         
Poor exercise Tolerance         
Level of Fatigue- Bedridden         
Level of Fatigue- Housebound         
Level of Fatigue- Inability to go out         
Level of Fatigue- Inability to work         
Level of Fatigue- Inability to study         
Level of Fatigue-Inability to relate to 
people 
        
  
 
  
 Current Severity Current Frequency 
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CARDIOVASCULAR         
Heart murmur or valve prolapse         
Heart palpitations or skips         
Chest wall pain or ribs sore         
Heaviness or pressure on the chest         
Dizziness/fainting         
Cold hands         
Cold feet         
RESPIRATORY         
Dyspnoea-Shortness of breath-at rest         
Shortness of breath-on exertion         
Unexplained chronic cough         
Wheeze         
Congestion         
MUSCULOSKELETAL         
Unexplained back pain         
Stiffness of the joints or back         
Muscle pain          
Muscular cramps         
Obvious muscle weakness         
Muscle twitches         
Muscle tremors         
Obvious muscle weakness         
Obvious muscle weakness         
Neck:         
Stiffness         
Pain         
Cracks         
Joint pain (circle which body part)         
Fingers, toes         
Ankles, wrists         
Knees, elbows         
Hips, shoulders         
Joint swelling (circle which body part)         
Fingers, toes         
Ankles, wrists         
Knees, elbows         
Hips, shoulders         
  
  
 Current Severity Current Frequency 
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M
o
d
er
at
e
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NEUROLOGICAL         
Twitching of the face or other muscles         
Tingling         
Numbness         
Burning sensations         
Stabbing sensations         
Shooting pains on skin         
Hypersensitivity to heat/cold         
Facial paralysis-Bell's Palsy         
Dental pain         
GASTROINTESTINAL         
Queasy stomach or nausea         
Vomiting         
Heartburn (reflux)         
Stomach pain         
Regurgitation of food         
Constipation         
Diarrhoea         
Low abdominal pain, cramps         
Abnormal hunger         
Bloating         
Belching         
Flatulence odorous         
Flatulence non-odorous         
Anal itch         
Anal bleeding         
Anal mucous         
GENITOURINARY         
Nocturia   (excessive urination at night)         
Frequency of Urination         
Pain of urination         
Stinging of urination         
Blood in urine         
Hesitancy of urination         
Incontinence         
Urinary retention         
Irritable bladder or bladder dysfunction         
Unexplained menstrual irregularity         
Painful period         
Heavy period         
Vaginal Thrush         
Erectile dysfunction         
Painful intercourse         
  
 Current Severity Current Frequency 
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e 
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COGNITIVE/BEHAVIOURAL         
Confusion, difficulty thinking         
Difficulty with concentration or 
reading 
        
Problem absorbing new 
information 
        
Word search, name block         
Forgetfulness, poor short term 
memory 
        
Poor attention         
Disorientation: getting lost, going 
to wrong places 
        
Speech errors- wrong word, 
misspeaking 
        
Inability to read         
Inability to write         
Inability to spell         
Brain fog         
Thought disorder         
Mood swings         
Irritability         
Depression         
Anxiety, panic attacks         
Psychosis (hallucinations, 
delusions, paranoia, bipolar) 
        
Anger outbursts         
Obsessive Compulsive Behaviour         
Agitation         
Panic attack         
Seizures         
Headache         
Migraine         
Brain Ache         
FOOD/CHEMICAL SENSITIVITIES         
Reactive to foods         
Reactive to allergens         
Reactive to chemicals         
Reactive to supplements         
Reactive to medication         
Reactive to movement         
  
  
 Current Severity Current Frequency 
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SENSORY         
Light sensitivity         
Sound sensitivity         
Conjunctivitis         
Sore eyes         
Red eyes         
Vision:          
double         
blurry         
Hearing:         
Buzzing         
Ringing         
decreased hearing         
Pain in ears         
Blocked ears         
Sinus Congestion         
Sinus Pain         
Post Nasal Drip         
Runny Nose         
Blocked Nose         
Bleeding Nose          
Increased motion sickness         
Vertigo         
Spinning         
Off balance, “tippy” feeling         
Light-headedness, wooziness         
Unavoidable need to sit or lie 
down 
        
SLEEP/WAKE CYCLE         
Insomnia-difficulty going to sleep         
Fractionated sleep/ frequent 
waking 
        
Early awakening         
Excessive night time sleep         
Napping during the day         
Unrefreshed sleep         
OTHER         
Unexplained milk production         
Breast pain         
Additional Comments (Please list any changes to medications/treatment): 
  
Appendix 6: CFX and CFT subgroup and control group symptoms analysis 
 Data table produced from Games-Howell post hoc testing on ANOVA analysis of symptom score 
comparisons between test sub-groups and control group. 
Multiple Comparisons 
Games-Howell 
       
Dependent Variable 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Swollen Glands X group T group -.136 .435 .95 -1.18 .91 
Control 
group 
1.746
*
 .253 0.00 1.14 2.35 
T group X group .136 .435 .948 -.91 1.18 
Control 
group 
1.882
*
 .387 .000 .95 2.82 
Control 
group 
X group -1.746
*
 .253 .000 -2.35 -1.14 
T group -1.882
*
 .387 .000 -2.82 -.95 
Sore Throat X group T group .229 .391 .828 -.71 1.16 
Control 
group 
1.834
*
 .278 .000 1.17 2.50 
T group X group -.229 .391 .828 -1.16 .71 
Control 
group 
1.605
*
 .351 .000 .76 2.45 
Control 
group 
X group -1.834
*
 .278 .000 -2.50 -1.17 
T group -1.605
*
 .351 .000 -2.45 -.76 
Fevers X group T group -.603 .385 .269 -1.53 .32 
Control 
group 
1.142
*
 .179 .000 .71 1.57 
T group X group .603 .385 .269 -.32 1.53 
Control 
group 
1.745
*
 .345 .000 .91 2.58 
Control 
group 
X group -1.142
*
 .179 .000 -1.57 -.71 
T group -1.745
*
 .345 .000 -2.58 -.91 
Hot Flushes 
 
X group T group -.068 .506 .990 -1.28 1.14 
Control 
group 
1.950
*
 .370 .000 1.06 2.84 
T group X group .068 .506 .990 -1.14 1.28 
Control 
group 
2.018
*
 .412 .000 1.03 3.01 
  
Control 
group 
X group -1.950
*
 .370 .000 -2.84 -1.06 
T group -2.018
*
 .412 .000 -3.01 -1.03 
Cold Flushes X group T group -.299 .455 .789 -1.38 .79 
Control 
group 
1.061
*
 .345 .009 .23 1.89 
T group X group .299 .455 .789 -.79 1.38 
Control 
group 
1.360
*
 .372 .002 .46 2.26 
Control 
group 
X group -1.061
*
 .345 .009 -1.89 -.23 
T group -1.360
*
 .372 .002 -2.26 -.46 
Sore Soles X group T group -.309 .486 .801 -1.47 .85 
Control 
group 
1.595
*
 .322 .000 .82 2.37 
T group X group .309 .486 .801 -.85 1.47 
Control 
group 
1.904
*
 .370 .000 1.00 2.80 
Control 
group 
X group -1.595
*
 .322 .000 -2.37 -.82 
T group -1.904
*
 .370 .000 -2.80 -1.00 
Profuse 
sweating 
X group T group -.280 .527 .857 -1.54 .98 
Control 
group 
1.724
*
 .345 .000 .89 2.56 
T group X group .280 .527 .857 -.98 1.54 
Control 
group 
2.003
*
 .417 .000 .99 3.01 
Control 
group 
X group -1.724
*
 .345 .000 -2.56 -.89 
T group -2.003
*
 .417 .000 -3.01 -.99 
Swollen lymph X group T group -.043 .434 .995 -1.08 1.00 
Control 
group 
1.653
*
 .250 .000 1.05 2.26 
T group X group .043 .434 .995 -1.00 1.08 
Control 
group 
1.696
*
 .358 .000 .83 2.57 
Control 
group 
X group -1.653
*
 .250 .000 -2.26 -1.05 
T group -1.696
*
 .358 .000 -2.57 -.83 
Rash X group T group -.253 .354 .756 -1.10 .59 
Control 
group 
.839
*
 .341 .042 .02 1.65 
T group X group .253 .354 .756 -.59 1.10 
Control 
group 
1.091
*
 .320 .003 .32 1.86 
Control 
group 
X group -.839
*
 .341 .042 -1.65 -.02 
T group -1.091
*
 .320 .003 -1.86 -.32 
Unexplained X group T group .496 .579 .668 -.88 1.88 
  
weight gain Control 
group 
1.911
*
 .415 .000 .90 2.92 
T group X group -.496 .579 .668 -1.88 .88 
Control 
group 
1.415
*
 .403 .003 .43 2.39 
Control 
group 
X group -1.911
*
 .415 .000 -2.92 -.90 
T group -1.415
*
 .403 .003 -2.39 -.43 
Unexmplained 
weight loss 
X group T group -.185 .437 .906 -1.23 .86 
Control 
group 
.864
*
 .261 .005 .23 1.50 
T group X group .185 .437 .906 -.86 1.23 
Control 
group 
1.049
*
 .351 .013 .19 1.90 
Control 
group 
X group -.864
*
 .261 .005 -1.50 -.23 
T group -1.049
*
 .351 .013 -1.90 -.19 
Unexplained 
hair loss. 
X group T group .199 .518 .922 -1.04 1.43 
Control 
group 
1.640
*
 .393 .000 .69 2.59 
T group X group -.199 .518 .922 -1.43 1.04 
Control 
group 
1.441
*
 .344 .000 .60 2.28 
Control 
group 
X group -1.640
*
 .393 .000 -2.59 -.69 
T group -1.441
*
 .344 .000 -2.28 -.60 
Poor stamina at 
rest/ Fatigue 
X group T group -.628 .501 .426 -1.82 .57 
Control 
group 
6.326
*
 .429 .000 5.30 7.35 
T group X group .628 .501 .426 -.57 1.82 
Control 
group 
6.954
*
 .399 .000 6.00 7.91 
Control 
group 
X group -6.326
*
 .429 .000 -7.35 -5.30 
T group -6.954
*
 .399 .000 -7.91 -6.00 
Heart murmur X group T group .103 .240 .903 -.47 .68 
Control 
group 
.444
*
 .154 .016 .07 .82 
T group X group -.103 .240 .903 -.68 .47 
Control 
group 
.341 .183 .163 -.11 .79 
Control 
group 
X group -.444
*
 .154 .016 -.82 -.07 
T group -.341 .183 .163 -.79 .11 
Heart 
palpitations 
X group T group .071 .425 .985 -.94 1.09 
Control 
group 
1.844
*
 .296 .000 1.13 2.56 
T group X group -.071 .425 .985 -1.09 .94 
  
Control 
group 
1.773
*
 .331 .000 .97 2.57 
Control 
group 
X group -1.844
*
 .296 .000 -2.56 -1.13 
T group -1.773
*
 .331 .000 -2.57 -.97 
Chest pain X group T group -.506 .473 .535 -1.64 .62 
Control 
group 
1.582
*
 .309 .000 .83 2.33 
T group X group .506 .473 .535 -.62 1.64 
Control 
group 
2.088
*
 .368 .000 1.19 2.98 
Control 
group 
X group -1.582
*
 .309 .000 -2.33 -.83 
T group -2.088
*
 .368 .000 -2.98 -1.19 
Dizziness X group T group .299 .474 .803 -.83 1.43 
Control 
group 
2.648
*
 .375 .000 1.75 3.55 
T group X group -.299 .474 .803 -1.43 .83 
Control 
group 
2.348
*
 .423 .000 1.33 3.36 
Control 
group 
X group -2.648
*
 .375 .000 -3.55 -1.75 
T group -2.348
*
 .423 .000 -3.36 -1.33 
Dysponea X group T group -.622 .484 .408 -1.78 .54 
Control 
group 
1.551
*
 .282 .000 .87 2.23 
T group X group .622 .484 .408 -.54 1.78 
Control 
group 
2.172
*
 .399 .000 1.20 3.14 
Control 
group 
X group -1.551
*
 .282 .000 -2.23 -.87 
T group -2.172
*
 .399 .000 -3.14 -1.20 
Chronic cough X group T group -.468 .410 .491 -1.45 .51 
Control 
group 
.764
*
 .233 .006 .20 1.33 
T group X group .468 .410 .491 -.51 1.45 
Control 
group 
1.233
*
 .340 .002 .40 2.06 
Control 
group 
X group -.764
*
 .233 .006 -1.33 -.20 
T group -1.233
*
 .340 .002 -2.06 -.40 
Back pain X group T group -.487 .678 .753 -2.11 1.13 
Control 
group 
2.816
*
 .492 .000 1.63 4.00 
T group X group .487 .678 .753 -1.13 2.11 
Control 
group 
3.303
*
 .527 .000 2.03 4.58 
Control X group -2.816
*
 .492 .000 -4.00 -1.63 
  
group T group -3.303
*
 .527 .000 -4.58 -2.03 
Back stiffness X group T group -.530 .630 .679 -2.03 .97 
Control 
group 
3.642
*
 .506 .000 2.43 4.85 
T group X group .530 .630 .679 -.97 2.03 
Control 
group 
4.172
*
 .520 .000 2.92 5.42 
Control 
group 
X group -3.642
*
 .506 .000 -4.85 -2.43 
T group -4.172
*
 .520 .000 -5.42 -2.92 
Muscle pain X group T group .443 .666 .784 -1.15 2.03 
Control 
group 
4.497
*
 .464 .000 3.37 5.62 
T group X group -.443 .666 .784 -2.03 1.15 
Control 
group 
4.054
*
 .495 .000 2.85 5.26 
Control 
group 
X group -4.497
*
 .464 .000 -5.62 -3.37 
T group -4.054
*
 .495 .000 -5.26 -2.85 
Muscular 
cramps 
X group T group .424 .459 .627 -.67 1.52 
Control 
group 
2.293
*
 .291 .000 1.59 3.00 
T group X group -.424 .459 .627 -1.52 .67 
Control 
group 
1.868
*
 .365 .000 .98 2.76 
Control 
group 
X group -2.293
*
 .291 .000 -3.00 -1.59 
T group -1.868
*
 .365 .000 -2.76 -.98 
Muscle 
weakness 
X group T group -.463 .675 .772 -2.08 1.15 
Control 
group 
3.929
*
 .389 .000 2.99 4.87 
T group X group .463 .675 .772 -1.15 2.08 
Control 
group 
4.392
*
 .557 .000 3.04 5.75 
Control 
group 
X group -3.929
*
 .389 .000 -4.87 -2.99 
T group -4.392
*
 .557 .000 -5.75 -3.04 
Neck stiffness X group T group -.059 .655 .996 -1.62 1.51 
Control 
group 
4.207
*
 .462 .000 3.10 5.32 
T group X group .059 .655 .996 -1.51 1.62 
Control 
group 
4.266
*
 .559 .000 2.92 5.61 
Control 
group 
X group -4.207
*
 .462 .000 -5.32 -3.10 
T group -4.266
*
 .559 .000 -5.61 -2.92 
Neck pain X group T group .633 .616 .562 -.84 2.10 
Control 
3.945
*
 .476 .000 2.80 5.09 
  
group 
T group X group -.633 .616 .562 -2.10 .84 
Control 
group 
3.313
*
 .497 .000 2.12 4.51 
Control 
group 
X group -3.945
*
 .476 .000 -5.09 -2.80 
T group -3.313
*
 .497 .000 -4.51 -2.12 
Neck cracks X group T group -.837 .598 .347 -2.27 .59 
Control 
group 
2.185
*
 .472 .000 1.05 3.32 
T group X group .837 .598 .347 -.59 2.27 
Control 
group 
3.022
*
 .586 .000 1.62 4.43 
Control 
group 
X group -2.185
*
 .472 .000 -3.32 -1.05 
T group -3.022
*
 .586 .000 -4.43 -1.62 
Joint pain 
fingers/toes 
X group T group -.686 .598 .488 -2.11 .74 
Control 
group 
2.283
*
 .401 .000 1.32 3.25 
T group X group .686 .598 .488 -.74 2.11 
Control 
group 
2.970
*
 .481 .000 1.80 4.13 
Control 
group 
X group -2.283
*
 .401 .000 -3.25 -1.32 
T group -2.970
*
 .481 .000 -4.13 -1.80 
Joint pain 
ankles/ wrists 
X group T group .414 .587 .761 -.99 1.82 
Control 
group 
2.648
*
 .395 .000 1.69 3.61 
T group X group -.414 .587 .761 -1.82 .99 
Control 
group 
2.234
*
 .442 .000 1.16 3.31 
Control 
group 
X group -2.648
*
 .395 .000 -3.61 -1.69 
T group -2.234
*
 .442 .000 -3.31 -1.16 
Joint pain 
knees/elbows 
X group T group -.279 .540 .864 -1.57 1.01 
Control 
group 
2.213
*
 .378 .000 1.30 3.13 
T group X group .279 .540 .864 -1.01 1.57 
Control 
group 
2.491
*
 .404 .000 1.51 3.47 
Control 
group 
X group -2.213
*
 .378 .000 -3.13 -1.30 
T group -2.491
*
 .404 .000 -3.47 -1.51 
Joint pain 
hips/shoulders 
X group T group .734 .614 .459 -.73 2.20 
Control 
group 
3.187
*
 .443 .000 2.11 4.26 
T group X group -.734 .614 .459 -2.20 .73 
  
Control 
group 
2.452
*
 .428 .000 1.41 3.49 
Control 
group 
X group -3.187
*
 .443 .000 -4.26 -2.11 
T group -2.452
*
 .428 .000 -3.49 -1.41 
Joint swelling 
fingers/toes 
X group T group .250 .320 .714 -.51 1.01 
Control 
group 
.898
*
 .233 .001 .33 1.46 
T group X group -.250 .320 .714 -1.01 .51 
Control 
group 
.647
*
 .225 .017 .10 1.19 
Control 
group 
X group -.898
*
 .233 .001 -1.46 -.33 
T group -.647
*
 .225 .017 -1.19 -.10 
Joint swelling 
ankles/wrists 
X group T group -.320 .348 .630 -1.16 .51 
Control 
group 
.533
*
 .181 .014 .09 .97 
T group X group .320 .348 .630 -.51 1.16 
Control 
group 
.854
*
 .297 .018 .13 1.58 
Control 
group 
X group -.533
*
 .181 .014 -.97 -.09 
T group -.854
*
 .297 .018 -1.58 -.13 
Joint swelling 
knees/elbows 
X group T group -.773 .425 .174 -1.80 .25 
Control 
group 
.387
*
 .148 .032 .03 .74 
T group X group .773 .425 .174 -.25 1.80 
Control 
group 
1.159
*
 .402 .017 .18 2.14 
Control 
group 
X group -.387
*
 .148 .032 -.74 -.03 
T group -1.159
*
 .402 .017 -2.14 -.18 
Joint swelling 
hips/shoulders 
X group T group -.657 .455 .325 -1.75 .43 
Control 
group 
.489 .233 .101 -.08 1.05 
T group X group .657 .455 .325 -.43 1.75 
Control 
group 
1.146
*
 .391 .015 .19 2.10 
Control 
group 
X group -.489 .233 .101 -1.05 .08 
T group -1.146
*
 .391 .015 -2.10 -.19 
Joint swelling 
twitching face 
X group T group -.328 .328 .580 -1.12 .46 
Control 
group 
1.004
*
 .179 .000 .57 1.44 
T group X group .328 .328 .580 -.46 1.12 
Control 
group 
1.332
*
 .288 .000 .63 2.03 
Control X group -1.004
*
 .179 .000 -1.44 -.57 
  
group T group -1.332
*
 .288 .000 -2.03 -.63 
Tingling 
senstation 
X group T group -.257 .502 .866 -1.46 .94 
Control 
group 
2.098
*
 .318 .000 1.33 2.87 
T group X group .257 .502 .866 -.94 1.46 
Control 
group 
2.355
*
 .392 .000 1.40 3.31 
Control 
group 
X group -2.098
*
 .318 .000 -2.87 -1.33 
T group -2.355
*
 .392 .000 -3.31 -1.40 
Numbness 
senstation 
X group T group -.341 .504 .777 -1.55 .86 
Control 
group 
1.964
*
 .313 .000 1.20 2.72 
T group X group .341 .504 .777 -.86 1.55 
Control 
group 
2.306
*
 .398 .000 1.34 3.27 
Control 
group 
X group -1.964
*
 .313 .000 -2.72 -1.20 
T group -2.306
*
 .398 .000 -3.27 -1.34 
Burning 
senstation 
X group T group -.128 .561 .972 -1.47 1.21 
Control 
group 
2.275
*
 .375 .000 1.37 3.18 
T group X group .128 .561 .972 -1.21 1.47 
Control 
group 
2.403
*
 .421 .000 1.38 3.43 
Control 
group 
X group -2.275
*
 .375 .000 -3.18 -1.37 
T group -2.403
*
 .421 .000 -3.43 -1.38 
Stabbing 
senstation 
X group T group -.420 .475 .651 -1.55 .71 
Control 
group 
1.520
*
 .293 .000 .81 2.23 
T group X group .420 .475 .651 -.71 1.55 
Control 
group 
1.940
*
 .377 .000 1.02 2.86 
Control 
group 
X group -1.520
*
 .293 .000 -2.23 -.81 
T group -1.940
*
 .377 .000 -2.86 -1.02 
Shooting pains X group T group -.398 .502 .708 -1.60 .80 
Control 
group 
1.333
*
 .302 .000 .60 2.06 
T group X group .398 .502 .708 -.80 1.60 
Control 
group 
1.732
*
 .401 .000 .76 2.71 
Control 
group 
X group -1.333
*
 .302 .000 -2.06 -.60 
T group -1.732
*
 .401 .000 -2.71 -.76 
Hypersensitivity 
to heat/cold 
X group T group .761 .688 .513 -.88 2.40 
Control 
4.200
*
 .487 .000 3.02 5.38 
  
group 
T group X group -.761 .688 .513 -2.40 .88 
Control 
group 
3.439
*
 .486 .000 2.26 4.62 
Control 
group 
X group -4.200
*
 .487 .000 -5.38 -3.02 
T group -3.439
*
 .486 .000 -4.62 -2.26 
Facial 
Paralysis/ Bell's 
Palsy 
X group T group -.261 .257 .570 -.88 .36 
Control 
group 
.178 .111 .258 -.09 .45 
T group X group .261 .257 .570 -.36 .88 
Control 
group 
.439 .232 .154 -.13 1.00 
Control 
group 
X group -.178 .111 .258 -.45 .09 
T group -.439 .232 .154 -1.00 .13 
Dental pain X group T group .053 .466 .993 -1.06 1.17 
Control 
group 
1.956
*
 .303 .000 1.22 2.69 
T group X group -.053 .466 .993 -1.17 1.06 
Control 
group 
1.902
*
 .354 .000 1.04 2.76 
Control 
group 
X group -1.956
*
 .303 .000 -2.69 -1.22 
T group -1.902
*
 .354 .000 -2.76 -1.04 
Queesy 
stomach 
X group T group -.211 .568 .927 -1.57 1.15 
Control 
group 
2.667
*
 .369 .000 1.77 3.56 
T group X group .211 .568 .927 -1.15 1.57 
Control 
group 
2.878
*
 .432 .000 1.83 3.93 
Control 
group 
X group -2.667
*
 .369 .000 -3.56 -1.77 
T group -2.878
*
 .432 .000 -3.93 -1.83 
Vomiting X group T group -.863 .474 .170 -2.00 .27 
Control 
group 
.844
*
 .268 .008 .20 1.49 
T group X group .863 .474 .170 -.27 2.00 
Control 
group 
1.707
*
 .391 .000 .76 2.66 
Control 
group 
X group -.844
*
 .268 .008 -1.49 -.20 
T group -1.707
*
 .391 .000 -2.66 -.76 
Heartburn 
(reflux) 
X group T group -.062 .560 .993 -1.40 1.28 
Control 
group 
1.746
*
 .370 .000 .86 2.64 
T group X group .062 .560 .993 -1.28 1.40 
  
Control 
group 
1.808
*
 .467 .001 .68 2.94 
Control 
group 
X group -1.746
*
 .370 .000 -2.64 -.86 
T group -1.808
*
 .467 .001 -2.94 -.68 
Stomach pain X group T group -.139 .528 .963 -1.40 1.12 
Control 
group 
2.279
*
 .363 .000 1.41 3.15 
T group X group .139 .528 .963 -1.12 1.40 
Control 
group 
2.418
*
 .433 .000 1.37 3.46 
Control 
group 
X group -2.279
*
 .363 .000 -3.15 -1.41 
T group -2.418
*
 .433 .000 -3.46 -1.37 
Constipation X group T group .126 .616 .977 -1.34 1.59 
Control 
group 
2.568
*
 .450 .000 1.48 3.66 
T group X group -.126 .616 .977 -1.59 1.34 
Control 
group 
2.443
*
 .443 .000 1.37 3.52 
Control 
group 
X group -2.568
*
 .450 .000 -3.66 -1.48 
T group -2.443
*
 .443 .000 -3.52 -1.37 
Diarrhoea X group T group .013 .464 1.000 -1.10 1.12 
Control 
group 
1.724
*
 .300 .000 1.00 2.45 
T group X group -.013 .464 1.000 -1.12 1.10 
Control 
group 
1.711
*
 .380 .000 .79 2.63 
Control 
group 
X group -1.724
*
 .300 .000 -2.45 -1.00 
T group -1.711
*
 .380 .000 -2.63 -.79 
Abdominal pain X group T group .132 .545 .968 -1.17 1.43 
Control 
group 
2.644
*
 .334 .000 1.84 3.45 
T group X group -.132 .545 .968 -1.43 1.17 
Control 
group 
2.512
*
 .431 .000 1.46 3.56 
Control 
group 
X group -2.644
*
 .334 .000 -3.45 -1.84 
T group -2.512
*
 .431 .000 -3.56 -1.46 
Abnormal 
hunger 
X group T group -.414 .487 .673 -1.58 .75 
Control 
group 
1.417
*
 .321 .000 .64 2.19 
T group X group .414 .487 .673 -.75 1.58 
Control 
group 
1.831
*
 .373 .000 .93 2.74 
Control X group -1.417
*
 .321 .000 -2.19 -.64 
  
group T group -1.831
*
 .373 .000 -2.74 -.93 
Nocturia X group T group -.602 .509 .466 -1.82 .61 
Control 
group 
1.422
*
 .366 .001 .53 2.31 
T group X group .602 .509 .466 -.61 1.82 
Control 
group 
2.024
*
 .354 .000 1.16 2.88 
Control 
group 
X group -1.422
*
 .366 .001 -2.31 -.53 
T group -2.024
*
 .354 .000 -2.88 -1.16 
Irritable bladder X group T group -.641 .407 .264 -1.62 .34 
Control 
group 
.787
*
 .212 .002 .27 1.30 
T group X group .641 .407 .264 -.34 1.62 
Control 
group 
1.428
*
 .351 .001 .57 2.28 
Control 
group 
X group -.787
*
 .212 .002 -1.30 -.27 
T group -1.428
*
 .351 .001 -2.28 -.57 
irregular 
menstruation 
X group T group .756 .519 .317 -.48 1.99 
Control 
group 
1.613
*
 .448 .002 .53 2.69 
T group X group -.756 .519 .317 -1.99 .48 
Control 
group 
.857
*
 .331 .032 .06 1.65 
Control 
group 
X group -1.613
*
 .448 .002 -2.69 -.53 
T group -.857
*
 .331 .032 -1.65 -.06 
Erectile 
dysfunction 
X group T group .154 .270 .836 -.49 .80 
Control 
group 
.422 .228 .165 -.13 .98 
T group X group -.154 .270 .836 -.80 .49 
Control 
group 
.268 .144 .163 -.08 .62 
Control 
group 
X group -.422 .228 .165 -.98 .13 
T group -.268 .144 .163 -.62 .08 
Confusion X group T group -.608 .516 .469 -1.84 .62 
Control 
group 
4.590
*
 .362 .000 3.71 5.47 
T group X group .608 .516 .469 -.62 1.84 
Control 
group 
5.199
*
 .380 .000 4.28 6.12 
Control 
group 
X group -4.590
*
 .362 .000 -5.47 -3.71 
T group -5.199
*
 .380 .000 -6.12 -4.28 
Concentration 
difficulty 
X group T group -.126 .540 .971 -1.41 1.16 
Control 
4.825
*
 .395 .000 3.87 5.78 
  
group 
T group X group .126 .540 .971 -1.16 1.41 
Control 
group 
4.950
*
 .424 .000 3.93 5.97 
Control 
group 
X group -4.825
*
 .395 .000 -5.78 -3.87 
T group -4.950
*
 .424 .000 -5.97 -3.93 
Problems with 
new 
information 
absorbtion 
X group T group -.314 .571 .847 -1.68 1.05 
Control 
group 
5.115
*
 .406 .000 4.13 6.10 
T group X group .314 .571 .847 -1.05 1.68 
Control 
group 
5.429
*
 .410 .000 4.43 6.43 
Control 
group 
X group -5.115
*
 .406 .000 -6.10 -4.13 
T group -5.429
*
 .410 .000 -6.43 -4.43 
Word/ name 
block 
X group T group -.167 .488 .938 -1.33 1.00 
Control 
group 
4.568
*
 .360 .000 3.70 5.44 
T group X group .167 .488 .938 -1.00 1.33 
Control 
group 
4.735
*
 .344 .000 3.90 5.57 
Control 
group 
X group -4.568
*
 .360 .000 -5.44 -3.70 
T group -4.735
*
 .344 .000 -5.57 -3.90 
Forgetfulness X group T group -.493 .507 .596 -1.70 .72 
Control 
group 
4.270
*
 .360 .000 3.40 5.14 
T group X group .493 .507 .596 -.72 1.70 
Control 
group 
4.763
*
 .391 .000 3.82 5.71 
Control 
group 
X group -4.270
*
 .360 .000 -5.14 -3.40 
T group -4.763
*
 .391 .000 -5.71 -3.82 
Poor attetnion X group T group .798 .577 .354 -.58 2.17 
Control 
group 
4.322
*
 .469 .000 3.20 5.45 
T group X group -.798 .577 .354 -2.17 .58 
Control 
group 
3.524
*
 .470 .000 2.40 4.65 
Control 
group 
X group -4.322
*
 .469 .000 -5.45 -3.20 
T group -3.524
*
 .470 .000 -4.65 -2.40 
Disorentation X group T group .355 .516 .771 -.88 1.59 
Control 
group 
2.040
*
 .370 .000 1.14 2.94 
T group X group -.355 .516 .771 -1.59 .88 
  
Control 
group 
1.685
*
 .366 .000 .80 2.57 
Control 
group 
X group -2.040
*
 .370 .000 -2.94 -1.14 
T group -1.685
*
 .366 .000 -2.57 -.80 
Speech errors X group T group -.312 .598 .861 -1.74 1.11 
Control 
group 
4.057
*
 .396 .000 3.10 5.02 
T group X group .312 .598 .861 -1.11 1.74 
Control 
group 
4.369
*
 .458 .000 3.26 5.48 
Control 
group 
X group -4.057
*
 .396 .000 -5.02 -3.10 
T group -4.369
*
 .458 .000 -5.48 -3.26 
Mood swings X group T group .171 .536 .946 -1.11 1.45 
Control 
group 
2.607
*
 .429 .000 1.58 3.64 
T group X group -.171 .536 .946 -1.45 1.11 
Control 
group 
2.436
*
 .410 .000 1.45 3.42 
Control 
group 
X group -2.607
*
 .429 .000 -3.64 -1.58 
T group -2.436
*
 .410 .000 -3.42 -1.45 
Irritability X group T group .549 .547 .577 -.76 1.85 
Control 
group 
3.092
*
 .413 .000 2.09 4.09 
T group X group -.549 .547 .577 -1.85 .76 
Control 
group 
2.544
*
 .393 .000 1.59 3.49 
Control 
group 
X group -3.092
*
 .413 .000 -4.09 -2.09 
T group -2.544
*
 .393 .000 -3.49 -1.59 
Depression X group T group -.442 .577 .724 -1.82 .93 
Control 
group 
2.248
*
 .436 .000 1.20 3.30 
T group X group .442 .577 .724 -.93 1.82 
Control 
group 
2.690
*
 .422 .000 1.67 3.71 
Control 
group 
X group -2.248
*
 .436 .000 -3.30 -1.20 
T group -2.690
*
 .422 .000 -3.71 -1.67 
Anxiety X group T group -.516 .503 .563 -1.72 .68 
Control 
group 
2.003
*
 .386 .000 1.07 2.93 
T group X group .516 .503 .563 -.68 1.72 
Control 
group 
2.519
*
 .361 .000 1.65 3.39 
Control X group -2.003
*
 .386 .000 -2.93 -1.07 
  
group T group -2.519
*
 .361 .000 -3.39 -1.65 
Psychosis X group T group -.208 .138 .294 -.54 .12 
Control 
group 
.133 .060 .080 -.01 .28 
T group X group .208 .138 .294 -.12 .54 
Control 
group 
.341
*
 .124 .023 .04 .64 
Control 
group 
X group -.133 .060 .080 -.28 .01 
T group -.341
*
 .124 .023 -.64 -.04 
Seizures X group T group -.081 .269 .951 -.72 .56 
Control 
group 
.333 .168 .129 -.07 .74 
T group X group .081 .269 .951 -.56 .72 
Control 
group 
.415 .209 .130 -.10 .92 
Control 
group 
X group -.333 .168 .129 -.74 .07 
T group -.415 .209 .130 -.92 .10 
Headache X group T group .330 .598 .846 -1.10 1.76 
Control 
group 
3.474
*
 .446 .000 2.40 4.55 
T group X group -.330 .598 .846 -1.76 1.10 
Control 
group 
3.144
*
 .456 .000 2.04 4.24 
Control 
group 
X group -3.474
*
 .446 .000 -4.55 -2.40 
T group -3.144
*
 .456 .000 -4.24 -2.04 
Light Sensory X group T group .524 .631 .685 -.98 2.03 
Control 
group 
4.342
*
 .438 .000 3.28 5.40 
T group X group -.524 .631 .685 -2.03 .98 
Control 
group 
3.818
*
 .457 .000 2.71 4.93 
Control 
group 
X group -4.342
*
 .438 .000 -5.40 -3.28 
T group -3.818
*
 .457 .000 -4.93 -2.71 
Sound sensory X group T group -.685 .643 .538 -2.22 .85 
Control 
group 
3.879
*
 .440 .000 2.81 4.94 
T group X group .685 .643 .538 -.85 2.22 
Control 
group 
4.564
*
 .484 .000 3.39 5.74 
Control 
group 
X group -3.879
*
 .440 .000 -4.94 -2.81 
T group -4.564
*
 .484 .000 -5.74 -3.39 
Conjunctavitis X group T group .306 .371 .689 -.58 1.19 
Control 
.867
*
 .263 .005 .23 1.51 
  
group 
T group X group -.306 .371 .689 -1.19 .58 
Control 
group 
.561 .261 .093 -.08 1.20 
Control 
group 
X group -.867
*
 .263 .005 -1.51 -.23 
T group -.561 .261 .093 -1.20 .08 
Double vision X group T group .355 .397 .645 -.59 1.30 
Control 
group 
1.111
*
 .295 .001 .40 1.83 
T group X group -.355 .397 .645 -1.30 .59 
Control 
group 
.756
*
 .265 .019 .11 1.40 
Control 
group 
X group -1.111
*
 .295 .001 -1.83 -.40 
T group -.756
*
 .265 .019 -1.40 -.11 
Blurred vision X group T group .167 .547 .950 -1.14 1.47 
Control 
group 
2.426
*
 .391 .000 1.48 3.37 
T group X group -.167 .547 .950 -1.47 1.14 
Control 
group 
2.259
*
 .391 .000 1.31 3.21 
Control 
group 
X group -2.426
*
 .391 .000 -3.37 -1.48 
T group -2.259
*
 .391 .000 -3.21 -1.31 
Buzzing X group T group -.396 .562 .762 -1.74 .95 
Control 
group 
1.341
*
 .340 .001 .52 2.16 
T group X group .396 .562 .762 -.95 1.74 
Control 
group 
1.737
*
 .494 .003 .54 2.93 
Control 
group 
X group -1.341
*
 .340 .001 -2.16 -.52 
T group -1.737
*
 .494 .003 -2.93 -.54 
Ringing X group T group -.515 .637 .698 -2.04 1.01 
Control 
group 
2.283
*
 .406 .000 1.31 3.26 
T group X group .515 .637 .698 -1.01 2.04 
Control 
group 
2.799
*
 .535 .000 1.50 4.09 
Control 
group 
X group -2.283
*
 .406 .000 -3.26 -1.31 
T group -2.799
*
 .535 .000 -4.09 -1.50 
Decreased 
hearing 
X group T group .219 .486 .894 -.94 1.38 
Control 
group 
1.720
*
 .332 .000 .91 2.53 
T group X group -.219 .486 .894 -1.38 .94 
  
Control 
group 
1.501
*
 .358 .000 .63 2.37 
Control 
group 
X group -1.720
*
 .332 .000 -2.53 -.91 
T group -1.501
*
 .358 .000 -2.37 -.63 
Pain in ears X group T group .031 .375 .996 -.86 .93 
Control 
group 
.898
*
 .289 .009 .20 1.60 
T group X group -.031 .375 .996 -.93 .86 
Control 
group 
.867
*
 .244 .003 .27 1.46 
Control 
group 
X group -.898
*
 .289 .009 -1.60 -.20 
T group -.867
*
 .244 .003 -1.46 -.27 
Motion 
sickness 
X group T group .511 .564 .638 -.83 1.86 
Control 
group 
2.440
*
 .414 .000 1.44 3.44 
T group X group -.511 .564 .638 -1.86 .83 
Control 
group 
1.929
*
 .389 .000 .98 2.87 
Control 
group 
X group -2.440
*
 .414 .000 -3.44 -1.44 
T group -1.929
*
 .389 .000 -2.87 -.98 
Vertigo X group T group -.415 .531 .715 -1.68 .85 
Control 
group 
1.684
*
 .340 .000 .86 2.51 
T group X group .415 .531 .715 -.85 1.68 
Control 
group 
2.099
*
 .413 .000 1.10 3.10 
Control 
group 
X group -1.684
*
 .340 .000 -2.51 -.86 
T group -2.099
*
 .413 .000 -3.10 -1.10 
Spinning X group T group -.296 .427 .768 -1.32 .72 
Control 
group 
1.498
*
 .269 .000 .84 2.15 
T group X group .296 .427 .768 -.72 1.32 
Control 
group 
1.794
*
 .335 .000 .98 2.61 
Control 
group 
X group -1.498
*
 .269 .000 -2.15 -.84 
T group -1.794
*
 .335 .000 -2.61 -.98 
Tippy X group T group .033 .505 .998 -1.17 1.24 
Control 
group 
2.595
*
 .323 .000 1.81 3.38 
T group X group -.033 .505 .998 -1.24 1.17 
Control 
group 
2.563
*
 .395 .000 1.60 3.52 
Control X group -2.595
*
 .323 .000 -3.38 -1.81 
  
group T group -2.563
*
 .395 .000 -3.52 -1.60 
Light 
headedness 
X group T group .849 .568 .299 -.51 2.21 
Control 
group 
3.729
*
 .406 .000 2.75 4.71 
T group X group -.849 .568 .299 -2.21 .51 
Control 
group 
2.880
*
 .404 .000 1.90 3.86 
Control 
group 
X group -3.729
*
 .406 .000 -4.71 -2.75 
T group -2.880
*
 .404 .000 -3.86 -1.90 
Need to sit/lie X group T group .731 .648 .500 -.82 2.28 
Control 
group 
4.475
*
 .437 .000 3.42 5.53 
T group X group -.731 .648 .500 -2.28 .82 
Control 
group 
3.745
*
 .481 .000 2.58 4.91 
Control 
group 
X group -4.475
*
 .437 .000 -5.53 -3.42 
T group -3.745
*
 .481 .000 -4.91 -2.58 
Insomnia X group T group -.036 .695 .999 -1.69 1.62 
Control 
group 
3.581
*
 .516 .000 2.34 4.82 
T group X group .036 .695 .999 -1.62 1.69 
Control 
group 
3.617
*
 .558 .000 2.27 4.96 
Control 
group 
X group -3.581
*
 .516 .000 -4.82 -2.34 
T group -3.617
*
 .558 .000 -4.96 -2.27 
Freq. waking X group T group .469 .650 .751 -1.08 2.02 
Control 
group 
4.296
*
 .531 .000 3.02 5.57 
T group X group -.469 .650 .751 -2.02 1.08 
Control 
group 
3.827
*
 .518 .000 2.58 5.07 
Control 
group 
X group -4.296
*
 .531 .000 -5.57 -3.02 
T group -3.827
*
 .518 .000 -5.07 -2.58 
Early wakening X group T group -.227 .633 .932 -1.74 1.28 
Control 
group 
2.679
*
 .441 .000 1.62 3.74 
T group X group .227 .633 .932 -1.28 1.74 
Control 
group 
2.906
*
 .497 .000 1.70 4.11 
Control 
group 
X group -2.679
*
 .441 .000 -3.74 -1.62 
T group -2.906
*
 .497 .000 -4.11 -1.70 
Excessive 
sleep 
X group T group -.386 .584 .787 -1.78 1.01 
Control 
1.746
*
 .394 .000 .80 2.70 
  
group 
T group X group .386 .584 .787 -1.01 1.78 
Control 
group 
2.132
*
 .460 .000 1.02 3.25 
Control 
group 
X group -1.746
*
 .394 .000 -2.70 -.80 
T group -2.132
*
 .460 .000 -3.25 -1.02 
Day naps X group T group -.292 .564 .863 -1.64 1.06 
Control 
group 
2.417
*
 .387 .000 1.48 3.35 
T group X group .292 .564 .863 -1.06 1.64 
Control 
group 
2.709
*
 .417 .000 1.70 3.72 
Control 
group 
X group -2.417
*
 .387 .000 -3.35 -1.48 
T group -2.709
*
 .417 .000 -3.72 -1.70 
Unexplained 
milk production 
X group T group -.057 .162 .933 -.45 .33 
Control 
group 
.089 .070 .417 -.08 .26 
T group X group .057 .162 .933 -.33 .45 
Control 
group 
.146 .146 .581 -.21 .50 
Control 
group 
X group -.089 .070 .417 -.26 .08 
T group -.146 .146 .581 -.50 .21 
Breast pain X group T group .177 .297 .823 -.53 .89 
Control 
group 
.933
*
 .212 .000 .42 1.45 
T group X group -.177 .297 .823 -.89 .53 
Control 
group 
.756
*
 .209 .002 .25 1.26 
Control 
group 
X group -.933
*
 .212 .000 -1.45 -.42 
T group -.756
*
 .209 .002 -1.26 -.25 
SUM X group T group -8.228 20.669 0.916 -57.60 41.15 
Control 
group 
208.619
*
 13.304 0.000 176.46 240.77 
T group X group 8.228 20.669 0.916 -41.15 57.60 
Control 
group 
216.847
*
 16.417 0.000 176.99 256.70 
Control 
group 
X group -208.619
*
 13.304 0.000 -240.77 -176.46 
T group -216.847
*
 16.417 0.000 -256.70 -176.99 
*. The mean difference is significant at the 0.05 level. 
 
  
  
 
Appendix 7:  ROC curve analysis of recombinant western blot antigens 
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Area Under the Curve 
Test Result Variable(s) Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
VIsE-Ba .642 .062 .022 .520 .764 
VIsE-Bb .658 .061 .011 .538 .779 
VIsE-Bg .665 .055 .008 .557 .773 
P83 .774 .053 .000 .669 .879 
P39 .643 .069 .021 .508 .777 
OSPC .753 .059 .000 .637 .869 
P21 .655 .063 .012 .531 .779 
P18 .671 .061 .006 .552 .790 
The test result variable(s): VIsE-Ba, VIsE-Bb, VIsE-Bg, P83, P39, OSPC, P21, P18 has at least one tie between the 
positive actual state group and the negative actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
  
Appendix 8: Examples of Western Blot test strips.  
Positive: 
 
Equivocal: 
 
Negative: 
 
These EuroLine western blot strips were used for testing IgG response against recombinant 
antibodies. The clear sections are gaps between the antibody strips (white sections). The 
antigens tested for, from left to right are; p 18, p 19, p 20, p21, p 58, Osp C, p 39, p 41, p 83, 
Lipid B. burgdorferi, Lipid B. afzelii, VlsE B. garinii, VlsE B. burgdorferi and VlsE B. afzelii. The 
intensity of the response to each antigen is evident through the shade of the bar formed 
(darker – more intense), it can also be determines through examining the area under the 
response curve to each antigen.  
